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ABSTRACT 
Vitiligo is the most common skin disorder resulting in 
depigmentation, but high-quality research is lacking.  A 
Cochrane review of interventions for vitiligo published in 2010 
highlighted methodological limitations with existing trials; 
which have generally been too small and heterogeneous to 
inform clinical recommendations.    
The objective of this thesis was to improve the evidence base 
for the treatment of vitiligo.   
This PhD was funded by the National Institute for Health 
5HVHDUFKDVSDUWRIWKHUHVHDUFKSURJUDPPHFDOOHG³6HWting 
Priorities and Reducing Uncertainties for people with Skin 
'LVHDVHV´,WLQFOXGHVWKHIROORZLQJLGHQWLI\LQJWKHPRVW
important research priorities for patients and clinicians, 
thereby informing the research agenda; 2) conducting a 
systematic review of outcome measures used in vitiligo trials 
and a survey of the most desirable outcomes for patients and 
clinicians; and 3) conducting a pilot double blind, randomised 
controlled trial (RCT) on home hand-held phototherapy in 
preparation of the first national multi-centre RCT for the 
treatment of vitiligo. 
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For the prioritisation exercise, a total of 660 treatment 
uncertainties were submitted by 460 patients and clinicians. 
The identified priority areas included interventions such as 
combination of topical agents and phototherapy.  The 
systematic review on outcome measures identified 25 different 
domains that had been used in previous trials. Although 
percentage repigmentation was measured in 96%; 48 different 
scales had been used. In contrast, patients and clinicians 
IDYRXUHGWKHXVHRI³FRVPHWLFDOO\DFFHSWDEOH´UHSLJPHQWDWLRQ
Finally, a 4-month pilot trial recruited 29 participants and 
tested the logistics of running a future RCT.   
This work resulted in a commissioned call and funding of a 
national RCT on vitiligo (topical corticosteroids in combination 
with home hand-held phototherapy); the initiation of an 
international consensus exercise on core outcome measures 
for use in vitiligo trials; and informed the design and conduct 
of a future national RCT.  
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Why did I choose to undertake this PhD? 
Throughout my studies in medical school I have come to 
realise that clinical practice should be accompanied by the 
principles of evidence based medicine. My university 
introduction to dermatology made me wish to pursue a career 
in this area. During my specialty training in Acute and General 
Medicine, I realised that the ability to diagnose inflammatory 
skin diseases and tumors, the satisfaction of diagnosis, 
investigation and treatment, surgical and histopathological 
expertise with understanding of the complex relationship 
between the skin and internal organs, put cutaneus physicians 
in a unique position of a clinician combining medical and 
surgical skills. Since then I have actively sought every 
opportunity to be involved in dermatology academic activities 
in order to contribute and to improve current clinical practice.  
The Centre of Evidence based Dermatology (CEBD) at 
the University of Nottingham is well recognised as a centre of 
excellence and has an international reputation for skin 
research and evidence-based practice. I strongly believe that 
my PhD project ³6HWWLQJ priorities and reducing uncertainties 
for the WUHDWPHQWRIYLWLOLJR´ in the Centre of Evidence based 
Dermatology will be crucial and extremely fruitful for my 
educational progression and career development towards the 
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achievement of my goal of becoming a Professor and 
Consultant Dermatologist. It will enable me to build on my 
attitude towards clinical excellence, develop a scientific critical 
approach and ethics and equip me with robust experience in 
order to continue my career in Academic Dermatology and 
ultimately help me to incorporate clinical research outcomes in 
clinical practice. 
 
Why do research on vitiligo? 
Skin diseases are very common, affecting over a quarter 
of the population in England and Wales. Although usually not 
life-threatening, skin diseases have a significant impact on the 
quality of life of patients and cause considerable psychological 
distress. 
My proposed research study focuses on vitiligo, a 
condition which results in the loss of pigment from the skin. 
7KLVFDQKDYHDGHYDVWDWLQJLPSDFWRQDSDWLHQW¶VTXDOLW\RI
life, especially for people with darker skin. Around 0.5 % of 
the world population has vitiligo and a variety of methods for 
repigmenting the skin of people with vitiligo have been tried in 
various parts of the world. There is some evidence from 
individual trials to support short term benefit from topical 
steroids, various forms of ultraviolet light with topical 
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preparations, and other therapies including skin grafting and 
ginkgo biloba, but long-term benefits and safety have been 
poorly reported. There is therefore, a great need for an 
extensive and well planned programme of research to find 
effective ways of managing this condition. 
 
What were the sources of funding for this research? 
This thesis is part of the wider research programme 
FDOOHG³6HWWLQJ3ULRULWLHVDQG5HGXFLQJ8QFHUWDLQWLHVIRUSHRSOH
ZLWK6NLQ'LVHDVH´63586'ZKLFKLVIXQGHGE\WKH National 
,QVWLWXWHRI+HDOWK5HVHDUFK1,+57KH³63586'´
programme includes 4 work-streams: eczema prevention, 
eczema treatment, squamous cell carcinoma and vitiligo. Each 
of the work-streams consists of the following key activities: 
1. Systematic  review of the existing evidence 
base for available treatments 
2. Definition and prioritisation of the most 
important research questions regarding treatment 
3. Outcomes work to establish which outcomes 
are most important for patients and clinicians 
4. Pilot work, with a view to submitting a 
funding application for multicentre efficacy trial  
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5. Generation of patient information and 
dissemination of findings. 
My thesis describes the work conducted for the vitiligo 
work-stream of the SPRUDS programme. 
 
What my research is about and what role have I 
played in it? 
My thesis comprises a mixture of projects including a 
priority setting partnership, a full systematic review of 
outcomes for vitiligo, a survey on outcomes amongst patients 
and clinicians and a multi-centre pilot, randomised, controlled 
double-blind trial. Each one has a very different methodology 
and represents a significant research project in its own right.  
Each one of the projects was performed in collaboration with 
my supervisors and colleagues from various disciplines to 
ensure diversity of opinions and views and validity of the 
results. I played a key role in each one of the projects, 
generated ideas, co-ordinated and undertook the vast majority 
of the work myself. Each chapter in this thesis refers to each 
one of the projects mentioned above and they are all written 
in a similar fashion with a brief abstract at the beginning to 
assist navigation through the entire manuscript, introduction, 
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methods, results and discussion sections. In the methods 
section of each chapter, I have outlined in detail what part of 
work was undertaken by me and which ideas were mine.  
My thesis comprises of the following: 
x Chapter 1: Literature review.                                    
There is very limited information available in the 
textbooks on vitiligo and therefore my first chapter is an 
up-to-date literature overview of the disease including 
definition, classification, aetiology, histopathology, 
prognosis, assessment and treatment. By doing this, I 
have attempted to gather and summarise existing 
evidence, hypotheses and suggestions, and also to 
identify some of the research gaps into various aspects 
of this neglected disease.   
x Chapter 2: Identifying the most important 
treatment uncertainties that need to be answered by 
research.                                                                                     
The Centre of Evidence Based Dermatology (CEBD) 
worked in collaboration with the James Lind Alliance 
(JLA), in organising a Priority Setting Partnership (PSP) 
to identify the Top 10 most important uncertainties 
about the treatment for vitiligo for patients and 
clinicians. The vitiligo PSP had 5 stages: initiation, 
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consultation, collation, ranking exercise and a final 
prioritisation workshop.  
x Chapter 3: Establishing the most appropriate 
outcomes to use.                                                           
A systematic review of outcome measures used in 
clinical trials for vitiligo was conducted.  Also, a survey 
of the most desirable outcomes for patients and 
clinicians was conducted. The results of the above were 
crucial in order to inform the best choice of outcome 
measures to be used in the subsequent trial.   
x Chapter 4: Multicentre, pilot, randomised, 
double blind control trial.                                                       
Based on the identified Top 10 priorities, a pilot trial was 
conducted to identify the strategic issues that need to be 
considered in developing a full randomised controlled 
trial (RCT). The pilot trial assessed issues such as the 
numbers of participants required for the main RCT, the 
ability to blind outcome assessment, and willingness of 
participants to be randomised. In addition, a face-to-
face training programme on home hand-held 
phototherapy was developed and tested in this pilot trial. 
x Chapter 5: Impact of my research.  
Reflection on the implications of my research for future 
Page 8 of 338 
vitiligo trials and in particular on the national multi-
centre randomised trial involving home hand-held 
phototherapy. This chapter also includes details of 
transferable skills and competencies that I learned, 
academic achievements and opportunities which arose 
during this PhD and which contributed towards my 
development as an academic clinician. 
 
Output from this research 
During my PhD, I have published five peer-reviewed 
papers in leading dermatological journals both as a first author 
and as a co-author with significant contribution to major 
publications. I have also written two book chapters: 
1) Eleftheriadou V, Thomas KS, Whitton ME, Batchelor JM, 
Ravenscroft JC. Which outcomes should we measure in 
vitiligo? Results of a systematic review and a survey 
amongst patients and clinicians on outcomes in vitiligo 
trials. British Journal of Dermatology 2012; 167: 804-
814. 
2) Eleftheriadou V, Whitton ME, Gawkrodger D, Batchelor 
JM, Corne J, Lamb B, Ersser S, Ravenscroft JC, Thomas KS 
and on behalf of the vitiligo priority setting partnership. 
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Future research into the treatment of vitiligo: where should 
our priorities lie? Results of the vitiligo priority setting 
partnership. British Journal of Dermatology 2011; 
164: 530±536.  
3) Eleftheriadou V. Implications for research after Cochrane 
6\VWHPDWLFUHYLHZ³,QWHUYHQWLRQVIRUYLWLOLJR´&XUUHQW
situation and future directions focusing on Western Europe. 
British Journal of Dermatology 2013 (accepted for 
publication). 
4) Eleftheriadou V, Thomas K, Batchelor J et al. Core 
outcomes in vitiligo trials: progress and challenges. 
Editorial. Clinical Investigation 2013; 3: 417-419.  
5) Gonzalez U, Whitton ME, Eleftheriadou V Pinart M, 
Batchelor J, Leonardi-Bee J. Guidelines for designing and 
reporting clinical trials in vitiligo. Archives of 
Dermatology 2011; 147: 1428-36. 
6) 7DLHE$$ORPDU$%|KP0'HOO¶$QQD0/'H3DVH$
Eleftheriadou V, Ezzedine K, Gauthier Y, Gawkrodger  DJ, 
Jouary T, Leone  G, Moretti S, Nieuweboer-Krobotova L, 
Olsson MJ, Parsad D, Passeron T, Tanew A, van der Veen 
W, van Geel N, Whitton M, Wolkerstorfer A, Picardo M and 
the writing group of the Vitiligo European Task Force (VETF) 
in cooperation with the European Academy of Dermatology 
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and Venereology (EADV) and the Union Européenne des 
Médecins Spécialistes (UEMS) (2012), Guidelines for the 
management of vitiligo: the European Dermatology Forum 
consensus. British Journal of Dermatology 2013; 168: 
5-19.   
7) Teovska Mitrevska N, Eleftheriadou V, Guarneri F. Quality 
of life in vitiligo patients. Dermatologic Therapy 2012; 
25: S28±S31 
Book chapters: 
a. Dadzie O, Petit A, Alexis A.(Editors) Ethnic Dermatology, 
2013, Wiley-%ODFNZHOO&KDSWHU³9LWLOLJR&OLQLFDO
3UHVHQWDWLRQDQG0DQDJHPHQW´E\9Eleftheriadou). 
b. /RWWL7+HUFRJRYD-6FKZDUW]5(GLWRUV9LWLOLJR:KDW¶V
QHZZKDW¶VWUXH" 2013, Wiley-Blackwell.(Chapter 
³5HVHDUFKLQWRYLWLOLJRFXUUHQWVLWXDWLRQDQGIXWXUH
GLUHFWLRQVIRFXVLQJRQ:HVWHUQ(XURSH´E\9
Eleftheriadou). 
The following two papers are currently in preparation: 
1) Eleftheriadou V, Thomas K, Ravenscroft J et al. Pilot, 
double-blind, placebo controlled randomised, multi-
centre trial on home hand-held phototherapy in vitiligo 
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(Hi-Light trial). Pigment Cell and Melanoma 
Research (under-peer review). 
2) Eleftheriadou V and Farley R. Hand-held NB-UVB 
phototherapy devices: output variations pre and post  
pilot double blind randomised, controlled, trial for the 
treatment of vitiligo trial. Photodermatology, 
Photoimmunology, Photomedicine (draft). 
Finally, I have presented my work at the following 
meetings: 
1) 8-11 May 2013, International Investigative 
Dermatology Conference, Edinburgh, Scotland. Poster 
presentation: Pilot double blind multi-centre randomised 
controlled trial on hand-held NB-UVB home phototherapy 
for focal or early vitiligo. 
2) 7-8 June 2012, 3rd International Conference for 
Ethnic Skin and Hair, London, UK (Invited speaker and 
faculty member). Oral presentation: Research update on 
vitiligo and clinical implications. 
3) 2-5 November 2011, The International School of 
vitiligo and pigmentary disorders, Barcelona, Spain. 
Oral presentation: Evidence-based Centre of 
Dermatology. Vitiligo Work-stream.  
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4) 20-24 September 2011, International Pigment Cell 
Conference, Bordeaux, France (Selected speaker). 
Eleftheriadou V, XXIst International Pigment Cell 
Conference, Bordeaux, France. Pigment Cell & Melanoma 
Research 2011; 24; 4: 742-663 (abstract only). 
5) 23-25 September 2010, 1st Vitiligo World Congress, 
Milan, Italy (Invited speaker, phototherapy session chair 
and member of the faculty). Oral presentation: 
Evidence-based management of vitiligo: How to define 
priorities for clinical research  
6) 4-7 September 2010, 16th meeting of the European 
Society of Pigment Cell Research, Cambridge, UK 
(Selected speaker). Eleftheriadou V, 16th Meeting of the 
European Society for Pigment Cell Research, Wellcome 
Trust Genome Campus, Hinxton, Cambridge, UK. 
Pigment Cell & Melanoma Research 2010; 23; 4: e1±e40 
(abstract only). 
 
Picture 1. Two children with vitiligo (Picture provided by the Vitiligo 
Society UK- a SDWLHQWV¶VXSSRUWJURXS). 
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Vitiligo is an acquired, chronic depigmenting disorder of 
the skin. It causes loss of pigment on the affected areas of the 
skin and/or mucosae and is characterised by milky white, non-
scaly macules with distinct margins. The hairs on the 
vitiliginous skin initially remain pigmented and after prolonged 
time, leucotrichia (whiteness of the hair) or poliosis could 
occur. Rarely, the eyes can be affected too. Vitiligo is 
sometimes referred to as leucoderma (-leu·co·der·ma) from 
the Greek ZRUGV³OHXFR´PHDQLQJ white and ³derma´PHDQLQJ 
skin.  It is characterised by depigmented lesions on the skin 
that results from loss or damage of melanocytes (Picardo, 
2010). 
 
 
 
 
Picture 1.1 Patient with vitiligo and 
leucotrichia (Courtesy of Dr Jane 
Ravenscroft) 
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1.1 Historical perspective of vitiligo 
Celsus was the first to use the name vitiligo in his Latin 
PHGLFDOFODVVLF³'H0HGLFLQD´DWWKHVHFRQGFHQWXU\%& (Nair, 
1978; Picardo et al., 2010). It is believed that the name 
GHULYHGIURP/DWLQ³YLWLXP´PHDQLQJGHIHFWRUblemish 
(Rosenblum, 1968), UDWKHUWKDQ³YLWHOOXV´PHDQLng calf 
(Panda, 2005; Picardo et a.l, 2010).  
The disease, which ³FDXVHVZKLte VSRWV´ was recognised 
in ancient times. Descriptions of vitiligo are found in Indian 
ancient sacred books, such as Atharva Veda (1400BC) and the 
Buddhist sacred book Vinay Pitak (224-544 B.C) (Picardoet al., 
2010). Also, it is believed that vitiligo like lesions were 
depicted in a Korean portrait painting of a Korean court 
scholar around mid-18th century (Lee, 1982)(Picture 1.2). 
 
 
Picture 1.2 Korean portrait painting 
illustrating vitiligo like lesions on the 
left side and the lower part of the 
PHQ¶VIDFHCourtesy of Dr Jeffrey 
Corne) 
However, vitiligo was not differentiated from leprosy. 
Hippocrates included lichen, leprosy and vitiligo under the 
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same category. In the Bible, the Old Testament, five broad 
categories of diseases that cause white spots are mentioned: 
(1) white spots per se, (2) white spots associated with 
regrowth of hair which turn white, (3) white spots associated 
with inflammation, (4) white spots with scaling and (5) white 
spots with atrophy. The first two categories are believed to be 
referring to vitiligo. Also, in the Koran, Arabic names used to 
describe vitiligo were translated as leprosy in many languages 
(Nair, 1978; Panda, 2005; Goldman et al., 1966; Picardo et al, 
2010). 
The confusion with leprosy is an important cause for the 
social stigma attached to the white spots of the skin. Since 
ancient times, men and women with white patches of the skin, 
were not respected in society, were disqualified from 
marriage, or if white spots occurred during the marriage, it 
provided reason for divorce (Picardo et al., 2010; Nair, 1978).  
 
1.2 Vitiligo European Task Force 
Vitiligo European Task force (VETF) is a group of 
dermatologists with a strong interest in vitiligo. The group 
originates from the European Society of Pigment Cell Research 
(ESPCR). ESPCR is part of the International Federation of 
Pigment Cell Research Societies (IFPCS), consisting of four 
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regional scientific societies devoted to the study of various 
aspects of pigment cells. The four Pigment Cell Societies are: 
Asian Society for Pigment Cell Research (ASPCR), European 
Society for Pigment Cell Research (ESPCR), Japanese Society 
for Pigment Cell Research (JSPCR) and Pan-American Society 
for Pigment Cell Research (PASPCR)(Societies). Through 
IFPSCR, VEFT members work closely with international groups 
and individuals who hold strong interest into vitiligo research. 
They convene consensus conferences on issues of global 
importance for vitiligo clinical research, such as the consensus 
definition and classification of vitiligo (Taieb and Picardo, 
2007; Ezzedine et al. 2012). Since 2010, I have been an 
active member, collaborated and initiated various international 
projects (see chapter 5) of the VEFT. 
 
1.3 Definition and types of vitiligo 
1.3.1 Definition of vitiligo  
There is a current lack of consensus in the definition and 
methods of assessment of this disorder, which makes it 
difficult to compare the outcomes of different studies of the 
same treatment (Whitton et al., 2010). 
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In 2007, the Vitiligo European Task Force (VEFT) 
published a consensus paper which proposed the following 
consensus definition and classification of vitiligo (Table 1.1). 
Vitiligo vulgaris/ Non-segmental vitiligo (NSV) is 
an acquired, chronic pigmentation disorder characterised by 
white patches, often symmetrical, which usually increase in 
size with time, corresponding to a substantial loss of 
functioning epidermal and sometimes hair follicle melanocytes 
(Taieb and Picardo, 2007). 
Segmental vitiligo (SV) is defined as for NSV, except 
for a unilateral distribution that may totally or partially match 
a dermatome, but not necessarily (Taieb and Picardo, 2007). 
Dermatome is defined as the area of the skin that is supplied 
by a single nerve, originating from a single spinal nerve root.  
Mixed vitiligo is characterised by presence of both non-
segmental and segmental macules in the same patient.  
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Table 1.1 Types of vitiligo (Taieb and Picardo, 2007) 
Type of vitiligo Subtypes 
Non-segmental 
(NSV) 
Focal, mucosal, acrofacial, generalised, universal 
Segmental (SV) 
Focal, mucosal, unisegmental, bi or 
plurisegmental 
Mixed (NSV+SV) According to severity of SV 
Unclassified 
Focal at onset, multifocal, asymmetrical non 
segmental, mucosal (one site) 
 
During the 2011 International Pigment Cell Conference 
(IPCC) several topics including revised classification, 
nomenclature and definition of stable vitiligo were discussed in 
seven working groups representing different geographical 
regions. A consensus emerged that segmental vitiligo should 
be classified separately from all other forms of vitiligo and that 
the term 'vitiligo' may be used as an umbrella term for all non-
segmental forms of vitiligo (Table 1.2). 
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Table 1.2 Revised classification of vitiligo (Ezzedine et 
al., 2012) 
Type of vitiligo Subtypes 
Vitiligo (NSV) 
Mucosal ( more than one mucosal site), 
acrofacial, generalised, universal, mixed 
(associated with SV), rare variants 
Segmental (SV) Unisegmental, bi or plurisegmental 
Undetermined/unclassified  Focal, mucosal (one site in isolation) 
 
In this thesis, I am using the 2007 Vitiligo European 
7DVN)RUFH¶VSURSRVHGFODVVLILFDWLRQ7DEOHIRUWKH
following reasons: 
x The new classification was published in June 2012 
when all the protocols and projects for this thesis were 
in their final stage. 
x The old classification is still widely used by 
research groups and clinicians worldwide and it will take 
some time to adopt the new classification. 
x The old classification was used in previously 
published literature e.g. epidemiological studies used in 
this thesis. 
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Various other terms are also currently used in the 
literature to clinically describe the condition of vitiligo such as 
acrofacial, generalised, focal, universal and mucosal. Vitiligo 
may evolve and progress over time with the result that 
patients shift from one subtype to another (Liu et al., 2005).  
1.3.2 Clinical subtypes of vitiligo 
Focal vitiligo is characterised by one or few macules on 
a localised, non dermatomal distribution (Picture 1.3) (Picardo 
et al., 2010). 
Picture 1.3 A 
teenage girl with 
focal, symmetrical 
lesions of non-
segmental vitiligo on 
both eyes (Courtesy 
of Dr Jane 
Ravenscroft). 
 
Acrofacial vitiligo affects periorificial facial areas and 
distal extremities. Periorificial vitiligo involves skin around the 
eyes, nose, ears, mouth and anus (Picardo et al., 2010). 
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Mucosal vitiligo affects the oral or/and genital 
mucosae. It can present as part of non-segmental vitiligo or as 
the only feature of vitiligo (Picardo et al., 2010). 
Generalised vitiligo is referring to the non-segmental 
vitiligo (Picardo et al., 2010). 
Vitiligo universalis is characterised by complete or 
almost complete depigmentation with possible small 
perifollicular pigmented areas on the sun exposed areas of the 
skin. It is the most severe form of non-segmental vitiligo 
(Picture 1.4) (Picardo et al., 2010). 
 
 
Picture 1.4 A Shri-Lankan woman with 
extensive generalised vitiligo all over her 
body, with only a few pigmented areas 
left on her face and extremities. Scalp 
poliosis is also present (Courtesy of Dr 
Bernard Lamb). 
 
Trichrome or multichrome vitiligo is mostly seen in 
darker skin phototypes. Within a vitiligo lesion, areas of 
depigmentation coexist with hypopigmented areas and with 
normal colour as in surrounding skin (Picardo et al., 2010). 
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Inflammatory vitiligo refers to lesions with raised red 
borders. Mild pruritis might be associated (Picardo et al., 
2010). 
Blue vitiligo refers to a blue discoloration of vitiligo 
patches reported after inflammatory vitiligo (Picardo et al., 
2010). 
Classification of segmental vitiligo of the face and 
neck was proposed by Gauthier in order to clinically describe 
the spreading pattern of the disease (Gauthier Y., 2006). The 
following 5 topographic patterns were proposed based on the 
ophthalmic (V1), maxillary (V2) and mandibular (V3) branches 
of trigeminal dermatome: Type I corresponding to the V1 
partial or total involvement, Type II corresponding to V2 
partial or total involvement, Type III corresponding to V3 
partial or total involvement, Type IV corresponding to mixed 
distribution and Type V corresponding to cervico-facial one 
(Gauthier Y., 2006). 
 
1.4 Prevalence of vitiligo and presentation 
1.4.1 Prevalence 
Vitiligo is the most common depigmenting disorder 
affecting around 0.5% of the world¶V population. The largest 
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epidemiological study was performed in 1977 on the island of 
Bornholm in Denmark, where vitiligo affected 0.38% of the 
population (Howitz et al., 1977). The majority of papers refer 
to an estimate of 0.5% to 1% prevalence worldwide. However, 
it is difficult to estimate the exact prevalence of vitiligo. 
Numbers, as high as 8.8%, have been reported in India (Behl, 
1972). This may be due to inclusion of cases with chemically 
induced depigmentation (Sehgal and Srivastava, 2007).  On 
the other hand, an attempt to estimate the prevalence of 
vitiligo in the black populations has been done in French West 
Indies, which concluded that the prevalence of vitiligo in black 
populations is comparable, or slightly less than, with the 
currently accepted data in white people (Boisseau-Garsaud et 
al., 2000). Overall, the highest incident rates have been 
recorded in India, followed by Mexico and Japan. The disparity 
between prevalence data and incidence figures may be due to 
a higher reporting of vitiligo, where attached social and 
cultural stigma may force patients to seek early consultation 
and/or the lesions are more prominent due to the darker skin 
colour of the population (Sehgal and Srivastava, 2007). 
1.4.2 Sex  
Adults and children of both sexes are equally affected 
although females often present for treatment more frequently, 
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probably due to the greater social consequences to women 
and girls affected by this condition (Singh et al., 1985; 
Fitzpatrick, 1964). 
1.4.3 Age 
Vitiligo develops at all ages but usually occurs in young 
people between the age of 10 and 30 (Singh et al., 1985; 
Fitzpatrick, 1964; Das et al., 1985; Howitz et al., 1977; 
Sehgal and Srivastava, 2007). However one epidemiological 
study showed that almost 50% of people develop vitiligo after 
the age of 40 (Howitz et al., 1977). It is estimated that almost 
half of patients present before the age of 20 years, and nearly 
70-80% before the age of 30 years (Sehgal and Srivastava, 
2007). A recent paper suggested that childhood onset vitiligo 
(before the age of 12) is common and affects 32% of patients 
(Nicolaidou et al., 2012) compared to previously reported 25% 
(Halder et al., 1987; Hu et al., 2006). Also, the same study 
confirmed that the majority of patients (89%) had a disease 
onset after the age of 4 (Nicolaidou et al., 2012). 
Non-segmental vitiligo can occur at any age whereas 
segmental vitiligo tends to occur at a young age (Nicolaidou et 
al., 2012) before the age of 30 in 87% of cases, and before 
the age of 10 in 41.3%. Segmental vitiligo accounts for 5% to 
16% of overall vitiligo cases (Hann and Lee, 1996). 
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Finally, a study in Jordan showed that vitiligo prevalence 
increases with age (0.45 %< 1 year old; 1% aged 1-5 years 
old, 2.1% aged 5-12 years old) (Al-Refu, 2012).  
1.4.4 Clinical presentation  
The most commonly affected initial sites in non-
segmental vitiligo are usually the face, followed by anterior 
trunk, neck and posterior trunk (Hann et al., 1997b).  It has 
been reported that generalised vitiligo can start at any site of 
the body but sun-exposed areas such as fingers, hands and 
face are commonly the initial sites reported by patients 
(Picardo et al., 2010). Interphalangeal joints, elbows and 
knees are the frequently affected extensor surfaces. For 
patients with vitiligo on the hands, vitiligo often progresses to 
the face. This explains the frequency of acrofacial vitiligo in 
these patients (Chun and Hann, 1997).  
In segmental vitiligo the most commonly involved areas 
are face (51.1%), anterior trunk (21.5%) and extremities 
(10.8%) (Hann and Lee, 1996). The same study showed that 
the most common dermatomal distribution of vitiliginous 
lesions is trigeminal, thoracic and cervical with 52.1%, 22.8% 
and 17.4% respectively.  Trigeminal dermatomal distribution 
affects the skin of the face, thoracic refers to the skin of the 
trunk and cervical dermatomal distribution affects the skull, 
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neck and upper extremities. (See definition of dermatome in 
the definition and types of vitiligo, page 18)  
1.4.5 Hair involvement in vitiligo 
Scalp poliosis (Picture 1.4) is the most frequent 
manifestation of hair involvement in vitiligo followed by 
eyebrows, pubic hair and axilla as reported in one study 
(Song, 1994). 
1.4.6 Eye and ear involvement in vitiligo 
Hypopigmented lesions on the iris are found in 20-50 % 
of patients with vitiligo according to several studies. However, 
no ophthalmic involvement has been reported in a small group 
of black patients with vitiligo (Albert et al., 1983; Albert et al., 
1979; Biswas et al., 2003; Bulbul Baskan et al., 2006; 
Rosenbaum et al., 1979; Ayotunde and Olakunle, 2005). Loss 
of otic melanocytes may also occur in some patients with 
vitiligo. Hearing disorders have also been reported in vitiligo 
patients (Dereymaeker et al., 1989; Nikiforidis et al., 1993; 
Orecchia et al., 1989; Tosti et al., 1987). 
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1.5 Differential diagnoses  
The aetiology of the disease is still unknown and 
therefore the definition and classification of vitiligo are purely 
descriptive. Where vitiligo is classical, the diagnosis is straight 
forward and can be made in primary care; however 
challenging cases require assessment by a dermatologist 
(Gawkrodger et al., 2008). 
The following depigmenting or hypopigmenting disorders 
should be considered in the differential diagnosis of vitiligo 
(Tables 1.3 and 1.4) (Gawkrodger et al., 2008; Taieb and 
Picardo, 2007; Picardo et al., 2010). 
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Table 1.3 Differential diagnoses for non-segmental vitiligo 
Disorders to be excluded from the definition 
of non-segmental vitiligo 
Clinical presentation 
Inherited or genetic 
induced hypomelanoses 
Hypopigmented lesions 
are present at birth, 
however in low 
phototypes are usually 
discovered after the first 
sun exposure. 
Piebaldism Midline body depigmentation, white 
forelock, bilateral shin depigmentation. 
Tuberus sclerosis Ash-leaf white spots, seizures, 
angiofibromas, mental retardation. 
Hypomelanosis 
of Ito 
Blascholinear distribution, uni or bilateral 
hypopigmented streaks. 
Albinism  To be considered for vitiligo universalis in 
case when the onset or the history of the 
disease is unknown. Classic 
oculocutaneous albinism associated with 
nystagmus and hair depigmentation is 
not a consideration, but milder syndromic 
albinisms should be considered (e.g. 
Hermanski-Pudlak syndrome, Griscelli 
syndrome). 
:DDQGHUEXUJ¶V
syndrome 
White forelock, hypertelorism (increased 
distance between to organs or two body 
parts), deafness, retinal pigment 
abnormalities. 
Post inflammatory 
hypomelanoses 
Psoriasis  
Diagnosis is usually made on clinical 
ground of primary skin inflammatory 
disease. 
Atopic eczema 
Lichen sclerosis 
Para-malignant 
hypomelanoses 
Mycosis 
fungoides 
In dark-skinned individuals, T-cell 
lymphoma can present as hypopigmented 
lesions. 
Melanoma 
associated 
depigmentation 
Characterised by depigmentation around 
a cutaneous melanoma and associated 
with spontaneous or vaccine-induced 
regression of primary melanoma. 
Occupational and drug 
induced depigmentation 
Occupational 
vitiligo 
Caused by exposure to depigmentation 
agents e.g. phenols.  
Drug induced 
depigmentation  
Caused by drugs such as recently 
reported depigmentation following 
treatment with imatinib, imiquimod, 
potent topical corticosteroids. 
Melasma Common 
hypermelanotic 
disorder 
$OVRNQRZQDV³PDVNRISUHJQDQF\´
Normal but hypochromic looking skin 
could be misleading when associated with 
hyperchromic lesions.   
Post traumatic leucoderma Deep burns or 
scars 
Lesions could be unusual shape, however 
may be difficult to distinguish from true 
vitiligo lesions when scaring is not 
obvious as in case of toxic epidermal 
necrolysis. 
Toxic epidermal 
necrolysis 
Para-infectious 
hypopigmentation 
Tinea versicolor Skin mycosis which cause hypopigmented 
lesions with scaling. 
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Leprosis Characterised by hypochromic lesions. 
Usually associated with loss of sensitivity 
and should be suspected in individuals 
living in endemic areas. 
 
 
Table 1.4 Differential diagnoses for segmental vitiligo 
Disorders to be excluded from 
the definition of non-segmental 
vitiligo 
Clinical presentation 
Naevus depigmentosus Congenital or detectable in the first year of life and 
stable in size and proportions to the child growth.  
Segmental or hemicorporeal 
hypomelanosis of Ito 
Characterised of narrow depigmented streaks following 
%ODVFKR¶VOLQHVFRXOGEHGLIILFXOWWRGLVWLQJXLVKLQFDVHV
of multisegmental vitiligo. 
 
1.6 Quality of life in vitiligo patients 
Porter et al reported that the cosmetic disfigurement of 
this seemingly inconsequential skin disease has a major 
impact on the quality of life of patients and negatively affect 
sexual relationships (Porter et al., 1979; Parsad et al., 2003a; 
Sukan and Maner, 2007). Many people are frightened and 
embarrassed by vitiligo. They experience discrimination from 
others and believe that they do not receive adequate support 
from their doctors (Porter et al., 1987; Sukan and Maner, 
2007). A recent survey conducted by the Vitiligo Society UK 
amongst their members showed that over half (56.6%) of 
respondents indicated that vitiligo moderately or severely 
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affects their quality of life (QOL) (Talsania et al., 2010). 
Finding a cure or effective lasting treatment was the main 
priority for most affected respondents. Disappointingly, most 
respondents obtain information about their disease from non-
medical sources: 431 (83%) from the Vitiligo Society and 129 
(25%) from the internet, compared with 61 (12.5%) from 
dermatologist (Talsania et al., 2010). 
Also, patients with vitiligo may receive limited or 
ambivalent support from friends and family, and experience a 
number of psychological problems such as shame, depression 
and anxiety, which can lead to low self-esteem and social 
isolation (Porter et al., 1978). Majority of patients with vitiligo 
on exposed areas complain of unpleasant emotions compared 
(88%) to 20% of those with lesions in unexposed areas 
(Nogueira et al., 2009). The most frequently cited emotions 
were fear, specifically spreading of vitiliginous lesions (71%), 
shame (57%), insecurity (55%), sadness (55%) and inhibition 
(53%) (Nogueira et al., 2009). Self-image of vitiligo patients is 
also considerably decreased. Mood disturbances are common, 
particularly in teenagers. Vitiligo that begins in childhood can 
be associated with significant psychological trauma that may 
have a long lasting effect on personal self-esteem. Children 
with vitiligo usually avoid or restrict sport activities and often 
lose vital days in school (Parsad et al., 2003a). A study in the 
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Netherlands on the impact of childhood vitiligo on adult life 
showed that psychosexual development of young adults with 
childhood vitiligo appears to be comparable with that of 
healthy controls. However, patients reporting negative 
experiences of their vitiligo during childhood reported 
significantly more problems in social development (Linthorst 
Homan et al., 2008). In addition, a small study suggested that 
female Muslim patients in Iran experience greater quality of 
life impairment than males (Parsad et al., 2003a). 
Finally, a study examined the extent of stigmatisation 
experienced by vitiligo patients considering the visibility of 
their lesions. Perhaps unsurprisingly, this study showed that 
patients with visible lesions experienced a higher level of 
stigmatisation (Schmid-Ott et al., 2007). 
At present, there is limited research done into the 
psychological impact of the disease and the efficacy of 
psychological therapy on patients with vitiligo is not fully 
understood (Picardo et al., 2010; Papadopoulos et al., 1999). 
Papadopoulos et al (1999) provided preliminary evidence that 
cognitive behaviour therapy could provide benefit in terms of 
coping and living with vitiligo and that psychological therapy 
itself may have a positive effect on progression of the disease.  
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1.6 Aetiology and pathogenesis  
The aetiology of vitiligo is poorly understood and has 
been disputed for decades. It is still not clear whether the 
melanocytes in vitiligo lesions have disappeared or are simply 
not functioning properly and why this is happening. Several 
theories have been developed to explain the pathogenesis of 
this proposed multifactorial disease (Dell'anna and Picardo, 
2006; Denman et al., 2008; Le Poole et al., 1993; Le Poole et 
al., 2004; Schallreuter et al., 2008; Taieb, 2000). The 
immunological and the genetic theories seem to provide the 
most robust evidence to date.  
The autoimmune aetiology of vitiligo has been 
considered strongly based on reports of its frequent 
association with other autoimmune disorders such as 
thyroiditis. Also, studies showed that the frequency of vitiligo 
and other autoimmune diseases was increased in relatives of 
vitiligo patients, supporting a genetic component to vitiligo.  
A large epidemiological survey of 374 Caucasian patients 
with generalised vitiligo (most with sporadic occurrence of the 
disease) and their families, 133 multiplex vitiligo families; 
were analysed in the UK and North America, showed that 
19.4% of vitiligo patients DJHG\HDUVROG, reported 
clinical history of autoimmune thyroid disease compared to 
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2.39% of the overall Caucasian population of the same age. 
Hyperthyroid was the most frequent of the reported forms. 
The same study reported significantly elevated frequency of 
pernicious anaemia (1.9%) with a 13-fold increase in 
frequency over the general population aged over 20 years old, 
$GGLVRQ¶V'LVHDVHZLWKD-fold increase in 
frequency over the general population aged over 20 years old, 
systemic lupus erythematosus (0.19%) with an 8-fold increase 
in frequency over the general population aged over 20 years 
old, irritable bowel disease frequency (0.67%) was elevated 
two-fold over the general population over 20 years old. The 
frequency of the above disorders was also elevated in their 
first degree relatives. No significant increase was observed in 
the frequencies of other autoimmune diseases such as 
alopecia areata, type 1 diabetes mellitus, psoriasis, 
UKHXPDWRLGDUWKULWLVVFOHURGHUPDDQG6MRJUHQ¶Vsyndrome. 
Around 30% of the patients with generalised vitiligo were 
affected with at least one additional autoimmune disorder 
(Alkhateeb et al., 2003). Another study in familial generalised 
vitiligo in Caucasian families reported that relatives of families 
with multiple affected members have higher frequencies of 
thyroid disease, rheumatoid arthritis, psoriasis, adult onset 
GLDEHWHVPHOOLWXVDQG$GGLVRQ¶VGLVHDVH,Wwas also suggested 
that familial generalised vitiligo is characterised by earlier 
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disease onset and a broader repertoire of associated 
autoimmune disorders than vitiligo with sporadic occurrence 
(Laberge et al., 2005). A large retrospective study in China, 
did not confirm the above reported associations with thyroid 
disease and the most frequently reported autoimmune 
diseases were rheumatoid arthritis (0.32%), chronic urticaria 
(0.45%), ichthyosis (0.27%) and alopecia areata (0.32%). 
This difference is believed to result mainly from the different 
ages of the studied populations, as most of the patients 
studied were under the peak-onset age of commonly 
associated diseases (Liu et al., 2005). 
Several smaller studies confirmed associations of vitiligo 
with thyroid disorders (Schallreuter et al., 1994; Dogra et al., 
2005; Birlea et al., 2008), type 1 diabetes mellitus (Dogra et 
al., 2005; Birlea et al., 2008) and rheumatoid arthritis (Birlea 
et al., 2008; Dogra et al., 2005). 
These findings also suggest that pathologic variants in 
specific genes predispose to vitiligo and the above mentioned 
autoimmune diseases. Several of these susceptibility genes 
have now been identified such as loci in the MHC (major 
histocompatability complex) (Majumder et al., 1988; Liu et al., 
2007), PTPN22 (LaBerge et al., 2008; Le Poole et al., 2001), 
and NALP1 (Jin et al., 2007). 
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In addition, according to immunological studies, T-cell 
infiltrates, particularly CD8+ has been found in vitiliginous skin 
(Van den Wijngaard et al., 2000; Le Poole et al., 1996). An 
increased number of CD8+ cytotoxic lymphocytes reactive to 
MELAN A/Mart 1, which is a melanoma antigen recognised by 
T-cells, and tyrosinase has been reported. Antibodies to 
melanocytes in the sera of vitiligo patients have been found. 
These antibodies are also present in the sera of healthy 
individuals, but their prevalence is much lower (Cui et al., 
1992; Cui et al., 1995; Farrokhi et al., 2005; Hann et al., 
1996; Harning et al., 1991; Naughton et al., 1983a; Naughton 
et al., 1983b). Correlations have been described between the 
incidence and level of melanocytes antibodies and disease 
activity, showing that circulating pigment cell antibodies are 
found in individuals with active disease  as well as suggesting 
that  antibodies are detected in patients with greater extend of 
depigmentation (Harning et al., 1991). So far a wide variety of 
pigment cells antigens have been identified as targets for 
vitiligo associated antibodies, such as tyrosinase, a 
melanogenic enzyme; however the exact role of these 
autoantibodies in the development of the disease still remains 
unclear (Cui et al., 1992; Cui et al., 1995; Farrokhi et al., 
2005; Hann et al., 1996; Harning et al., 1991; Naughton et 
al., 1983a; Naughton et al., 1983b; Kemp et al., 1997).  
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Indeed, the above results show that vitiligo is associated 
with other autoimmune diseases, such as thyroiditis, and 
suggest that there is a genetic predisposition in vitiligo.  
However a large epidemiological study to verify these possible 
associations is still lacking (Picardo et al., 2010). 
Other theories such as oxidative stress theory.RHEQHU¶V
phenomenon theory, cytokines theory, neuronal theory have 
also been suggested amongst others. 
According to the oxidative stress theory, it has been 
suggested that melanocytes degeneration is caused by free 
radicals and other toxins produced intra or extracellularly. In 
vitiliginous skin, the melanocytes are damaged by the 
increased ROS (reactive oxygen species) levels generation of 
free radicals and toxic metabolites or due to a defective 
antioxidant pathway (Boissy and Manga, 2004; Jimbow et al., 
2001; Le Poole et al., 1993; Schallreuter et al., 2008; Taieb, 
2000). Also, cultured vitiliginous melanocytes show decreased 
levels of the catalase, the principle enzyme that is involved in 
the H2O2 removal and are more susceptible to the toxic effects 
of hyproperoxide and UV (Dell'Anna et al., 2007b; Jimbow et 
al., 2001; Kroll et al., 2005; Maresca et al., 1997).  
On the other hand, vitiligo lesions have been described 
at sites of repeated trauma such as repeated friction or 
Page 38 of 338 
pressure and scars, burns, wounds and other types of 
abrasions (Eyre and Krueger, 1982; Gauthier and Surleve-
Bazeille, 1992; Gauthier et al., 2003; Hatchome et al., 1990; 
Levai, 1958b; Levai, 1958; Mulekar et al., 2007; Sweet, 
1978). 7KH.RHEQHU¶VSKHQRPHQRQQDPHGDIWHU*HUPDQ
dermatologist in 1877, refers to the appearance of new 
psoriatic lesions on lines of trauma. Later in 1890, Kaposi was 
WKHILUVWWRFRQQHFWWKH.RHEQHU¶VSKHQRPHQRQZLWKWKH
appearance of new vitiligo lesions (Picardo et al., 2010). 
Consequently, it has been hypothesised that many lesions of 
non-segmental vitiligo could be related to repeated frictions 
occurring during washing, dressing, personal care, sports and 
other activities (Eyre and Krueger, 1982; Gauthier and 
Surleve-Bazeille, 1992; Gauthier et al., 2003; Hatchome et al., 
1990; Levai, 1958b; Levai, 1958a; Mulekar et al., 2007; 
Sweet, 1978) (Picture 1.5). 
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Picture 1.5  Koebner's Phenomenon (Taieb and Picardo, 2009).  
 
In Koebner's phenomenon, vitiligo patches develop in an 
isomorphic response to the friction or pressure resulting from 
such common activities as brushing hair, drying skin with a 
towel, and wearing a belt or watch. 
Based on the Koebner¶V phenomenon, so called 
koebnerisation could occur at the site of melanocytes and 
grafts transplantation and therefore it is important to evaluate 
the risk of inducing new lesions prior to surgical or cosmetic 
procedures in vitiligo patients (Hatchome et al., 1990; Mulekar 
et al., 2007). 
Also, studies have shown that human epidermal melanin 
unit, represents the symbiotic relationship in which one 
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melanocyte transports pigment-containing melanosomes 
through its dendrites to approximately 36 keranocytes 
(Fitzpatrick, 1964; Fitzpatrick and Breathnach, 1963). 
Moreover, data suggest that melanogenesis is regulated via 
specific melanogenic cytokines produced and released by 
keratinocytes and that fibroblasts derived growth factors can 
contribute to the regulation of melanocytes activities and skin 
pigmentation as well. Finally, vitiliginous skin, exhibits an 
impaired expression of keratynocyte-derived cytokines and 
growth factors affecting melanocytes activities and survival. 
Such an imbalance possibly plays a role in melanocytes 
disappearance, according to the cytokines and growth factors 
theory (Cario-Andre et al., 2006; Norris et al., 1996; Valyi-
Nagy et al., 1990).  
And finally, distribution of depigmentation in segmental 
vitiligo similar to the herpes zoster dermatomal distribution 
has been observed, as discussed in the definition and types of 
vitiligo section. It has been proposed that segmental vitiligo 
could result from the dysfunction of sympathetic nerves in the 
affected area (Koga, 1977; Koga and Tango, 1988). According 
to the neurogenic theory, an abnormal effect of 
neurohormones and neuropeptides has been suggested to 
cause the melanocyte loss or damage in segmental vitiligo 
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(Al'Abadie et al., 1994; McGuire, 1970; Chanco-Turner and 
Lerner, 1965).  
In conclusion, various theories have been suggested to 
explain the pathogenesis of vitiligo. Together, the available 
data suggest that vitiligo is multifactorial and may be a 
syndrome rather than a single disease (Wolff, 2007; Le Poole 
et al., 1993). No single theory fully explains the 
pathoaetiology of vitiligo(Picardo et al., 2010). 
 
1.7 Histopathology 
The diagnosis of vitiligo can be made on clinical grounds, 
however in difficult cases, a skin biopsy can be performed to 
differentiate vitiligo from other pigmentary disorders (Tables 
1.3 and 1.4) (Picardo et al., 2010). 
The main histopathological finding in vitiliginous skin is 
the lack of melanocytes in the basal layer of the lesion and 
loss of melanin pigment from the epidermis. Otherwise skin 
appears to be normal in all other aspects. Occasionally, 
reduced number of melanocytes characterised by degenerative 
changes can be present in vitiligo lesions as well (Maize, 1998; 
Elder, 2005; Hann et al., 2000). 
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When performing a biopsy of hypopigmneted lesions, the 
inclusion of normal skin in the specimen is advised (Picardo et 
al., 2010). It is also important to indicate on the specimen if 
the disease is active or stable, as it has been shown that the 
histopathological findings differ according to the 3 phases of 
the disease: early stages, established lesions and long 
standing lesions (Hann et al., 2000). Established vitiligo 
lesions and long-standing lesions show absence of melanin in 
the epidermal layer and otherwise normal skin. In addition, in 
the long-standing vitiligo lesions, degenerative changes in 
cutaneous nerves and adnexal structures (skin appendages 
such as hair, skin muscles and glands) have been reported 
(Elder, 2005). In contrast, in early stage lesions, there may be 
lymphocytic inflammation infiltrates at the margin of 
vitiliginous lesion. The inflammation is usually lichenoid with 
little if any epidermal damage. Also, few melanocytes are 
present and melanin in the epidermal basal layer can be either 
reduced or not (Elder, 2005; Maize, 1998; Wolf, 2007; Picardo 
et al., 2010). 
In conclusion, the previous histopathological changes are 
referring to non-segmental vitiligo only, as the data for 
segmental lesions is insufficient  to reach a conclusion (Attili 
and Attili, 2008). Therefore research into the histopathology of 
early stage non-segmental lesions and segmental vitiligo 
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lesions would perhaps contribute to our understanding of the 
aetiology of vitiligo. 
 
1.8 Natural history and prognosis 
Despite being a common condition, which may have a 
major negative impact on its patients, there are no studies on 
the natural history of vitiligo. Therefore, evidence and 
recommendation are based on consensus view (Gawkrodger et 
al., 2008). 
Dermatology text books fail to comment on the natural 
history of the disease and despite some reports of 
spontaneous repigmentation, this is unlikely. The British 
Association of Dermatologist guidelines for diagnosis and 
management of vitiligo suggest that vitiligo is a chronic and 
persistent disorder characterised by active, inactive and stasis 
periods (Gawkrodger et al., 2008). 
Currently, there is lack of agreement on the definition 
and assessment of stability and activity of vitiligo. Several 
authors define stable vitiligo as a period when the condition 
does not progress from 4 months to 3 years (Parsad and 
Gupta, 2008; Njoo et al., 1998; Gupta, 2009).  
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A set of objective criteria, the vitiligo disease activity 
score (VIDA) has been suggested by Njoo et al (1999) to 
follow the course of vitiligo lesions, but it has limitations. This 
is a 6-point scale evaluating the disease activity by the 
appearance of new lesions or enlargement of pre-existing 
vitiligo lesions during a period from 6 weeks to a year. 
Reduction in VIDA score indicates better control of the vitiligo 
(Njoo et al., 1999) (Figure 1.1). 
Figure 1.1 Vitiligo Disease Activity Score (Njoo et al., 1999) 
  
Few prognostic features of vitiligo have been identified 
mainly from epidemiological studies. Leukotrichia has been 
referred to as a feature of poor prognosis for repigmentation, 
Vitiligo Disease Activity score 
on a 6-pont scale
Vitiligo Activity Time                 Period VIDA Score
Active 6 weeks or less                          +4 
Active 6 weeks to 3 months +3 
Active 3 - 6 months                                +2 
Active 6 - 12 months                              +1 
Stable 1 year or more 0 
Stable with spontaneous                        -1 
repigmentation 1 year or more 
Njoo et al 1999
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with the assumption that there are no melanocytes left within 
the depigmented area (Parsad et al., 2004). Family history, 
associated autoimmune diseases and the presence of mucosal 
involvement have also been suggested as poor prognostic 
indicators (Dave et al., 2002; Harning et al., 1991). According 
to one study, when the trunk and hands were the initial site 
affected by vitiligo, there was more widespread progression 
and when the initial sites were face and hands, the 
progression of the disease seemed to be less aggressive (Hann 
et al., 1997a). 
The progression of segmental vitiligo differs from the 
non-segmental type and is usually limited to months or a few 
years (Hann and Lee, 1996; Koga and Tango, 1988). Also, 
segmental vitiligo does not usually cross the midline and 
spreads along the initially affected unilateral dermatome 
(Koga, 1977; Hann and Lee, 1996; Hann et al., 1997b). In 
conclusion, defining the prognosis of the disease is of great 
importance to patients in allowing them to adjust to their 
disease. It is also important in choosing a treatment option 
and predicting the effectiveness of therapy and therefore, a 
longitudinal epidemiological study is needed to define the 
natural history of vitiligo (Picardo et al., 2010; Gawkrodger et 
al., 2008).  
Page 46 of 338 
1.9 Evaluation and assessment  
The updated Cochrane systematic review ³,QWHUYHQWLRQV
IRUYLWLOLJR´ concluded that the majority of studies differ 
greatly in the ways in which vitiligo is measured and in the 
myriad combination of interventions assessed (see page 53 for 
information on Cochrane Systematic reviews and Cochrane 
collaboration). Despite the fact that the majority of the studies 
scored the percentage repigmentation, no two studies used 
exactly the same method of scoring; therefore the outcomes 
were pre-specified by the authors of the review. Only 9% 
(5/57) of studies addressed patient-rated quality of life. 
Cessation of spread of vitiligo or stabilisation of the disease 
was only reported in 9% (5/57) of the studies also. As a 
result, with the exception of one meta-analysis, it was not 
possible to pool data (Whitton et al., 2010).  
Hamzavi et al. (2004) have introduced a quantitative 
parametric score, named Vitiligo Area Scoring Index (VASI).  
The total body VASI is calculated using a formula that includes 
contributions from all body regions (possible range, 0±100) 
(Figure 1.2).  
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Figure 1.2 VASI score formula by Hamzavi et al (2004). 
VASI=All Body Sites [Hand Units]× Residual Depigmentation. 
One hand unit, which encompasses the palm plus the 
volar surface of all the digits, is approximately 1% of the total 
body surface area and is used as a guide to estimate the 
baseline percentage of vitiligo involvement in each body area 
(Hamzavi et al., 2004). 
As previously mentioned, the Vitiligo European Task 
Force was established with one of its aims to create a 
consensus scoring system (Taieb and Picardo, 2007). VEFT 
produced an evaluation check list for non-segmental vitiligo 
(Table 1.5) and the following scoring system (Figure 1.3).
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Figure 1.3 VEFT recommendations for scoring extend, 
stage and spread of vitiligo provided by Taieb et al. on behalf 
of the other VEFT members (Taieb and Picardo, 2007). 
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During clinical examination, it is necessary to take 
enough time for the first visit, for up to 30 minutes. For fair-
skinned patients, a dark room and examination with Wood 
lamp might be necessary as vitiligo is less visible to the naked 
eye in these patients. Skin biopsy is usually not required, 
except when other diagnoses cannot be ruled out (Picardo et 
al., 2010). 
The following check list (Table 1.5) provides guidance on 
information necessary for clinical evaluation of the disease as 
well as for research purposes. Although, the referred check list 
has been designed for non-segmental vitiligo, it is applicable 
for both segmental vitiligo and unclassified forms (Picardo et 
al., 2010). 
The Vitiligo European Task Force scoring system is a 
clinical assessment tool, which combines analysis of the 
extent, grading of depigmentation and progression. For the 
HYDOXDWLRQRIWKHH[WHQWRIGHSLJPHQWDWLRQWKH³UXOHRIQLQH´
has been adopted from the already used SCORAD (Severity 
Scoring for Atopic Dermatitis) index for atopic eczema. The 
³UXOHRIQLQH´LVXVHGWRFDOFXODWHWKHDIIHFWHGDUHDDVD
percentage of the whole body, by estimating the face and 
neck, and the upper limbs, as 9% of the whole body surface 
each, 18% for the lower limbs and anterior trunk each and 1% 
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each for genitals, each palm and the back of each hand. To 
determine extent, the sites affected by vitiligo are shaded on a 
drawing of a body (European Task Force,1993) (Figure 1.3). 
 
Table 1.5 Evaluation check list for non-segmental vitiligo 
(Taieb and Picardo, 2007; Picardo et al., 2010) 
 
 
3DWLHQW¶VIHDWXUHV Disease features 
Family 
history 
Interventions 
Phototype                  
)LW]SDWULFN¶VVNLQ
type) 
Ethnic origin 
Age of onset 
Occupation 
Stress/anxiety levels 
Halo nevus 
History of 
autoimmune disease 
Global Quality of life 
DVVHVVPHQW³KRZ
vitiligo does affects 
\RXUHYHU\GD\OLIH"´
(10-point analogue 
scale) 
Duration 
Activity 
(Progressive, 
regressive, stable 
over the last 12 
months) 
Episodes of 
repigmentation 
.RHEQHU¶V
phenomenon 
Itch before flares 
Thyroid disease 
Vitiligo on genitalia 
Clinical 
photographs  
Premature 
hair greying 
Vitiligo  
Autoimmune 
disease in 
family 
Type and duration of 
previous treatments 
including opinion if 
effective/useful. 
Other diseases 
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The proposed evaluation of the stage of the disease is 
based on the repigmentation pattern as following: 
x Stage 0 ± normal pigmentation 
x Stage 1- incomplete depigmentation 
x Stage 2- complete depigmentation and may 
include hair whitening in the minority of hairs, less than 
30% 
x Stage 3- complete depigmentation with hair 
whitening more than 30% 
Finally, the spreading of the disease is evaluated as: 
x 0 - stable disease 
x -1 - observed on-going repigmentation 
x +1 - additional depigmentation patches in a given 
area 
In addition, the Vitiligo European Task Force commented 
during the Rome workshop, that in order to test and evaluate 
WKHGHVFULEHGVFRULQJV\VWHPLWZDVIHOWWKDWSDWLHQWV¶RSLQLRQ
should be used in the grading evaluation (Taieb and Picardo, 
2007). Also, as vitiligo is a psychologically devastating disease 
(see Quality of life in vitiligo patients), inclusion of a more 
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detailed questionnaire, to fully evaluate the severity and the 
psychological impact of the disease, in the standard clinical 
assessment would be useful. Ideally, development of a specific 
vitiligo Quality of life scale would probably be helpful (Picardo 
et al., 2010). 
Recently, during the 2011 International Pigment Cell 
Conference (IPCC), it was recommended that the overall 
stability may best be assessed based on the stability of 
individual lesions rather than the overall stability of the 
disease as the latter is very difficult to define reliably and 
precisely (Ezzedine et al., 2012). It is not uncommon for 
individual lesions in a patient to follow different courses: some 
regress, some stay stable and some progressing 
simultaneously. The VEFT tool and the VASI score both allow 
such regional follow-up (Ezzedine et al., 2012; Taieb and 
Picardo, 2007; Hamzavi et al., 2004). Ideally stability should 
be assessed using a combination of a clinical scoring tool, 
SDWLHQW¶VRZQKLVWRU\DQGGLJLWDOSKRWRJUDSKVRIVSHFLILF
lesions over at least 12 months (Ezzedine et al., 2012). 
Only recently, an attempt was made to develop and 
validate a patient-defined benefit questionnaire for the 
WUHDWPHQWRIYLWLOLJR7KHSDWLHQW¶VEHQHILWLQGH[3%,IRU
vitiligo was validated based on data of 1023 vitiligo patients in 
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Germany and showed high correlation with prior selected 
parameters of therapeutic success, such as Dermatology 
Quality of Life Index (DLQI) and 5-Dimentional European 
Quality of Life Questionnaire (EQ-5). The PBI is calculated on 
the basis of two questionnaires: a patLHQW¶VGHILQHGQHHG
questionnaire completed prior to starting a treatment and a 
SDWLHQW¶VEHQHILWTXHVWLRQQDLUHFRPSOHWHGDIWHUWKHUDS\*OREDO
value PBI is calculated using the following algorithm, where 
the importance of each treatment goal is divided by the sum of 
all importance value and multiplied by the goal attainment 
value. Specifically, the PBI is the arithmetic mean of all rated 
benefits (PBQ items) weighted by the relative importance of 
each corresponding need item (PNQ) for each patient (Figure 
1.4) (Augustin et al., 2008).  
 
Figure 1.4 Patient benefit index (PBI) with k preference items 
(PNQ range 0±4) and benefit items (PBQ range 0±4)  
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Finally, the index of potential repigmentation was 
recently proposed (Benzekri et al., 2012). All vitiliginous 
lesions in a given patient are examined and classified 
according to the following classification: Type A-hypochromic 
lesions, Type B-achromic with dark hairs and Type C-achromic 
lesions with white hair. The index is calculated by dividing the 
addition of (percentage of Type A lesions + percentage of Type 
B lesions) by the addition of (percentage of Type D lesions + 
percentage of Type B lesions). The index is a scale from zero 
to nine. Values superior to five predict good response to 
treatment. On the other hand, values inferior to five predict 
refractory to treatment vitiligo (Benzekri et al., 2012). 
In conclusion, there is lack of consensus on the scales 
and scores used in clinical trials for vitiligo. Standardised 
methodologies for classifying vitiligo and for assessing the 
effect of interventions need to be developed and all 
researchers should adopt the same standards so that the data 
from future trials can be more easily pooled. Patient-centred 
outcomes should be incorporated into the design of all future 
studies (Whitton et al., 2010). 
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1.10 Management overview 
The Cochrane Collaboration is an international network 
of more than 28,000 dedicated people from over 100 
countries. They work together to help healthcare practitioners, 
policy-makers, patients and carers, make well-informed 
decisions about health care, by preparing, updating, and 
promoting the accessibility of Cochrane Reviews. Over 5,000 
Cochrane Reviews are published so far and they are available 
online in the Cochrane Database of Systematic Reviews, part 
of The Cochrane Library.  
Cochrane systematic review is a meta-analysis of trials. 
There are three types of Cochrane Review: intervention 
reviews, diagnostic test accuracy reviews and methodology 
reviews address issues relevant to how systematic reviews and 
clinical trials are conducted and reported. Cochrane Reviews 
base their findings on the results of trials which meet certain, 
strict quality criteria, such as double-blind randomised 
controlled trials; therefore Cochrane reviews are 
internationally recognised as being the benchmark for high 
quality information about the effectiveness of health care 
(Cochrane collaboration http://www.cochrane.org/). 
The fiUVW&RFKUDQHV\VWHPDWLFUHYLHZ³Interventions for 
YLWLOLJR´ was conducted in 2006. This review was updated in 
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2010 (Whitton et al., 2010). The aim of this review was to 
assess all interventions used in the management of vitiligo. 
The updated Cochrane systematic review ³,QWHUYHQWLRQV
for vitiligo´ concluded that no cure and no way of limiting the 
spread of the disease has been found to date. The above 
review identified 38 randomised controlled studies that had 
been published between 2006 and 2009, resulting in 57 
studies overall with 3139 participants. However, until the 
aetiology of the disease is clear, treatments will continue to be 
based on the many theories that exist for this disease 
(Whitton et al., 2010). 
In 2008,  a detailed guideline for the diagnosis and 
management of vitiligo was published in the UK (Gawkrodger 
et al., 2008). This user-friendly guideline was based on 
evidence from the first Cochrane systematic review 2006 and 
expert consensus taking into account patient choice and 
clinical expertise (Gawkrodger et al., 2008). Current British 
Association of Dermatologists (BAD) clinical guidelines for the 
diagnosis and management of vitiligo, recommend NB-UVB, 
tacrolimus and topical steroids (Gawkrodger et al., 2008). 
Recently, a new guideline on vitiligo was developed by 
WKH*XLGHOLQH6XEFRPPLWWHH³9LWLOLJR´Rf the European 
Dermatology Forum and brought several changes into the 
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previously proposed management of vitiligo (Taieb et al., 
2013) (Table 1.6). This guideline suggests early treatment of 
small lesions of recent onset and childhood vitiligo with 
combination of phototherapy and topical agents (Taieb et al., 
2013).  This new European Guideline aims to bring clarity into 
the treatment options available for various types of vitiligo and 
provide expert advice based on the best available evidence 
and specialist consensus (Taieb et al., 2013). 
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Table 1.6 Summary of new European guideline for the 
management of vitiligo (Taieb et al., 2013) 
Type of 
vitiligo 
Level Usual management 
SV or limited 
NSV(<2-3% 
of BSA) 
First 
line 
Avoidance of triggering factors, topical therapies 
(corticosteroids, calcineurin inhibitors) 
 Second 
line 
Localised NB-UVB therapy, especially excimer 
monochromatic lamp or laser 
 Third 
line 
Consider surgical techniques if repigmentation 
cosmetically unsatisfactory on visible areas 
NSV First 
line 
Avoidance of triggering » aggravating factors. 
Stabilisation with NB-UVB therapy, at least 3 months. 
Optimal duration at least 9 months, if response. 
Combination with systemic»topical therapies, including 
reinforcement with localised UVB therapy. 
 Second 
line 
Systemic steroids (e.g. 3±4-month mini-pulse therapy) 
or immunosuppressants if rapidly progressing disease or 
absence of stabilisation under NB-UVB 
 Third 
line 
Graft in non-responding areas especially with high 
cosmetic impact. However, Koebner phenomenon limits 
the persistence of grafts. Relative contraindication in 
areas such as dorsum of hands 
 Fourth 
line 
Depigmentation techniques (hydroquinone monobenzyl- 
ether or 4-methoxyphenol alone or associated with Q-
switched ruby laser) in non-responding widespread (> 
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50%) or highly visible recalcitrant facial »hands vitiligo 
A no treatment option (zero line) can be considered in patients with a fair 
complexion after discussion. For children, phototherapy is limited by 
feasibility in the younger age group and surgical techniques are rarely 
proposed before pre-pubertal age. There is no current recommendation 
applicable to the case of rapidly progressive vitiligo, not stabilized by 
ultraviolet (UV) therapy. For all subtypes of disease or lines of treatment, 
psychological support and counselling, including access to camouflage 
instructors is needed.  
 
The following table summarises the existing evidence 
from the updated Cochrane systematic review, the new 
European Dermatology Forum guideline on vitiligo, the British 
Associations of Dermatologist guidelines for diagnosis and 
management of vitiligo, and the Indian Association of 
Dermatologists, Venereologists and Leprologists standard 
guidelines of care for vitiligo surgery (Gawkrodger et al., 
2008; Whitton et al., 2010; Parsad and Gupta, 2008; Taieb et 
al., 2013) (Table 1.7). This table aims to provide an overview 
of various treatment modalities tested for vitiligo over decades 
and provide a concise summary of clinical recommendations 
for each modality. I believe that it is helpful, in light of such a 
large heterogeneity of interventions, to summarise our 
existing knowledge for each intervention from several sources 
in one table and its applicability for clinical practice. 
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Interventions in this table are classified into one of the 
following categories: topical treatments, phototherapy, 
complementary treatments, systemic treatments, 
psychological treatments, depigmentation or cosmetic 
camouflage. This classification was adopted from the Cochrane 
Systematic review 2010 (Whitton et al., 2010). Several 
interventions, which were not mentioned in the Cochrane 
Systematic review but were mentioned in the clinical 
guidelines (as above), were also added to one of the above 
mentioned categories such as skin grafts, self-tanning 
products, p-benzyloxy-phenol, hair grafts, micropigmentation. 
   In addition, I have also included interventions that are 
still in an early investigative stage; trials are currently on-
going or not yet published (Table 1.8).  
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Table 1.7 Summary of interventions for vitiligo
Broad category Intervention Agents/Techniques
Randomised controlled trial/
Cochrane systematic review
2012
Comments and recommendations
1.Topical treatments
(monotherapies and
combination with
light therapies)
1.1 Topical
corticosteroids
Betamethasone; Clobetasol;
Clobetasol plus UVB; Fluticasone
with UVA; Fluticasone alone
(Kandil, 1974);(Khalid et al.,
1995);(Sanclemente et al.,
2008); (Kumaran et al., 2006);
(Lepe et al., 2003); (Lim-Ong et
al., 2005); (Westerhof et al.,
1999)
The use of highly potent or potent topical
corticosteroids (TCS) is recommended for
generalised symmetrical vitiligo in both children
and adults (Gawkrodger et al., 2008).Once-daily
application of potent TCS is advisable for patients
with limited, extra-facial involvement for a period
no longer than 3 months, according to a
continuous treatment scheme or, better, to a
discontinuous scheme (15 days per month for 6
months) (Taieb et al., 2013). As potent TCS
appear to be at least as effective as very potent
TCS, the first category should be the first and
safest choice.
The combination of corticosteroids with UVA light
is reported to be more effective than topical
corticosteroids alone (Whitton et al., 2010). Anti-
inflammatory properties of the steroids may act
on the immune /inflammatory component, mainly
in recent and active lesions, lowering the total
amount of administered UV radiation. Although
prospective studies are still lacking, the
combination of TCS and UVB sources (NB-UVB and
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308 nm excimer lasers or lamps) may be
promising for difficult to-treat areas, e.g. over
bony prominences. Potent topical steroids applied
once a day (3 weeks out of 4) can be used on
vitiligo lesions for the first 3 months of
phototherapy (Taieb et al., 2013).
1.2 Calcineurin
inhibitors (CI)
Pimecrolimus; Pimecrolimus plus
NB-UVB; Tacrolimus plus Xenon
Chloride Eximer Laser (XCEL);
Tacrolimus alone; Tacrolimus plus
NB-UVB
(Cestari et al., 2001); (Dawid et
al, 2006); (Esfandiarpour et al.,
2009); (Kawalek et al., 2004);
(Lepe et al., 2003); (Mehrabi and
Pandya, 2006)
In adults and children topical pimecrolimus should
be considered as an alternative to the use of
topical steroid. The side effects profile of
pimecrolimus and others CI is better than that of a
highly potent topical steroid (Gawkrodger et al.,
2008; Taieb et al., 2013). Topical CI should
considered in adults and children with vitiligo as
an alternative to topical steroids for new, actively
spreading, lesions on thin skin. The use of topical
CI should be restricted to selected areas, in
particular the head and neck region. Twice-daily
applications are recommended. The treatment
should be prescribed initially for 6 months. During
this period of treatment, moderate but daily sun
exposure should be recommended. If effective,
prolonged treatment (e.g. longer than 12 months)
may be proposed (Taieb et al., 2013).
The combinations of calcineurin inhibitors with
excimer laser or NB-UVB has been tested and
showed promising results, however these should
be treated with caution as long term data
carginogenicity is still lacking (Whitton et.al.,
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2010; Taieb et al., 2013).
1.3 Vitamin D
analogues
Calcipotriol; Calcipotriol plus
PUVA; Calipotriol plus excimer
laser; Calcipotriol plus NB-UVB;
Tacalcitol; Tacalcitol plus NB-
UVB; Tacalcitol plus
monochromatic excimer light
(MEL)
(Kumaran et al., 2006); (Akhyani
et al., 2005); (Ermis et al.,
2001); (Goldinger et al., 2007);
(Arca et al., 2006); (Rodriguez-
Martin et al., 2009); (Leone et
al., 2006); (Lu-yan et al., 2006)
The use of topical calcipotriol as monotherapy and
in combination with phototherapy is not
recommended (Gawkrodger et al., 2008; Taieb et
al., 2013).
1.4 Khellin Topical Khellin plus UVA (KUVA) (Procaccini et al., 1995) Although khellin appears to be less phototoxic in
comparison with psoralens, there is currently
insufficient evidence to recommend khellin with
UV for the treatment of vitiligo (Whitton et al.,
2010; Gawkrodger et al., 2008).
1.5 Pseudocatalase Dead sea climatotherapy plus
psedocatalase
(Schallreuter et al., 2002);
(Bakis-Petsoglou et al., 2009)
This combination treatment has shown promising
results in a pilot non randomised controlled trial.
However 1 subsequent study failed to confirm
these data (Bakis-Petsoglou et al., 2009; Taieb et
al., 2013).
1.6 Melagenina Melagenina plus infra-red light (Souto et al., 1997) This intervention derived from human placental
extract is used topically in conjunction with light to
treat vitiligo. The study didn't examine any
outcomes of interest. Burning with infra-red light
was reported (Whitton et al., 2010).
1.7 Intralesional
steroid injections
Triamcinolone acetonide
suspension
(Vasistha and Singh, 1979) This intervention is not used in practice. One
study showed that intralesional steroid injections
are no better than placebo (Gawkrodger et al.,
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2008). This study also showed adverse effects
such as telangiectasia, infection, skin atrophy and
intradermal haemorrhage (Whitton et al., 2010).
1.8
Catalase/dismutase
superoxide
Catalase/dismutase superoxide
C/DSO with brief sun exposure
(Sanclemente et al., 2008) Catalase/dismutase superoxide is plant based
topical treatment with antioxidant properties. The
study didn't examine any outcomes of interest.
Self-limiting erythematous popular rash was
reported (Whitton et al., 2010).
1.9 Lactic acid Topical 15% lactic acid; Topical
15% lactic acid plus UVA
(Sharquie, 2005) One study examined the effectives of topical lactic
acid alone and in conjunction with UVA. The
results were not reliable due to 63% dropouts with
no reason given (Whitton et al., 2010).
1.10 Antioxidant
mitochondrial
stimulating cream
Antioxidant and mitochondrial
stimulating cream; Antioxidant
mitochondrial stimulating cream
plus oral antioxidants and
phenylalanine
(Rojas-Urdaneta, 2007) Only one small trial examined the effectiveness of
antioxidant and mitochondrial stimulating cream
alone and in combination with oral antioxidant
and/or phenylalanine. The only side effects
reported were mild acne and pruritis (Whitton et
al., 2010).
2.Phototherapy 2.1 PUVA(psoralen
and UVA) and
PUVAsol (psoralen
and sunlight)
Topical PUVA (Trimethylpsoralen
or 8-methoxypsoralen); Oral
PUVA; Topical PUVAsol; Oral
PUVAsol; Oral PUVAsol plus
calcipotriol
(Bhatnagar et al., 2007); (Ruiz
Maldonado and Tamayo , 1975);
(Khalid et al., 1995); (Pathak et
al., 1984); (Akhyani et al.,
2005); (Cestari et al., 2001);
(Ermis et al., 2001); (Parsad et
al., 1998); (Farah et al., 1967)
In most patients NB-UVB should be used in
preference to PUVA. PUVA is not recommended in
children. The recommended treatment regimen
should not exceed 150 PUVA treatments
(Gawkrodger et al., 2008). PUVA is claimed to be
particularly effective in darker skinned individuals,
however, evidence is lacking (Gawkrodger et al.,
2008; Whitton et al., 2010). There is an
uncertainty regarding the risk of skin cancer in
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patients with vitiligo and therefore clinicians
should be caution in prescribing PUVA
(Gawkrodger et al., 2008). Side effects of oral
PUVA and PUVAsol such as nausea, pruritis,
dizziness, headaches, eye discomfort and vague
gastrointestinal symptoms were reported (Whitton
et al., 2010).
2.2 UVA UVA (El-Mofty et al., 2006);
(Procaccini et al., 1995);
(Sharquie, 2005)
Conclusions cannot be drawn if UVA is more
effective in comparison with other phototherapies
as there is no such a study (also see PUVA)
(Whitton et al., 2010).
2.3 UVB BB-UVB ( broad band UVB); NB
UVB (narrow band UVB); NB-UVB
plus Er-YAG laser ablation plus 5
Fluorouracil
(Asawanonda et al., 2008); (Arca
et al., 2006); (Bhatnagar et al.,
2007); (Hamzavi et al., 2004);
(Yones et al., 2007); (Anbar et
al., 2008); (Casacci et al., 2007);
(Lim-Ong et al., 2005); (Mehrabi
and Pandya, 2006)
NB-UVB is indicated for generalized NSV. Total
body treatment is suggested for lesions involving
more than 1520% of the body area. Total NB-
UVB has also been proposed as treatment for
active spreading vitiligo, however only limited
supportive data are available. Targeted
phototherapies (laser and non-laser) are indicated
for localized vitiligo and in particular for small
lesions of recent onset and childhood vitiligo, to
avoid side-effects due to total body irradiation
with UVB, and in all cases where contraindications
exist for total body irradiation (risk for melanoma
or non-melanoma skin cancer, photo-aggravated
disease, etc.). The BAD guidelines suggest that
treatment regimen for patients with skin types I-
III should not exceed 200 UVB treatments;
however there is as yet no consensus as to the
optimum treatment duration of NBUVB or targeted
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phototherapy. Many therapists tend to stop
irradiation if no repigmentation occurs within the
first 3 months of treatment or in case of
unsatisfactory response (< 25% repigmentation)
after 6 months of treatment. Phototherapy is
usually continued as long as there is on-going
repigmentation or over a maximum period of 1 or
2 years. Maintenance irradiation is not
recommended, but regular follow-up examinations
are suggested for detecting relapse (Gawkrodger
et al., 2008; Taieb et al., 2013).
Combination topical therapies with NB-UVB
showed to be more effective than NB-UVB
monotherapy. Erythema, itching, burning and
blistering has been reported. BB-UVB is not
properly evaluated (Whitton et al., 2010).
Home NB-UVB phototherapy (Wind et al., 2010) Only one study evaluated the effectiveness of
home versus hospital NB-UVB therapy. Although
the results showed that both treatments are
comparable, with similar repigmentation and
occurrence of side-effects, satisfaction with the
result was significantly lower in the home group.
It is suggested that home NB-UVB therapy is a
valuable alternative to outpatient light therapy for
vitiligo (Wind et al., 2010).
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2.4 Lasers Xenon-chloride excimer laser
(XCEL); Xenon Chloride excimer
(XCEL) laser plus tacrolimus;
308nm excimer laser; 308nm
excimer plus topical
hydrocortisole
(Goldinger et al., 2007);
(Hofer et al., 2005); (Passeron et
al., 2004); (Sassi et al., 2008);
(Kawalek et al., 2004); (Casacci
et al., 2007); (Lu-yan et al.,
2006)
Excimer laser delivers a condensed beam of UVB
light to the skin. It is commonly used in
conjunction with topical therapies. The
combinations of light therapies with topical
tacrolimus or calcipotriol are reported to be more
effective in repigmenting vitiligo lesions. Reported
side effects include burning, stinging, erythema,
oedema, hyperpigmentation (Whitton et al.,
2010).
One study claims that 308nm MEL therapy is more
effective than NB-UVB for treatment of vitiligo
(Casacci et al., 2007, Whitton et al., 2010).
2.5 Other light
sources
308nm Monochromatic excimer
light (MEL); MEL plus Tacalcitol
3.Complementary
and alternative
therapies
3.1 Zengse pills Zengse pills and cobamamide
tablets; Zengse pills alone
(Shi et al., 2008) Only one study evaluated the effectiveness of
Zengse pills with or without cobamamide and
psoralea tincture. Although the design of study
was unclear the authors reported positive results.
Side effects such as redness, itching and
constipation were reported (Shi et al., 2008;
Whitton et al., 2010).
3.2 Gingko biloba Gingko biloba (Parsad et al., 2003b) Oral Gingko biloba is a herb with
immunomodulatory and antioxidant properties.
One study has reported that Gingko biloba pills
has significantly improved repigmentation and
stopped the disease spreading. Nausea was the
only observed side effect (Parsad et al., 2003b;
Whitton et al., 2010). The use of oral Gingko
biloba cannot be recommended unless further
studies confirm the above effects (Gawkrodger et
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al., 2008).
4. Oral treatments
(monotherapies and
combination with
light therapies)
4.1 Polypodium
leucotomos
Polypodium leucotomos plus NB-
UVB; Polypodium leucotomos plus
PUVA
(Middelkamp-Hup et al., 2007);
(Reyes et al., 2006)
Polypodium leucotomos is a type of fern with
photoprotective and immunomodulatory
properties. It has been reported that Polypodium
leucotomos plus PUVA is more effective than PUVA
in repigmenting vitiligo lesions (Reyes et al.,
2006). However combination of Polypodium
leucotomos plus NB-UVB does not improve
patients quality of life (Middelkamp-Hup et al.,
2007). Currently there is no convincing evidence
that this treatment has a role in the treatment of
vitiligo (Gawkrodger et al., 2008).
4.2 Levamisole Oral levamisole plus
momethasone furoate cream
(Agarwal et al., 2005) One study has shown no statistically significant
difference in repigmentation between the oral
levamisole plus momethasone furoate cream
group and the topical mometasone plus placebo
group (Whitton et al., 2010).
4.3 Oral
corticosteroids
Oral Minipulses (OMP) of
bethamethasone plus PUVA; OMP
plus NB-UVB OMP plus BB-UVB;
OMP alone; oral dexamethasone
(Rath et al., 2008); (Radakovic-
Fijan et al., 2001)
OMP plus NB-UVB showed better repigmentation
compared to OMP alone, in contrary with OMP plus
PUVA or BB-UVB compared to OMP alone (Whitton
et al., 2010, Rath et al., 2008). Dexamethasone
has been reported to stop the spreading of the
disease (Radakovic-Fijan et al., 2001).
OMP therapy is not considered useful for
repigmenting stable vitiligo. The use of oral
dexamethasone cannot be recommended due to
the side effects such as weight gain, acne,
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menstrual irregularity and hypertrichosis
(Gawkrodger et al., 2008, Taieb et al., 2013).
4.4 Azathioprine Azathioprine plus PUVA (Radmanesh and Saedi, 2006) No recommendation could be made based on one
study only, however the combination of
Azathioprine plus PUVA has shown an enhanced
repigmentation compared with PUVA alone
(Gawkrodger et al., 2008).
4.5 L-phenylalanine Oral L-Phenylalanine plus UVA (Siddiqui et al., 1994) There was no statistically significant difference
between the Oral L-Phenylalanine plus UVA and
the no treatment group (Whitton et al., 2010).
4.6 Vitamin B12
and folic acid
Vitamin B12 and folic acid plus
NB-UVB
(Tjioe et al., 2002) Authors reported that the addition of Vitamin B12
and folic acid to the NB-UVB does not improve the
outcome of treatment (Tjioe et al., 2002).
4.7 Oral
antioxidants
Antioxidants pool (AP) (alpha
lipoic acid, Vitamin B and C, and
polyunsaturated fatty acids) plus
NB-UVB
(Dell'Anna et al., 2007a) Although the authors reported that oral
supplementation with AP containing a-lipoic acid
before and during NB-UVB significantly improves
the clinical effectiveness of NB-UVB, the Cochrane
systematic review found no statistically significant
difference between the treatment and the control
group (Whitton et al., 2010; Dell'Anna et al.,
2007a). Larger trials are needed to evaluate the
effectiveness of this modality.
5. Surgical
treatments
(monotherapies and
5.1 Skin grafts Suction epidermal blister grafts;
Punch grafts plus PUVA or topical
corticosteroids; Minipunch
grafting; Split skin grafts;
(Ozdemir et al., 2002); (Barman
et al., 2004); (Khandpur et al.,
2005); (Navarro, 2002);
(McGovern et al., 1999); (Lahiri
Surgery is indicated for all types of stable vitiligo
that do not respond to medical treatment. Test
grafting may be performed in doubtful cases to
detect stability. The choice of surgical intervention
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combined with light
therapies)
Autologous skin minigrafts plus 8-
methoxypsoralen (8-MOP);
Minigrafts alone; Flip-top
grafting; Autologous cultured
epithelial grafts
et al., 2004); (Hasegawa et al.,
2007); (Pai et al., 2002);
(Achauer et al., 1994); (Kahn and
Cohen, 1998); (Ozdemir et al.,
2002); (Guerra et al., 2003);
(Pianigiani et al., 2005);
(Toriyama et al., 2004)
should be individualised (Parsad and Gupta, 2008,
Taieb et al., 2013). Punch grafts is the easiest and
the least expensive method and may be used on
all areas other than nipples and the angle of the
mouth. Suction blister epidermal grafting has the
advantage that the chances of scaring are minimal
as the graft is epidermal. However these 2
methods are not suitable for large lesions. On the
other hand, split skin grafts have the advantage of
treating large areas in a short period of time but
require skills and experience (Parsad and Gupta,
2008). Split skin grafting is recommended as the
best option when a surgical treatment is required.
Minigrafts are not recommended due to a high
incidence of side effects and poor cosmetic results
(Gawkrodger et al., 2008).
5.2 Other tissue
grafts
Hair grafts (Malakar and Dhar, 1999);
(Laxmisha et al., 2006); (Agrawal
and Agrawal, 1995); (Na et al.,
1998)
Hair follicle grafting has been performed by a few
authors for treating small patches in hair bearing
area and has been found useful in treating lesions
with leukotrichia (Parsad and Gupta, 2008).
5.3
Micropigmentation
No studies found (Whitton et al.,
2010)
Micropigmentation is a form of semi-permanent
tattooing. It has been used on areas resistant to
treatment such as the lips and the tips of the
fingers (Whitton et al., 2010).
5.4 Melanocyte
transplantation
Autologus epidermal cell
suspension (non-cultures
melanocytes grafting)
transplantation; Cultured
(Czajkowski, 2004); (Van Geel et
al., 2004); (Olsson and Juhlin,
1998); (Olsson and Juhlin, 2002);
(Mulekar, 2003); (Olsson and
Autologous epidermal suspension applied to a
laser abraded lesion followed by PUVA or NB-UVB
is recommended as the optimal surgical
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autologous melanocytes
transplantation; Suction blister
transplantation; Autologous
cellular suspension (melanocytes
medium plus hyalouronic acid
plus epidermal cells) plus NB-UVB
or PUVA; Autologous transplant of
epidermal suspension from skin
graft
Juhlin, 1995); (Czajkowski et al.,
2007); (Chen et al., 2004);
(Tegta et al., 2006)
transplantation (Gawkrodger et al., 2008).
The major advantage of these procedures is they
can treat large areas of vitiligo lesions, however
do require a properly equipped laboratory and
trained personnel (Parsad and Gupta, 2008).
Phototherapy (NB-UVB or PUVA) should be used
for 3 or 4 weeks after surgical procedures to
enhance repigmentation (Taieb et al., 2013).
6. Depigmentation p-(benzyloxy)phenol
(monobenzyl ether of
hydroquinone)
No RCT found (Whitton et al.,
2010)
Depigmentation should be reserved for adults with
extensive generalised vitiligo (more than 50%
depigmentation) or who have extensive
depigmentation on their face or hands
(Gawkrodger et al., 2008; Taieb et al., 2013)
7. Psychological
therapy
Group cognitive behaviour
therapy; Person centred therapy
(Papadopoulos L, 2004) Despite the small evidence base on CBT the
psychological support and strategies to cope with
the effects of disfigurement are an important part
of the treatment of vitiligo. Psychological
interventions should be offered as a way of
improving coping mechanisms in patients with
vitiligo. Parents of affected children should be
offered psychological counselling (Gawkrodger et
al., 2008; Taieb at al., 2012).
8. Cosmetic
camouflage
Self-tanning products; Cover
products
No RCT found (Whitton et al.,
2010)
There is wide choice of cosmetic agents. Specialist
camouflage services are available (Gawkrodger et
al., 2008; Taieb et al., 2013).
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Table 1.8 Treatments for vitiligo that are still in an early investigative stage, trials are on-going or not yet published.
Broad category Intervention Reference Comments
a. Topical
treatments
Piperine (Faas et al., 2008) Combination of piperine and UV showed induced marked pigmentation response
in mice, which support its potential use in treating vitiligo (Faas et al., 2008).
b.Phototherapy Helium neon Laser;
Helium neon Laser plus
tacrolimus
(Wu et al., 2008) Helium laser is a gas laser, which operates in the red spectrum and is the latest
invention for treating vitiligo combined with topical treatments such as
tacrolimus (Wu et al., 2008, Whitton et al., 2010).
PUVB (Mofty et al., 2001) One study, non-randomised (Whitton et al., 2010), suggested that the use of
psoralen plus broadband UVB is as effective as PUVA in the treatment of vitiligo.
However, the long-term side effects of psoralen plus UVB are unknown (Mofty et
al., 2001).
c. Oral
treatment
Oral Ginkgo Biloba plus
NB-UVB; Vitamin E plus
NB-UVB
Alghamdi 2009 (on-going study:
ClinicalTrials.gov NCT01006421;
(Elgoweini and El Din, 2009)
It has been suggested that oral vitamin E may represent a valuable adjuvant
therapy to NB-UVB (Elgoweini and El Din, 2009).
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It is clear from the above tables that over the years, a 
large number of procedures and interventions have been tried. 
It total, 82 interventions have been studied over a period of 
43 years (1967-2010). To summarise, there is a tendency 
towards exploring combinations of interventions and invention 
of new techniques, without properly exploring the currently 
used interventions such as topical corticosteroids, tacrolimus 
and NB-UVB. Current clinical recommendations for vitiligo that 
is limited to only a few patches include treatment with topical 
agents such as corticosteroids and calcineurin inhibitors, and 
localised NB-UVB phototherapy such as excimer laser. For 
more extensive or spreading disease, whole body NB-UVB 
phototherapy is recommended. Surgical treatments are 
reserved for stable vitiligo and especially for vitiligo that is 
non-responsive to previous treatments areas. Surprisingly, the 
only licensed treatment for vitiligo at the moment is cosmetic 
camouflage (Gawkrodger et al. 2010).  
In addition, a large national study of 1023 patients in 
Germany assessed the clinical features, treatment outcomes 
and satisfaction in patients with vitiligo. The study showed that 
most of the patients with vitiligo have already experienced a 
broad spectrum of interventions; however the most frequently 
prescribed treatments, such as topical corticosteroids and 
vitamin D analogues as well as surgical transplantation were 
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rated mostly negatively. Only a few therapies were considered 
WREHEHQHILFLDOIURPDSDWLHQWV¶SHUVSHFWLYH6XUSULVLQJO\WKH
pseudocatalase with Dead Sea climatotherapy and cosmetic 
camouflage were the most valued interventions. The study 
concluded that there is a great need for beneficial options for 
the  treatment of vitiligo and for continuing medical education 
of doctors, in prescribing appropriate treatment while 
supporting the psychological needs of their patients (Radtke et 
al., 2010). 
Finally, the recently updated Cochrane systematic review 
2010 revealed that no firm clinical recommendations for the 
treatment of vitiligo can be made. Fifty seven RCTs with 3,139 
participants have been analysed, however most of the trials 
had fewer than 50 participants and few lasted longer than 6 
months (Whitton et al., 2010). It was not possible to conduct 
meta-analysis of any of the included interventions due to 
heterogeneity of trial design (Whitton et al., 2010). 
The "Implications for research" section of this Cochrane 
Review, comments on the issues around research into vitiligo 
and suggestions are made to overcome these in light of the 
evidence that has been summarised (Gonzalez and Williams, 
2011). 
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The major issues around vitiligo trials have been 
identified as (Whitton et al., 2010): 
1. Lack of consensus on the classification and 
definition of vitiligo  
2. Lack of consensus on the methods of assessment  
and outcome measures of vitiligo 
3. Large heterogeneity of interventions compared  
4. Need for a large definitive trial on combination 
phototherapy treatments 
In conclusion, my research addresses most of the above 
mentioned issues (Table 1.9). As mentioned at the beginning 
of this chapter, international efforts have been made to 
address the issue of classification of vitiligo.  
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Table 1.9 Summary of research described in this thesis, in 
light of issues identified by the Cochrane Systematic review 
2010  
Chapter Title of chapter Brief outline of chapter 
Issue identified 
by the Cochrane 
review 2010 
1 
Introduction and 
Background 
Literature review on vitiligo. 
Issues around vitiligo 
research  
 
2 
Future research 
into the treatment 
of vitiligo: where 
should our 
priorities lie?  
Priority Setting Partnership 
amongst patients and 
clinicians aiming to identify 
the Top 10  important 
uncertainties on the 
treatment of vitiligo  
Large 
heterogeneity of 
interventions 
compared 
3 
Which outcomes 
should be 
measured in 
future vitiligo 
trials? 
A systematic review of 
outcomes used in RCTs and a 
VXUYH\RISDWLHQWV¶DQG
FOLQLFLDQV¶YLHZV 
Lack of consensus 
on the outcome 
measures of vitiligo 
4 
Hi-light pilot trial 
for vitiligo 
A pilot randomised controlled 
double blind multi-centre trial 
on home hand-held 
phototherapy for the 
treatment of vitiligo 
Need for a large 
definitive trial on 
combination 
phototherapy 
treatments 
5 
Impact of my 
research  
Reflection on the above and 
implications on future vitiligo 
trials such as application for a 
national multicentre RCT. 
Personal academic 
achievements and 
transferable skills learned 
As above 
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In conclusion, there is a great need for international 
consensus on the future research agenda and core outcome 
measures for vitiligo. The former and the latter could be used 
in future trials in order to gather and steer the efforts of 
clinicians and researchers all over the world towards aspects 
important to both patients and clinicians. It is sad and 
disappointing that no large, well conducted trials have yet 
been conducted on any of the current available treatments for 
vitiligo.  
Finally, the aetiology and pathogenesis of vitiligo 
remains unclear. It is still not understood what causes the 
destruction of melanocytes (Chapter 1.6, page 33). Also, 
uncertainties remain about the natural history and 
epidemiology of this disease (Chapter 1.8, page 43). If a cure 
for vitiligo is to be found, further research is required in 
understanding the aetiology, epidemiology and natural history 
of vitiligo. Current treatments help to alleviate symptoms i.e. 
temporary repigmentation of vitiliginous patches, but these do 
not cure the underlying disease. 
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CHAPTER 2: FUTURE RESEARCH INTO THE 
TREATMENT OF VITILIGO. WHERE 
SHOULD OUR PRIORITIES LIE? 
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Abstract 
Background 
A recently XSGDWHG&RFKUDQHV\VWHPDWLFUHYLHZ³,QWHUYHQWLRQV
IRUYLWLOLJR´VKRZHGWKDWWKHUHVHDUFKHYLGHQFHIRUWUHDWPHQWRI
vitiligo is poor, making it difficult to make firm 
recommendations for clinical practice. 
Objective 
The aim of the vitiligo Priority Setting Partnership was to 
stimulate and steer future research in the field of vitiligo 
treatment, by identifying the ten most important research 
areas for patients and clinicians 
Methods 
The vitiligo Priority setting Partnership was established and 
included patients, healthcare professionals and researchers 
with an interest in vitiligo. Vitiligo treatment uncertainties 
were gathered from patients and clinicians, and then 
prioritised in a transparent process, using a methodology 
advocated by the James Lind Alliance.  
Results 
A total of 660 treatment uncertainties were submitted by 460 
participants. These were reduced to a list of the 23 most 
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popular topics through an online / paper voting process. These 
23 topics were then prioritised at a face-to-face workshop in 
London. The final list of the top ten treatment uncertainties, 
included interventions such as systemic immunosuppressants; 
topical treatments; light therapy; melanocyte-stimulating 
hormones (MSH) analogues; gene therapy; and the impact of 
psychological interventions on the quality of life of vitiligo 
patients. 
Conclusions 
The top ten research areas for the treatment of vitiligo provide 
guidance for researchers and funding bodies, to ensure that 
future research, answers questions that are important to both 
clinicians and patients. 
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2.1 Introduction  
2.1.1 Why set priorities in vitiligo?  
Eighty two interventions for vitiligo have been evaluated 
in clinical trials over the last 43 years. However, due to the 
small numbers of participants and heterogeneity of design of 
trials to date, it is difficult to make firm recommendations for 
clinical practice (Whitton et al., 2010). Indeed, in the face of 
so many treatment options and with so little information 
regarding their relative efficacy, it is difficult to identify which 
clinical trials are most important and timely.  
 
In order to address this concern, the Vitiligo Priority 
Setting Partnership was established, with the aim of helping to 
identify:  
i) Which interventions should be evaluated? 
ii) What the most important topics are to patients and 
clinicians? 
iii) Could these topics be answered by clinical research? 
 
2.1.2 Why involve patients and doctors in clinical 
research? 
It is increasingly recognised that patients and healthcare 
professionals have a key role to play in identifying important 
areas for research. The James Lind Alliance (JLA) is a 
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Department of Health and Medical Research Council funded 
initiative, which has been established to bring patients and 
FOLQLFLDQVWRJHWKHULQµ3ULRULW\6HWWLQJ3DUWQHUVKLSV¶WRLGHQWLI\
and prioritise the unanswered questions that they agree are 
most important (Chalmers, 2004). The pharmaceutical and 
medical technology industries and academia play an essential 
role in developing new treatments (James Lind Alliance, 
2010). However, the priorities of industry and academics are 
not necessarily the same as those of patients and clinicians. 
For this reason many areas of potentially valuable research are 
neglected. Therefore, it is essential that researchers and 
funding bodies are aware of the needs of patients and 
clinicians (James Lind Alliance, 2010). 
Vitiligo Priority Setting Partnership (PSP) was the first 
priority setting partnership in the field of dermatology and the 
third of its kind to have been convened by the JLA. Previous 
partnerships have been conducted in the fields of asthma 
(James Lind Alliance, 2010) and urinary incontinence (Buckley 
et al., 2010). 
All the uncertainties identified by the priority setting 
partnerships are added to the Database of Uncertainties about 
the Effects of Treatments (DUETs) 
(http://www.library.nhs.uk/duets/), in order to provide 
reference for funding bodies and researchers. Research 
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funding bodies in the UK, systematically scan important 
research resources to identify evidence gaps and make 
recommendations for research. This includes Cochrane 
systematic reviews and more recently DUETs. 
DUETs has been established in the UK to publish 
uncertainties about the effects of treatment which cannot 
currently be answered by referring to reliable up-to-date 
systematic reviews of existing research evidence. A treatment 
XQFHUWDLQW\H[LVWVZKHQ³QRXS-to-date systematic review 
exists, or up-to-date systematic reviews show that uncertainty 
FRQWLQXHV´(Lloyd et al., 2006), i.e. more research needs to be 
done to establish the effectiveness and safety of an existing or 
innovative treatment modality. 
 
2.2 Methods 
The aim of the vitiligo PSP was to reduce the number of 
uncertainties surrounding the treatment of this condition and 
to steer future research to questions of importance to both 
people living with the disease and people treating the disease. 
The James Lind Alliance provided guidance and support in 
conducting this PSP and played a role of facilitator to ensure 
the transparency and fairness of the process. The vitiligo PSP 
had 5 stages and adopted the methods advocated by the JLA 
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(James Lind Alliance, 2010) (Figure 2.1). I coordinated the 
vitiligo PSP, refined and complemented their current guidelines 
to meet the needs of this particular PSP and provided an 
important insight into their methodology. Stakeholders 
included professional organisations and patient support groups 
as outlined below.  
 
2.2.1 Stage 1: Initiation  
The aim of this stage was to establish the vitiligo PSP by 
raising awareness, identifying and engaging potential 
stakeholders.  
To raise awareness and to build the PSP, relevant professional 
bodies and patient support groups were  approached during 
this stage: British Association of Dermatologists (BAD); UK 
Dermatology Clinical Trials Network; NHS Evidence-Skin 
Disorders; Cochrane Skin Group; British Dermatological 
Nursing Group; Changing Faces; British Red Cross Camouflage 
Service; Skin Care Campaign; Primary Care Dermatology 
Society; Vitiligo European Task Force; British Association of 
Skin Camouflage and Vitiligo Society. Individual researchers, 
dermatologists, specialist nurses and psychologists with a 
special interest in vitiligo, were also informed. An invitation to 
participate was sent to the above relevant organisations and 
individuals. Representatives of interested organisations and 
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individual clinicians signed a response slip declaring their 
intention to take part in the process. The organisations were 
acting as advocates for their members; however it was 
essential that individuals with vitiligo (and their 
parents/carers), directly participated in the PSP process. In 
order to recruit these individuals, organisations advertised the 
PSP through various communication channels, such as articles 
in their newsletter (the Vitiligo Society UK) and adverts on 
their website (the Vitiligo Society UK and the Changing Faces). 
Information on the PSP was also available on the website 
(www.vitiligostudy.org.uk).  
Organisations were excluded from participating if they 
were considered to have conflicts of interest that may affect 
their views (Buckley et al., 2007). 
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Figure 2.1 Summary of methods of the vitiligo Priority Setting 
Partnership 
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The vitiligo PSP Steering group was established and 
included 12 members with knowledge and interest in vitiligo 
and representatives of relevant organisations such as the 
British Association of Dermatologists, the UK Dermatology 
Clinical Trials Network, the Vitiligo Society, the NHS Evidence-
Skin Disorders, the Cochrane Skin Group, the British 
Dermatological Nursing Group, Changing Faces, James Lind 
Alliance, and the Centre of Evidence Based Dermatology 
(CEBD) (see acknowledgment section). The role of the 
Steering Group was to oversee the overall development of the 
process, to advise on the direction and implementation of the 
research project, to ensure transparency and to resolve any 
disputes arising from differences of opinions, and generally to 
address any issue with major implications for the project. 
Initiation stage took place from August 2008 until February 
2009. 
 
2.2.2 Stage 2: Consultation 
The aim of this stage was to collect treatment 
uncertainties. An online and paper survey was undertaken that 
encouraged patients and clinicians to submit their questions 
about the treatment of vitiligo (see appendix 1, vitiligo survey 
for the vitiligo Priority Setting Partnership).  
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Literacy skills were considered when developing this 
survey and consequently they were designed to be simple in 
reading ability. The information sheets were designed to be 
easy to understand and provided the names of the 
investigators. They also outlined the importance of the study, 
what the study involved, the voluntary nature of the study, 
the complaints procedure, the confidential and anonymous 
nature of the research (Oppenheim, 2000), when and where 
the results of the study will be published, the name of the 
organisation commissioning the study and the organisation 
undertaking the study.  
Completing the survey was considered consenting to 
participate in the research and for allowing the uncertainties 
provided to be published on DUETs.  
Basic demographics on participants such as age, sex, 
relation to the subject (patient, clinician, parent or carer of 
child with vitiligo) were also gathered. Participants were 
assured of anonymity. 
All data were stored safely and securely. Electronic files 
were password protected and hard copies of data (e.g. 
surveys) were stored in a locked filing cabinet, with only the 
investigators directly involved in this study having access, in 
accordance with the Data Protection Act (1998).  
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Surveys were chosen as the data collection method 
rather than structured interviews or focus groups, because 
there was no potential for interview bias (Grey, 2004) or 
interview effects (Aldridge, 2001). Furthermore, because the 
researcher did not have to be present whilst the survey was 
completed, the sample could be drawn from a wide 
geographical area (Aldridge, 2001). For practical and ethical 
reasons, the parents of children with vitiligo were asked to 
complete the sXUYH\RQWKHLUFKLOG¶VEHKDOI 
It was anticipated that approximately 100 individuals 
would be recruited to take part in this study. Ideally, random 
selection of participants would have been used; however time 
constraints, budgets and the sample to be recruited, meant 
that this was not plausible. Consequently, the sample was 
recruited utilising a combination of sampling methods, 
including volunteer sampling, purposive sampling and 
convenience sampling. Volunteer sampling involved recruiting 
participants that responded to an advert in a newsletter or on 
a website of relevant organisations as above and volunteered 
to take part (Grey, 2004). Purposive sampling, involved 
selecting a sample with attributes of interest to this PSP 
(Aldridge, 2001). In other words, articles were placed in 
newsletters and on websites targeting the population of 
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interest i.e. patients with vitiligo and their carers and clinicians 
with interest in this disease.  
Convenience sampling, consisted of deliberately 
targeting and selecting participants (Aldridge, 2001). 
Individuals with vitiligo who were in contact with the CEBD and 
the JLA previously, were directly contacted, informed of the 
study and asked if they would like to participate. These 
sampling methods were chosen in order to recruit as larger 
sample as possible from the population of interest.  
Therefore, paper copies of the questionnaire and 
participant information leaflets with a stamped addressed 
envelope were sent to the Vitiligo Society (n = 1268) and to 
the British Association of Dermatologists (n = 835). Emails 
were sent to members of the UK Dermatology Clinical Trials 
Network (n = 500), and details of the project (with link to the 
online survey www.vitiligostudy.org.uk) were advertised on 
the websites and in the newsletters of the relevant 
organisations listed above. 
Additional treatment uncertainties  and research 
recommendations were identified from existing sources of 
current evidence: updated Cochrane systematic review  2010 ´
,QWHUYHQWLRQVIRUYLWLOLJR´(Whitton et al., 2010) and the BAD 
guidelines for diagnosis and management of vitiligo 
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(Gawkrodger et al., 2008). The consultation stage took place 
from March 2009 to the end of August 2009. 
 
2.2.3 Stage 3: Collation 
7KHDLPRIWKLVVWDJHZDVWRFUHDWHD³ORQJ-OLVW´RI
uncertainties by collating, refining submitted uncertainties and 
rewording similar questions following the methodology below: 
x Step 1: creation of taxonomy based on currently 
known interventions. 
Before going through each submitted question 
individually, a list of know existing treatment options i.e. 
treatment taxonomy was created. The vitiligo PSP 
taxonomy was based on the Cochrane systematic review 
³,QWHUYHQWLRQV IRUYLWLOLJR´7KHPDLQFDWHJRULHVRI
LQWHUYHQWLRQVZHUHDGRSWHGIURPWKH³GHVFULSWLRQRI
LQWHUYHQWLRQ´VHFWLRQRIWKHUHYLHZDQGLQFOXGHG
phototherapy, systemic (oral) treatments, topical 
treatments, complementary treatments, combination 
treatments and other treatment modalities. Other main 
categories included diet and lifestyle, vitamins and 
supplements and complementary/alternative treatments. 
After the main categories were created, subcategories 
were added to each one of these (Table 2.1).  
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Table 2.1 Examples of main categories and subcategories for 
vitiligo PSP.  
Main category Subcategories 
Phototherapy (light therapy) Narrow Band-UVB 
Broad Band-UVB 
UVA 
PUVA 
PUVAsol 
Excimer light 
Other light therapies 
Psychological interventions Cognitive Behavioural Therapy 
Group therapy 
One to one therapy 
Other psychological interventions 
Diet and lifestyle Diet   
Lifestyle 
Other treatments  Gene therapy 
Stem cells 
Other treatments  
 
x Step 2: allocation of originally submitted uncertainty to 
the created taxonomy. 
Each submitted uncertainty was allocated into at least 
one of the previously created categories. 
x Step 3: confirmation that submitted question was an 
uncertainty. 
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All uncertainties were checked against the existing 
systematic review and the BAD guidelines to ensure that 
they had not been answered already.  
x Step 4:  exclusion of non-treatment uncertainties. 
Non-specific questions, statements and questions about 
prevention, aetiology or genetics of vitiligo were 
excluded (Table 2.2).  
x Step 5: long list of indicative uncertainties  
An indicative uncertainty was defined as a refined and 
rephrased uncertainty which combined two or more of 
originally submitted uncertainties covering the same or 
similar topic. Each indicative uncertainty, represented a 
broad area for research, rather than focussing on a 
specific research question. This was necessary in order 
to reduce the list of uncertainties to a manageable 
number (Table 2.3). Duplicate submissions were 
combined, but their frequency and source was recorded. 
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Table 2.2 Examples of non-treatment uncertainties  
Originally submitted uncertainty Reference to 
What is the cause of acquired vitiligo?   Aetiology 
Which is the best method/treatment available to aid 
repigmentation? 
Non-specific 
Why patchy distribution?  Non-specific 
The source of the disease: is it viral, genetic or 
environmental? Why is it only certain patterns occur 
in some areas of body?   
Aetiology and 
distribution 
What makes vitiligo become active after being stable 
for many years? 
Triggering 
factors/Spreading 
Can you diagnose the condition or the faulty gene in 
an unborn child? 
Genetics 
My personal opinion: stress appears to exaggerate 
depigmentation Is there any evidence of this and if 
stress relief eases the condition? 
Aetiology/Triggering 
factors 
GP/Dermatologists views on treatments available for 
vitiligo is usually negative.  
Guidance needed 
I have tried UVB light treatment for 4 years and 
ZHQWWR'HDG6HDLQ-RUGDQ««,KDGJRRG
improvement on the face but rest of the body still 
same (no change). 
Statement 
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Table 2.3 Examples of formatting originally submitted 
questions into indicative uncertainties in vitiligo PSP. 
 
Originally submitted 
uncertainty 
Indicative 
uncertainty 1 
Indicative 
uncertainty 2 
Comments 
1 What foods/vitamins help? What role does 
diet play in the 
management 
of vitiligo? 
What role do 
vitamins and 
supplements 
play in the 
management of 
vitiligo? 
Reference made 
to two 
interventions 
2 Topical tacrolimus plus light  How effective is UVB light when 
combined with creams and 
ointments for the treatment of 
vitiligo? 
Due to the large 
number of 
combinations of 
UVB and topicals, 
these were 
combined  
3 Steroids plus NB-UVB 
4 Is long term tacrolimus 
ointment safe and effective 
for vitiligo treatment? 
Are calcineurin 
inhibitors 
effective? 
 
 Are there any 
side effects 
associated with 
using topical 
calcineurin 
inhibitors for the 
treatment of 
vitiligo? 
Reference made 
to effectiveness 
and safety 
5 Do calcineurin inhibitors really 
work? 
 
6 How long should patient use 
tacrolimus to treat vitiligo? 
What is the optimal duration and 
optimal timing for the treatment of 
vitiligo with tacrolimus? 
 
7 How often does (super) 
potent steroid or tacrolimus 
result in useful 
repigmentation? 
Which treatment is more effective: 
steroid cream or 
tacrolimus/pimecrolimus? 
Due to the large 
number of 
combinations of 
various strengths 
of topical steroids  8 How does tacrolimus 
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compared to steroid? and calcineurin 
inhibitors, these 
were combined  
9 Effectiveness or potent topical 
steroid or Protopic RCT: 
potent steroid vs. Protopic vs. 
placebo 
10 My grandmother had her 
thyroid removed and I have 
heard there may be a link 
between thyroid problems and 
vitiligo. Are there tests and 
treatments linked to this that 
could be further investigated? 
Is there any evidence that 
people with vitiligo who have 
also been treated for thyroid 
problems see any 
improvement in their skin? 
Does the treatment of underlying 
autoimmune condition in patient 
with vitiligo is of any benefit? 
Autoimmune 
conditions include 
thyroid problems, 
diabetes etc. 
11 Is there link to other 
conditions such as thyroid, 
diabetes that prescribed 
medicines could help? 
 
x Step 6: Dealing with non-specific uncertainties.  
Non-specific uncertainties mainly referred to a group of 
interventions. Being too broad, they could not be 
translated into meaningful indicative uncertainties, they 
were counted. This information assisted during the final 
workshop (Table 2.4).  
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Table 2.4 Examples of non-specific treatment uncertainties 
and their count information. 
Non-specific indicative 
uncertainties 
Count Source 
Effectiveness of light therapy 
for the treatment of vitiligo  
32 Systematic review, Vitiligo Society, 
British Association of Dermatologists 
Surgical procedures for vitiligo 11 British Association of Dermatologists 
Which is the most effective 
topical treatment? 
10 Systematic review, British Association 
of Dermatologists 
Optimal maintenance regime 
after light therapy 
3 Systematic review, Vitiligo Society, 
British Association of Dermatologists 
Safety of topical treatments 1 British Association of Dermatologists 
 
Throughout the process, the Steering Group members 
conducted ten teleconferences in order to resolve disputable 
issues such as whether a submitted question should be 
excluded or which category it fits best. All indicative 
XQFHUWDLQWLHVLH³ORQJOLVW´ZHUHHQWHUHGLQWRDVSUHDG-sheet 
and into DUETs.  Collation stage took place between August 
2009 and December 2009. 
 
2.2.4 Stage 4: Ranking exercise (Interim prioritisation 
exercise) 
7KHDLPRIWKHUDQNLQJH[HUFLVHZDVWRFUHDWHD³VKRUW-
OLVW´RIXQFHUWDLQWLHVfor the final prioritisation workshop and to 
reduce their number to no more than 23. As the majority of 
participants from the consultation stage expressed a 
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willingness to engage in the process further, a link to the 
website (www.vitiligostudy.org.uk) was sent via email to those 
people. The ranking exercise was also advertised on the 
websites and in the newsletters of relevant organisations, as 
per the consultation stage. In addition, advertisements and 
articles were placed in the Voice magazine for black and ethnic 
minorities, the British Dermatological Nursing Group magazine 
(Eleftheriadou et al., 2009) and the bulletin of the Primary 
Care Dermatology Society (Eleftheriadou, 2009) to target 
specific groups that had been under-represented during the 
consultation stage.  Advertisements were also disseminated to 
attendees of the RoyDO6RFLHW\RI0HGLFLQHPHHWLQJ³0HGLFLQH
DQG0HYLWLOLJR´ 
 
2.2.4.1 Ranking website 
During the ranking exercise, a specific study website was 
developed (www.vitiligostudy.org.uk) to allow participants to 
rank uncertainties online. An innovative voting system was 
conceived by myself and developed with IT support from the 
University of Nottingham. All the uncertainties for the ranking 
exercise were written in a patient-friendly format making them 
comprehensive for participants without clinical or scientific 
background. The voting system was piloted before going 
online. 
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All uQFHUWDLQWLHVIURPWKH³ORQJOLVW´ZHUHGLYLGHGLQWR
broad categories based on the taxonomy created during the 
collation stage. These broad categories were displayed in a 
circle on the first page of the website (Picture 2.1).  
 
 
Picture 2.1 Ranking website: broad categories displayed in a circle. The 
mouse arrow is placed on the surgical treatments category and the yellow 
box contains the pop up help text on the same category. 
 
Displaying categories in a circle was used to guard 
against selection bias, which might have been an issue if the 
broad categories were put into a list. The order in which the 
categories were displayed was random every time a new 
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participant entered the website. Instructions on how to vote 
and information on the vitiligo PSP was also available on the 
website. A demonstrating video 
(http://www.youtube.com/watch?v=VeWl6RPjYxU) was also 
available on the website. 
Help text, with brief information on treatment modalities 
which were included in each broad category appeared by 
placing the mouse arrow on each category. By clicking on each 
broad category, participants were able to review all treatment 
modalities included in more details. These treatment 
modalities were also displayed into a randomly rotating format 
same as the broad categories (Picture 2.2).  
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Picture 2.2 Ranking website: treatment modalities included in the topical 
treatments (treatments applied to skin) category. The mouse arrow is 
placed on the piperine/black pepper subcategory. The yellow box contains 
pop up help text on piperine. 
 
Alongside popular and widely used treatment modalities 
such as topical corticosteroids, other less known interventions 
such as melagenina were also included in the long list; 
therefore it was important that participants were familiar with 
all of the proposed treatments before voting. 
 ,QRUGHUWRHQVXUHWKDWDQGWRDYRLG³WDUJHWHGYRWLQJ´
i.e. viewing only one or two broad categories, which interested 
participants more or were more familiar to them and ignoring 
the rest of the categories, it was mandatory to view all six 
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broad categories (by clicking on them) before voting.  In order 
to assist the participants in keeping track of which main 
categories they had already reviewed, the category button 
changed colour indicating that it was accessed (Picture2.3). 
 
 
Picture 2.3 Ranking website: topical treatments (treatments applied to 
skin) broad category changed colours from blue to green indicating that 
this category was accessed. 
 
After clicking on all 6 broad categories and choosing the 
intervention of their choice, participants were able to review 
specific uncertainties surrounded each intervention  and vote 
for up to 3 selected uncertainties (Picture 2.4). 
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Picture 2.4 Ranking website: three uncertainties selected 
 
Paper copies of the questionnaire were also available to 
download from the website, or by contacting the study team 
directly. The order in which uncertainties appeared on the 
paper survey was randomised in order to guard against 
response bias.  
People responding to the survey were asked to complete 
their demographics details. The same demographic questions 
were recorded as per consultation stage of survey including 
age, sex, and relation to the subject (patient, clinician, parent 
or carer of child with vitiligo). The Steering Group 
recommended the inclusion of ethnicity question at this stage 
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as it was important to know the ethnic grouping of participants 
for this work, given the nature of the condition.  
The online and paper votes were pooled together for the 
final meeting of the Steering group. The aim of the meeting 
was to review the results of the ranking exercise DQG³VKRUW
OLVW´WKH7RS. In order to ensure that short listing for the 
final priority setting workshop was well balanced and 
representative of all groups, the list of Top 25 uncertainties for 
each representative group (healthcare professionals, patients 
and black and ethnic minorities) were also reviewed.  
The ranking exercise was open for a period of one 
month, from January 2010 until February 2010. 
 
2.2.5 Stage 5: Final Prioritisation Workshop 
The aim of this workshop was to identify the top ten 
most important treatment uncertainties for vitiligo by creating 
consensus through a face-to-face meeting of healthcare 
professionals and patients. Members of the Steering Group 
and participants from the ranking exercise attended the final 
prioritisation workshop. A participant pack was prepared for 
each attendee and included: glossary of research terms, 
background information on vitiligo PSP including the aim of the 
Final Prioritisation Workshop and agenda of the day.  
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In preparation for the workshop, cards were made for 
each shortlisted uncertainty. Each card included detailed 
information on each of the 23 uncertainties: a list of original 
submitted uncertainties, which were later merged into this one 
uncertainly and whether the uncertainty was featured in the 
systematic review or guidelines for vitiligo or the top 25 for 
patients, clinicians, black and ethnic minorities groups.  
Efforts were made to ensure that equal numbers of 
patients and healthcare professionals attended. The workshop 
was a full day event, held at the London offices of the British 
Association of Dermatologists on 25th March 2010 (Picture 
2.5). 
Consensus was reached by using a nominal group 
technique (James Lind Alliance Guidebook 2010). The 
participants were separated into four small groups comprising 
a mixture of healthcare professionals and patients. Initially, 
the groups shared their reflections on the shortlisted 
uncertainties and submitted their personal rankings.  
The groups were then asked to place the uncertainties in 
order of priority. The ranked uncertainties from each group 
were reported to the facilitator and pooled to give an 
aggregated score for each uncertainty. The aggregate scores 
were then revealed to the groups and discussed again. Groups 
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were again asked to agree their top ten uncertainties, in light 
of the previous discussions, and these were pooled to achieve 
a revised and final list that was agreed by all participants 
(Picture 2.6). 
 
 
Picture 2.5 Final prioritisation workshop at the British Association of 
Dermatologists House, London, UK 
From left up to right down: Dr Viktoria Eleftheriadou; group of attendees; 
Mrs Sally Crowe-Independent JLA advisor and Chair of the Steering Group; 
Mrs Jennifer Viles-Chair of the Vitiligo Society UK (patient support group) 
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Picture 2.6 Fours groups of participants during the final prioritisation 
workshop at the British Association of Dermatologists House, London, UK  
The above methods used during the vitiligo Priority 
Setting Partnership, as well as previous PSPs are outlined in 
the James Lind Alliance guidebook 
(http://www.jlaguidebook.org/). 
2.2.6 Personal contribution 
The initiation of the process was already in place when I 
commenced the post of Research Associate at the Centre of 
Evidence Based Dermatology (CEBD) (August 2009). 
Representatives of the JLA, as well as my predecessor had 
established the Steering group and contacted relevant 
organisations, as above.  I took over the project since then, 
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amended the original protocol in light of submissions from the 
consultation stage. I undertook all the tasks from processing 
the uncertainties, creating the taxonomy and the step by step 
approach described above, to inputting the final ³long list´ into 
a spread-sheet, ready for uploading on DUETs database.   
Also, I conceived and developed the innovative voting 
system, the text and the demonstration video for the vitiligo 
study website. I worked closely with IT support team to bring 
my idea and vision into practice and developed a user-friendly, 
easy to navigate website.  
Finally, I analysed all the data from all stages of the 
PSP, organised and prepared the necessary material and 
played a role of organiser and facilitator during the Final 
Prioritisation workshop. 
 
2.2.7 Ethics 
This project was approved by the Medical School 
Research Ethics Committee, University of Nottingham, UK.  
Ethics Reference No: G/2/2009 
 
2.2.8 Statistical methods  
We aimed for a minimum of 100 participants in the 
consultation and the ranking exercise and for 20 participants 
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for the final prioritisation workshop. This sample size was 
estimated on the basis of previous JLA priority setting 
partnerships (Elwyn et al., 2009), and determined by the 
timeframe available for the vitiligo PSP. Data from all stages 
were stored and analysed in MS Access 2007. 
 
2.3 Results  
2.3.1 Stages 2 and 3: Consultation and collation 
The response rate for members of the Vitiligo Society 
was 24% (307/1268) and for BAD/UKDCTN members was 
14% (119/835).  Sixty-six per cent of responses (302/461) 
were from patients, 31% (142/461) were from healthcare 
professionals, and 3% were from other sources. More women 
responded than men (53% women, 30% men, 17% did not 
specify), and the majority were aged 30-60 years old (8% 
were <30 years, 50% were 30-60 years, 25% were > 60 
years, and 17% did not specify).  
Of the 2,303 surveys circulated, 461 (20%) were 
returned. This resulted in 1,427 questions about vitiligo. Non-
treatment questions (n = 767), about the natural history of 
vitiligo, its aetiology and prevention, were excluded. Overall, 
660 uncertainties that specifically related to the treatment of 
vitiligo were gathered during the consultation stage. Thirty-
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one per cent were from healthcare professionals (206/660), 
48.5% were from patients (320/660) and 20.5% were 
unknown (134/660). An additional 58 treatment uncertainties 
were identified from the BAD guidelines and the updated 
Cochrane systematic review. The resulting 718 uncertainties 
ZHUHUHILQHGLQWRD³ORQJ-OLVW´RIWUHDWPHQWXQFHUWDLQWLHV
which were used for the ranking exercise.  
 
2.3.2 Stage 4: Ranking exercise (Interim prioritisation 
exercise) 
In total, 230 people (patients: 72%, health care 
professionals: 23%, did not specify: 5%) responded to the 
ranking exercise, submitting 638 individual votes.  Each 
participant voted for up to three of their favourite 
uncertainties. Forty one per-cent of participants (95/230) 
submitted their vote by completing a paper copy 
questionnaire, 48% (111/230) opted for online ranking and 
11% (24/230) submitted their votes by submitting an 
electronic copy of the questionnaire. 
Twenty per-cent of paper (19/95) voters were excluded 
as they submitted more than three favourite topics. The 
number of votes per uncertainty ranged from 49 to 0 (median 
5). The demographic characteristics of participants in the 
ranking exercise were broadly similar to those in the 
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consultation stage (63% were women, and 55% were aged 
between 30 and 60 years). Of those who specified their 
ethnicity (n = 127), 42% were white and 12.6% were from 
black and ethnic minorities. At the end of this stage, 23 
indicative uncertainties were identified for use in the final 
prioritisation workshop (Table 2.5). 
 
2.3.3 Stage 5: Final Prioritisation Workshop 
The workshop was attended by 47 people: 21 were 
SDWLHQWVRUSDWLHQWV¶UHSUHVHQWDWLYHVZHUHKHDOWKFDUH
professionals (including dermatologists, specialist nurses, 
general practitioners with specialist interest in dermatology, 
researchers, camouflage practitioners, and a trichologist / 
psychologist). In addition, 7 JLA facilitators were present, and 
2 observers (one from the National Institute of Health and 
Clinical Excellence (NICE), and one from the National Institute 
of Health Research National Evaluation, Trials and Studies 
Coordinating Centre (NIHR NETSCC, Internal Relations 
Directorate) (see vitiligo PSP acknowledgement section).  
By the end of the workshop, a ranked list of the top ten 
treatment uncertainties had been collated and agreed by 
consensus. In addition, two treatment uncertainties were 
suggested as ³RQHVWRZDWFK´DVWKHVHLQWHUYHQWLRQVZHUH
either still in an early investigative stage, or trials were 
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currently on-going (Table 2.5). A summary of the results of 
the vitiligo PSP is presented in Figure 2.2. 
 
Table 2.5 The Top 10 DQGWKHWZR³WRZDWFK´treatment 
uncertainties (grey shading) and the raking order of all 23 
treatment uncertainties (short list) for vitiligo, following the 
final prioritisation workshop  
Rank Indicative uncertainty 
1 How effective are immunosuppressants in treating vitiligo? 
2 How much do psychological interventions (such as counselling) help people 
with vitiligo?   
3 Which treatment is more effective for vitiligo: light therapy or calcineurin 
inhibitors (e.g. tacrolimus, pimecrolimus)?  
4 How effective is UVB light therapy when combined with creams or 
ointments (e.g. steroid creams) in treating vitiligo? 
5 What role might gene therapy play in the treatment of vitiligo?  
6 How effective are hormones or hormone related substances that stimulate 
pigment cells (MSH analogues, afamelanotide) in treating vitiligo? 
7 Which treatment is more effective for vitiligo: calcineurin inhibitors (e.g. 
tacrolimus, pimecrolimus) or steroid creams/ointments? 
8 Which treatment is more effective for vitiligo: steroid creams/ointments or 
light therapy? 
9 How effective is the addition of psychological interventions to patients using 
cosmetic camouflage for improving their quality of life? 
10 How effective is pseudocatalase cream (combined with brief exposure to 
UVB light) in treating vitiligo?  
11 How effective is piperine (black pepper) cream in treating vitiligo? 
ONE TO WATCH 
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12 What role might stem cell therapy play in treating vitiligo?  
ONE TO WATCH  
13 How effective is the transplant of pigment cells (autologous melanocyte 
transplantation) in treating vitiligo? 
14 Which treatment is more effective for vitiligo: PUVA or UVB light therapy? 
15 Which treatment is more effective for improving the quality of life of 
patients with vitiligo: cosmetic camouflage or a treatment to aid 
repigmentation? 
16 What role do vitamins and supplements play in the management of vitiligo? 
17 How much does depigmentation help patients with vitiligo? 
18 What role does diet play in the management of vitiligo? 
19 How effective is natural sunlight in achieving repigmentation of the skin in 
patients with vitiligo? 
20 What role might lifestyle (e.g. stress, smoking) play in the management of 
vitiligo? 
21 How effective are steroid injections into the skin in treating vitiligo? 
22 How effective is VITIX in treating vitiligo? 
23 How effective are homeopathic remedies in treating vitiligo? 
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Figure 2.2 Summary of the results of the vitiligo priority 
setting partnership 
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In addition, important recurring themes for researchers 
to consider when developing future trials on vitiligo emerged 
from non-specific submissions (see collation stage: step 6) 
and are summarised below (Table 2.6).  
 
Table 2.6 General themes to be considered when designing 
future vitiligo trials. 
General themes 
1. Which treatments are effective and safe for children?  
2. Do treatment success rates differ according to the site(s) affected, or the 
gender/age/ethnicity/skin phototypes of patients? 
3. What are the long term outcomes of treatments for vitiligo (especially side-
effects)?  
4. What is the optimal duration and optimal timing for treatments of vitiligo?  
5. What is the optimal maintenance regimen in order to prevent relapse?  
6. Interventions for segmental vitiligo  
 
Finally, feedback following the final prioritisation 
workshop showed that attendees were either very satisfied 
(8/22) or satisfied (14/22) with the workshop outcome: 
³([FHOOHQWZHOORUJDQLVHG´³)RUPDWDOORZHGIRUYDULHG
H[SHUWLVHDQGVKDULQJRIYLHZVDQGRSLQLRQV´³([FHOOHQW
H[FKDQJHRIYLHZV´´3HRSOHZHUHOLVWHQHGWR´³$YHU\
VXFFHVVIXOGD\´The chair of the JLA, Mr Lester Firkin, 
commented on the above resuOWV³All of these are very good 
indeed - I would be thrilled if any PSP I ran came back at half 
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this level´9LWLOLJR363ZDVDQQRXQFHGWKHPRVWVXFFHVVIXO
PSP so far by the JLA. 
 
2.4 Discussion 
Vitiligo has traditionally been given a relatively low 
priority in the dermatology research agenda, as shown by the 
number and quality of studies on vitiligo to date.  At present, 
the only intervention licensed for use in vitiligo patients is 
camouflage, and there is an urgent need for randomised 
controlled trials of interventions for vitiligo (Gawkrodger et al., 
2008). The updated systematic review (Whitton et al., 2010) 
is helpful in identifying many important research gaps for 
clinical trials, but these have largely come from the research 
community, and may not reflect the questions that patients 
and clinicians have.  
 
2.4.1 Implications for research 
The identified uncertainties provide a steer for future 
research activity by guiding researchers and funding bodies to 
questions of importance to patients and healthcare 
professionals. All of the uncertainties have been added to 
DUETs, and are freely available at www.duets.nhs.uk. At this 
point it is important to remember that the vitiligo Priority 
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6HWWLQJ3DUWQHUVKLSDLPVWRLGHQWLI\³WUHDWPHQWXQFHUWDLQWLHV´
These, are then used as refeUHQFHWRLQIRUPIXWXUH³UHVHDUFK
TXHVWLRQV´DVGHYHORSHGE\LQGLYLGXDOUHVHDUFKWHDPV,WLV
entirely possible that one treatment uncertainty will result in 
several related research questions.  
Based on the identified most important treatment 
uncertainties for vitiligo, the following are recommended: 
x More research on the effectiveness and safety of 
systemic immunosuppresants for the treatment of 
vitiligo such as methotrexate, cyclosporine. Research in 
this field would potentially contribute to our knowledge 
about the aetiology of the disease, which is believed to 
have a strong autoimmune component (Rezaei et al., 
2007; Westerhof and d'Ischia 2007) (1st uncertainty). 
x Evaluation of NB-UVB combination therapies with 
topical agents (which also reflects the current research 
trend). It was shown by the Cochrane systematic review 
that combination treatments seem to be more effective 
than monotherapies (Whitton et al., 2010) (4th 
uncertainty). 
x Evaluation of the effectiveness and safety of NB-
UVB. More detailed information is needed to answer 
TXHVWLRQVVXFKDV³VKRXOGWKHILUVWOLQHWUHDWPHQWIRU
vitiligo be topical agents (topical steroids or calcineurin 
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inhibitors) or more aggressive intervention such as NB-
89%´$IDFWRULDOWULDOGHVLJQFRXOGHYDOXDWHDOOWKUHH
treatment options in one trial (3rd and 8th uncertainties). 
x Evaluation of currently available and widely used 
treatments such as topical corticosteroids and 
calcineurin inhibitRUVLQD³KHDGWRKHDG´UDQGRPLVHG
controlled trial (7th uncertainty).   
x Evaluation of psychological interventions by 
conducting a systematic review of the current literature, 
and substantial pilot / and exploratory qualitative work 
prior to progressing to a full randomised controlled trial. 
Together with active treatments, psychological 
interventions are believed to be of great importance. 
More evidence is needed to establish the role of 
psychological support as monotherapy (2nd uncertainty), 
as well as in combination with other treatments for 
vitiligo (9th uncertainty). 
x Evaluation of innovative treatments such as 
afamelanotide and pseudocatalase, which seem to be 
important and promising to both clinicians and patients 
(6th and 10th uncertainty). It is prudent to express some 
degree of scepticism regarding the effectiveness of 
pseudocatalase based on the up-to-date evidence. Only 
one pilot non-randomised controlled trial has been 
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published claiming the effectiveness of pseudocatalase 
for the treatment of vitiligo (Schallreuter et al., 2002). 
However, a subsequent randomised double-blind 
placebo-controlled trial failed to confirm previous 
success (Bakis-Petsoglou et al., 2009). In addition, 
results of a large randomised controlled trial, funded by 
the pharmaceXWLFDO³6WLHIHO´LV\HWWREHSXEOLVKHG
despite the fact that the trial was finished many years 
ago (personal communication with participants of the 
trial from the Vitiligo Society). 
x More research to be done into the pathophysiology 
and the aetiology of the disease, based on the great 
interest expressed by clinicians and patients on 
exploration of potential effectiveness of gene therapy 
and stem cells (5th uncertainty and 12th ³RQHWRZDWFK´
uncertainty). 
To conclude, I would like to note that by recommending 
the above, I am not commenting on the legitimacy of the 
interventions that have been prioritised, but simply reporting 
what clinicians and patients identified as important research 
topics in order to meet their needs. 
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2.4.2 Reflections on the process 
One might argue that the response rate for the vitiligo 
PSP was rather low (consultation stage response rate=20%); 
however the number of the participants by far exceeded our 
expectations and approximately doubled the number of 
participants who took part in previous priority setting 
partnerships (Elwyn et al., 2009). This was mainly due to the 
strength of existing collaborations with the UK DCTN and the 
Vitiligo Society.  I believe that the innovative and unusual 
nature of this project means that it is inappropriate to apply 
the same criteria for the response rate of this PSP as for other 
surveys.  
In order to inform future Priority Setting Partnerships, it 
is helpful to outline the following key challenges and 
considerations that I faced during the management of this 
PSP: 
x Large number of participants. Involving such a 
large number of participants in all stages of the process 
was extremely challenging. This was mainly due to 
various levels of expertise, background information, and 
experience of the vitiligo PSP participants. This was 
particularly relevant during the final prioritisation 
workshop, where participants were making decisions 
based on very different frames of reference. It is 
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prudent, therefore, to identify attendees of the final 
prioritisation workshop as soon as possible and keep 
them fully informed at every stage of the PSP. It would 
also be helpful to allow time at the start of the final PSP 
workshop to ensure that all participants are aware of the 
current evidence base for the treatment uncertainties 
being considered on the day. 
x Online ranking website. Previously, the interim 
prioritisation stage of a PSP was done by using a paper 
FRS\RIWKH³ORQJOLVW´RIWUHDWPHQWXQFHUWDLQWLHV and 
asking participants to read through it and choose up to 3 
uncertainties. In vitiligo PSP, with so many uncertainties 
involved and because I was concerned that members of 
the Priority Setting Partnership may not be sufficiently 
representative of the wider vitiligo community, I opted 
to develop an online ranking tool. This proved to be 
time-consuming and technically challenging; mainly 
because this KDGQ¶WEHHQ done before and it was difficult 
to estimate the amount of time and resources of IT 
personnel required to perform this task. Nevertheless, it 
held several methodological advantages, in that the 
website was open to anyone with an internet connection 
and an interest in vitiligo. The innovative voting system 
considerably reduced the number of uncertainties that 
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participants needed to review prior to submitting their 
votes, whilst still providing an overview of all the 
treatment modalities. Also, the website allowed us to 
provide far more information about the scope and aims 
of the project. By creating this online tool, less resources 
and time was required to print, pack and send paper 
questionnaires to the participants. Based on the voting 
results, roughly equal number of participants opted for 
paper and online ranking. However, 20% of paper votes 
were excluded as more than three options were 
submitted compared to none (0%) of online votes (as 
the tool did not allow submission of more than three 
uncertainties). Both paper and online, are suitable 
methods to use and both have their advantages and 
disadvantages. For future PSP exercises, the choice of 
method used will depend on the number of uncertainties 
created, and the availability of technical support. 
x Structure of indicative uncertainties. Many of the 
originally submitted uncertainties (during consultation 
stage) were broad and non-specific, could imply various 
potential research questions, or did not specify the 
comparator, the duration of treatment or the population. 
On the other hand, some of the uncertainties derived 
from the systematic review, the BAD guidelines, and 
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individual responders, were very specific and focused. 
For that reason, it might be useful to keep the indicative 
uncertainties as broad as possible to allow flexibility but 
sufficiently narrow to ensure the question is meaningful. 
The following format for different types of questions 
submitted was proposed (Table 2.7). 
 
2.4.3 Implementation of the results  
The next step of my research was to conduct a pilot RCT 
on one of the top ten uncertainties and to work with the UK 
Dermatology Clinical Trials Network (UK DCTN) 
(www.ukdctn.org) to develop a protocol for a national multi-
centre RCT. 
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Table 2.7 Structure used to refine the questions into 
indicative uncertainties. 
Type of question Format of question 
Effectiveness of a single treatment How effective is [treatment X] in 
treating vitiligo? 
One treatment compared to another Which treatment is more effective 
in treating vitiligo: [treatment X 
or treatment Y]? 
One treatment combined with another How effective is [treatment X] 
when combined with [treatment 
Y] in treating vitiligo? 
Management of the disease, rather than 
³WUHDWPHQW´HJFDPRXIODJHRU
psychological interventions) 
How much does [treatment X] 
help patients with vitiligo? 
Speculative treatments not yet on the 
market (e.g. gene therapy, stem cell 
therapy) 
What role might [treatment X] 
play in the treatment of vitiligo? 
 
In March 2010, five research vignettes (Table 2.8) were 
submitted to the NIHR HTA prioritisation panel in order to try 
and influence their research agenda based on the identified 
topics. Following various stages of the process, two of the 
uncertainties (4th and 8th) were merged and the topic was 
advertised as an open call by the HTA, at the beginning of 
2012 (see Chapter 5).  
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Table 2.8 Research activity and research suggestions 
following Vitiligo PSP (From 2007 until December 2012) 
Treatment uncertainty on vitiligo Research commissioned/notes 
1. Does treatment with 
immunosuppressants help patients 
with vitiligo? 
HTA suggest a case series first before 
trial feasibility (Oct 2010) 
2. How much do psychological 
interventions (such as counselling) 
help people with vitiligo?   
 
Submitted as an HTA vignette. 
Combined with 9th uncertainty: 
How effective is the addition of 
Cognitive Behavioural Therapy (CBT) to 
patients using cosmetic camouflage for 
improving their quality of life?  
3. Which treatment is more effective 
for vitiligo: light therapy or 
calcineurin inhibitors (e.g. 
tacrolimus, pimecrolimus)?  
Submitted as an HTA vignette: 
Is narrow band ultra-violet light 
therapy (NB-UVB) better than 
calcineurin inhibitors for the treatment 
of vitiligo?  
4. How effective is UVB light therapy 
when combined with creams or 
ointments (e.g. steroid creams) in 
treating vitiligo? 
Submitted as an HTA vignette. 
Feasibility trial on hand-held home 
phototherapy is now completed as part 
of SPRUSD Programme Grant (Chapter 
4).  
5. What role might gene therapy play 
in the treatment of vitiligo? 
Too early for HTA  
Basic science research 
6. How effective are hormones or 
hormone related substances that 
stimulate pigment cells (MSH 
analogues, afamelanotide) in treating 
vitiligo? 
Clinuvel is running  a small pilot multi-
centre trial on afamelanotide for the 
treatment of vitiligo 
 
7. Which treatment is more effective 
for vitiligo: calcineurin inhibitors 
Submitted as an HTA vignette: 
Is combination of calcineurin inhibitors 
Page 126 of 338 
(e.g. tacrolimus, pimecrolimus) or 
steroid creams/ointments? 
with topical corticosteroids better than 
use of either treatment alone for the 
treatment of patients with vitiligo? 
8. Which treatment is more effective 
for vitiligo: steroid creams/ointments 
or light therapy? 
 
Submitted as an HTA vignette: 
Is narrow band ultra-violet light 
therapy (NB-UVB) better than 
calcineurin inhibitors for the treatment 
of vitiligo?  
9. Does the addition of psychological 
interventions (e.g. counselling, 
support) to patients receiving 
cosmetic camouflage improve their 
quality of life? 
See  2nd uncertainty  
10. Is pseudocatalase cream 
combined with brief exposure to UVB 
light as recommended, effective in 
treating vitiligo?  
Too early for HTA submission 
 
 
A variety of research methodologies will now be required 
in order to start answering some of the questions that have 
been identified through this priority setting process.  
For some areas, such as psychological interventions, 
work is needed to define the interventions themselves. In 
other areas, where the interventions are well defined and 
currently used in clinical practice, a large pragmatic, head-to-
head trial of currently used treatments may be warranted. 
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Similarly, a factorial trial could answer two related questions 
by evaluating treatments both alone and in combination.  
Dissemination of the results of the vitiligo PSP was an 
essential step towards bringing unity to the international 
efforts into the treatment of vitiligo. I presented the Top 10 
treatment uncertainties at the 16th Meeting of the European 
Society of Pigment Cell research, Cambridge, UK (September 
2010) and at the First Vitiligo World Congress, Milan, Italy 
(October 2010). 
In addition, the vitiligo PSP was the first PSP with such a 
large number of originally submitted uncertainties; therefore, 
the methodology and taxonomy I developed, was adopted by 
the JLA in subsequent PSPs. I complemented the James Lind 
Alliance guidebook (http://www.jlaguidebook.org/ ) with a 
chapter on how to deal with originally submitted uncertainties 
in a systematic way. My methodologies as well as my 
UHFRPPHQGDWLRQVGHVFULEHGLQWKH³UHIOHFWLRQVRQWKH
SURFHVV´VHFWLRQRIWKLVFKDSWHUZHUH implemented by the 
eczema PSP, the epidermolysis bullosa PSP, the cleft palate 
PSP and the sight loss and vision PSP. 
I am hopeful that the Top 10 important treatment 
uncertainties have prompted other research groups and 
pharmaceutical companies to take a fresh look at vitiligo 
research and the needs of vitiligo patients.   
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Finally, I would recommend that researchers continue to 
work with patients and clinicians in meaningful partnerships in 
developing their future research activity, in line with current 
guidelines.  
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CHAPTER 3: WHICH OUTCOMES SHOULD 
BE MEASURED IN FUTURE VITILIGO 
TRIALS? 
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Abstract  
Background 
Relevant and reliable outcomes play a crucial role in the 
correct interpretation and comparison of the results of clinical 
trials. There is a lack of consensus around methods of 
assessment and outcome measures for vitiligo, which makes it 
difficult to compare results of randomised controlled trials and 
perform meta-analysis. 
Objective 
The objective of this study was to describe the heterogeneity 
in outcome measures used in published randomised controlled 
trials of vitiligo treatments, and to report the most desirable 
RXWFRPHVIURPSDWLHQWV¶ DQGFOLQLFLDQV¶SHUVpectives.  
Methods 
A systematic review of outcome measures used in randomised 
controlled trials (RCTs), as well as a survey of the most 
desirable outcomes identified by patients and clinicians was 
conducted, as part of a vitiligo Priority Setting Partnership. 
Results 
Outcomes from 54 eligible trials were analysed and compared 
to outcomes suggested by patients and clinicians.   
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In the systematic review, 25 different outcomes were reported. 
Only 22% of trials had clearly stated primary outcome 
measures. Repigmentation was the most frequently reported 
outcome in 96% of trials and was measured using 48 different 
scales. Only 9% of trials assessed quality of life. Thirteen per-
cent measured cessation of spreading of the disease and 17% 
of studies reported patientV¶RSLQLRQVDQGVDWLVIDFWLRQZLWKWKH
treatment.   
In contrast, out of 438 suggestions made by patients and 
clinicians, cosmetically acceptable repigmentation (rather than 
percentage of repigmentation) was the most desirable 
outcome (68%), followed by cessation of spread of vitiligo 
(15%), quality of life (6%) and maintenance of repigmentation 
(4%). 
Conclusions 
Future vitiligo trials should include the following outcomes: 
repigmentation, cosmetic acceptability of results, global 
assessment of the disease, quality of life, maintenance of 
repigmentation, stabilisation of vitiligo and side effects. 
International consensus amongst clinicians, researchers and 
patients is needed to establish an agreed core outcome set for 
future vitiligo trials. 
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3.1 Introduction 
RHFHQWO\LWKDVEHHQSURSRVHGWKDW³FRUHRXWFRPHV´
should be agreed  amongst researchers,  to be measured and 
reported in all trials in order to allow the results of trials to be 
compared and combined in meta-analyses (COMET Initiative: 
Core Outcomes Measures Initiative www.comet-initiative.org). 
This does not imply that outcomes in a particular study should 
be restricted to the core outcomes only, but rather that the 
core outcomes should be collected and reported alongside 
others, that researchers feel are important. 
There is currently a lack of consensus in the definition 
and methods of assessment of vitiligo (Whitton et al., 2010) 
which makes it difficult to perform meta-analyses or to 
compare the outcomes of different studies (Whitton et al., 
2010; Gonzalez et al. 2011). Although a new international 
consensus definition and classification of vitiligo has been 
proposed, consensus for the measurement of disease   
response is still unclear (Gonzalez et al., 2011; Ezzedine et al., 
2012). Over a period of 43 years, 82 different, single or 
combination interventions have been evaluated in 57 
randomised controlled trials (RCTs) (Whitton et al., 2010). An 
updated Cochrane systematic review published in 2010 
concluded that the majority of studies differ greatly in the 
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ways in which vitiligo is measured and in the myriad 
combinations of interventions assessed. The heterogeneity of 
studies in the review made it impossible to combine trial 
results in meta-analyses (Whitton et al., 2010).  
In clinical trials the selection of appropriate outcomes, 
which are relevant to patients and those making decisions 
about healthcare (Tugwell et al., 2007), is crucial to the 
assessment of whether one intervention is better than another 
(Sinha et al., 2008). Vitiligo is a cosmetically and 
psychologically devastating disease causing great distress, 
embarrassment and difficulties in relationships (Lerner and 
Nordlund, 1978). Therefore, one would expect that subjective 
SHUFHSWLRQRIWKHGLVHDVHLHSDWLHQWV¶YLHZVRQWKH
effectiveness of a treatment) would be considered important. 
However, patient-centred outcomes have rarely been included 
in vitiligo trials, despite previous recommendations for 
inclusion in studies on vitiligo (Whitton et al., 2010) and other 
dermatological conditions (Townshend et al., 2008). 
Therefore, it is important to create consensus amongst 
researchers to ensure that the outcomes used in the trials for 
vitiligo treatment are reliable, clinically relevant and important 
to both clinicians and patients. 
The main aim of this study was to extract and report all 
the outcomes reported in RCTs of vitiligo treatments and to 
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compare these to the outcomes that patients and clinicians 
considered to be important. 
The secondary objectives were to establish: 
I. What scales were used to measure these 
outcomes. 
II. Methods of assessment of these outcomes. 
III. :KHWKHUSDWLHQWV¶YLHZVDQGWKHLUVXEMHFWLYH
perception of the treatment effectiveness were 
incorporated in the reported outcomes. 
This is a first step towards developing recommendations 
for outcomes to be used in future trials of treatments for 
vitiligo. 
 
3.2 Methods 
3.2.1 Systematic review of outcome measures in 
randomised controlled trials of treatments for vitiligo 
As mentioned in Chapter 1 (page 46), the updated 
&RFKUDQHV\VWHPDWLFUHYLHZ³,QWHUYHQWLRQVIRUYLWLOLJR´0, 
concluded that the majority of studies differ greatly in the 
ways in which vitiligo is measured. Despite the fact that the 
majority of the studies scored the percentage repigmentation, 
no two studies used exactly the same method of scoring; 
therefore the outcomes were pre-specified by the authors of 
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the Cochrane review. This meant that the authors of the 
Cochrane systematic review only retrieved the following 
outcomes from the included trials: quality of life measured by 
the Dermatology Life Quality Index (DLQI) or Skindex-29, 
percentage of repigmentation (more than 75%), cessation of 
spread of vitiligo, long term permanence of repigmentation 
and side effects (Whitton et al., 2010). The authors of the 
Cochrane review did not seek to report which outcomes were 
measured in randomised controlled trials for the treatment of 
vitiligo and what scales were used to measure these outcomes.  
A review was conducted of the outcome measures used 
in RCTs published in English and included in the updated 
&RFKUDQHV\VWHPDWLFUHYLHZ³,QWHUYHQWLRQVIRUYLWLOLJR´
published in 2010. The Cochrane review on the effectiveness 
of interventions for the treatment of vitiligo included 57 
randomised controlled trials published up to November 2009. 
All the outcomes reported in the included RCTs were retrieved 
and the scales and measures used to monitor these were 
collated (see systematic review of outcome measures data 
extraction form in the appendix). Information on outcome 
assessors was also collected. Studies with no full English text 
available were excluded. 
I extracted the data from each eligible study using a 
standardised proforma. A second data extraction was 
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performed by two other researchers. In the event of any 
discrepancies, a third researcher adjudicated.  
 
3.2.2 Survey of the most desirable outcomes for vitiligo 
identified by patients and clinicians  
A survey was conducted as part of the Vitiligo Priority 
Setting Partnership (Vitiligo PSP) (see chapter 2) 
(Eleftheriadou et al.2011). Patients and healthcare 
professionals were asked in an open-ended questionnaire to 
submit details of their uncertainties regarding vitiligo 
treatment, along with their views on what outcomes should be 
measured in future vitiligo trials. $TXHVWLRQ³ZKDWVKRXOGZH
PHDVXUHLQIXWXUHYLWLOLJRWULDOV"´ZDVDVNHG 
 
3.2.3 Ethics 
The survey was approved by the Medical School 
Research Ethics Committee, University of Nottingham, U.K, 
Ethics Reference No. G »2 »2009. 
 
3.2.4 Statistical methods 
Data was stored and analysed in MS Excel 2007 and 
processed by myself. 
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3.3 Results 
3.3.1 Systematic review of outcome measures in 
randomised controlled trials of treatments for vitiligo  
Fifty seven RCTs were evaluated. Fifty four trials were 
included and three were excluded as published English 
translations were not available. Only 22% (12/54) of trials had 
clearly stated the primary outcome measures in the abstract 
or the main text.  The majority of these trials defined the 
primary outcome as repigmentation (10/12; 83%). Other 
primary outcomes included the size of target lesions (1/12; 
8.3 %) and the number of new vitiliginous lesions (1/12; 
8.3%). 
In total, 25 different outcomes were reported in 54 RCTs 
on the treatment of vitiligo. The most frequently reported 
outcome was repigmentation (Table 3.1), which was measured 
in 96% (52/54) of trials, followed by side effects (46/54; 
85%), number of treatment sessions or time (17/54; 31.5%) 
and cumulative dose (12/54; 22%) to reach repigmentation. 
Other outcomes, less frequently reported, included pattern of 
repigmentation (17%, 9/54), patient opinion on treatment 
efficacy and degree of satisfaction including cosmetic 
acceptability of the results (9/54; 17%), cessation of spread of 
vitiligo (7/54; 13%), quality of life (5/54; 9%), independent 
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assessment of colour matching of newly repigmented lesions 
compared with unaffected skin (3/54; 5.5% ), clinical global 
assessment (3/54; 5.5%), stability of gained repigmentation 
(2/54; 4%), general health (1/54; 2%), body image (2/54; 
2%),  self-esteem (1/54; 2%), time to suction blister 
formation (1/54; 2%) and response to treatment in light vs. 
dark skin types (2/54; 2%). 
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Table 3.1 Outcomes assessed in 54 Randomised Controlled trials for the treatment of vitiligo from 1967 to 2009
Outcome Trials References
1 Repigmentation 52
(96%)
(Anbar et al., 2008), (Arca et al., 2006), (Asawanonda et al., 2008), (Barman et al., 2004), (Bhatnagar et al., 2007), (Casacci et
al., 2007), (Cestari et al., 2001), (Czajkowski 2004), (Dawid et al., 2006), (Dell'Anna et al., 2007a), (El-Mofty et al., 2006), (Ermis
et al., 2001), (Esfandiarpour et al., 2009), (Farah et al., 1967), (Goldinger et al., 2007), (Hamzavi et al., 2004), (Hofer et al.,
2005), (Kandil, 1974), (Kawalek et al., 2004), (Khalid et al., 1995), (Khandpur et al., 2005), (Kumaran et al., 2006), (Leone et al.,
2006), (Lepe et al., 2003), (Lim-Ong et al., 2005), (Lu-yan et al., 2006), (Mehrabi and Pandya, 2006), (Middelkamp-Hup et al.,
2007), (Navarro et al., 2002), (Ozdemir et al., 2002), (Parsad et al., 1998), (Parsad et al., 2003b), (Passeron et al., 2004), (Pathak
et al., 1984), (Procaccini et al., 1995), (Radmanesh and Saedi, 2006), (Rath et al., 2008), (Reyes et al., 2006), (Rodriguez-Martin
et al., 2009), (Rojas-Urdaneta et al., 2007), (Ruiz Mandonado and Tamayo, 1975), (Sanclemente et al., 2008), (Sassi et al., 2008),
(Schallreuter et al., 2002), (Siddiqui et al., 1994), (Shi et al., 2008), (Tegta et al., 2006), (Tjioe et al., 2002), (Van Geel et al.,
2004), (Vasistha and Singh, 1979), (Yones et al., 2007), (Westerhof et al., 1999)
2 Side effects and harms
(including blood
parameters for
monitoring purposed
only)
46
(85%)
(Anbar et al., 2008), (Asawanonda et al., 2008), (Barman et al., 2004), (Bhatnagar et al., 2007), (Casacci et al., 2007), (Cestari et
al., 2001), (Czajkowski 2004), (Dawid et al., 2006), (Dell'Anna et al., 2007a), (Ermis et al., 2001), (Esfandiarpour et al., 2009),
(Hamzavi et al., 2004), (Hofer et al., 2005), (Kandil, 1974), (Kawalek et al., 2004), (Khalid et al., 1995), (Khandpur et al., 2005),
(Kumaran et al., 2006), (Leone et al., 2006), (Lepe et al., 2003), (Lim-Ong et al., 2005), (Lu-yan et al., 2006), (Mehrabi and
Pandya, 2006), (Middelkamp-Hup et al., 2007), (Navarro et al., 2002), (Ozdemir et al., 2002), (Parsad et al., 1998), (Parsad et al.,
2003b), (Passeron et al., 2004), (Pathak et al., 1984), (Radmanesh and Saedi, 2006), (Rath et al., 2008), (Reyes et al., 2006),
(Rodriguez-Martin et al., 2009), (Rojas-Urdaneta et al., 2007), (Ruiz Maldonado and Tamayo, 1975), (Sanclemente et al., 2008),
(Sassi et al., 2008), (Siddiqui et al., 1994), (Shi et al., 2008), (Tegta et al., 2006), (Tjioe et al., 2002), (Van Geel et al., 2004),
(Vasistha and Singh, 1979), (Yones et al., 2007), (Westerhof et al., 1999)
3 Number of treatment
sessions/time to reach
repigmentation
17
(31%)
(Anbar et al., 2008), (Asawanonda et al., 2008), (Bhatnagar et al., 2007), (Casacci et al., 2007), (Czajkowski 2004), (Dell'Anna et
al., 2007a), (Ermis et al., 2001), (Hamzavi et al., 2004), (Hofer et al., 2005), (Kawalek et al., 2004), (Kumaran et al.,
2006),(Leone et al., 2006), (Lu-yan et al., 2006), (Radmanesh and Saedi, 2006), (Rodriguez-Martin et al., 2009), (Tegta et al.,
2006), (Yones et al., 2007)
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Outcome Trials References
4 Cumulative dose 12
(22%)
(Asawanonda et al., 2008), (Casacci et al., 2007), (Cestari et al., 2001), (Ermis et al., 2001), (Goldinger et al., 2007), (Hofer et al.,
2005), (Lim-Ong et al., 2005), (Lu-yan et al., 2006), (Middelkamp-Hup et al., 2007), (Passeron et al., 2004), (Procaccini et al.,
1995), (Tjioe et al., 2002)
5 Pattern of
repigmentation
9
(17%)
(Anbar et al., 2008), (Casacci et al., 2007), (Cestari et al., 2001), (Esfandiarpour et al., 2009), (Kumaran et al., 2006),
(Radmanesh and Saedi, 2006), (Rodriguez-Martin et al., 2009), (Van Geel et al., 2004), (Yones et al., 2007)
6 Cessation of disease
activity
7
(13%)
(Dawid et.al., 2006), (Dell'Anna et al., 2007a), (Lim-Ong et al., 2005), (Papadopoulos et al., 2004), (Parsad et al., 2003b), (Rath et
al., 2008), (Siddiqui et al., 1994)
7 Quality of life 5 (9%) (Agarwal et al., 2005), (Middelkamp-Hup et al., 2007), (Papadopoulos et al., 2004), (Sassi et al., 2008), (Yones et al., 2007)
8 Patient Global
assessment
4
(7.5%)
(Hamzavi et al., 2004), (Middelkamp-Hup et al., 2007), (Rodriguez-Martin et al., 2009), (Yones et al., 2007)
9 Satisfaction with the
treatment
4
(7.5%)
(Hofer et al., 2005), (Mehrabi and Pandya, 2006), (Passeron et al., 2004), (Westerhof et al., 1999)
10 Colour matching 3
(5.5%)
(Bhatnagar et al., 2007), (Tegta et al., 2006), (Yones et al., 2007)
11 Clinician global
assessment
3
(5.5%)
(Hamzavi et al., 2004), (Middelkamp-Hup et al., 2007), (Sassi et al., 2008)
12 Histological samples 3
(5.5%)
(Rojas-Urdaneta JE, 2007), (Navarro et al., 2002), (Westerhof et al., 1999)
13 Cytokines, T-
lymphocytes
3
(5.5%)
(Middelkamp-Hup et al., 2007), (Reyes et al., 2006), (Shi et al., 2008)
14 Stability of gained 2 (4%) (Kumaran et al., 2006), (Lim-Ong et al., 2005)
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Outcome Trials References
repigmentation
15 Tolerability of
treatment
1 (2%) (Passeron et al., 2004)
16 Concentration of
epidermal H2O2
1(2%) (Schallreuter et al.,2002)
17 Change in colour 1(2%) (Sanclemente et al.,2008)
18 Cosmetic acceptability 1(2%) (Barman et al., 2004)
19 Stress 1(2%) (Papadopoulos et al., 2004)
20 Body image 1(2%) (Papadopoulos et al., 2004)
21 Self esteem 1(2%) (Papadopoulos et al., 2004)
22 General health 1(2%) (Papadopoulos et al., 2004)
23 Response to treatment
(light vs. dark skin
types)
1(2%) (Middelkamp-Hup et al., 2007)
24 Catalase activity, ROS,
saturation of lipids
1(2%) (Dell'Anna et al., 2007a)
25 Time to suction blister
formation & duration of
cell cultures
1(2%) (Czajkowski 2004)
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3.3.1.1 Repigmentation  
Although it was the most frequently reported outcome in 
the RCTs, repigmentation was measured using a great variety 
of scales (Table 3.1) including grades, scores (e.g. 0-4), 
categories (e.g. poor to excellent, partial to complete), 
quartiles and other quintiles (e.g. 0-24, 25-50, 51-74, 75-100),  
percentages (e.g. 0-40, 40-60, 60-100, 0-30, 31-50, 51-75, 
75-100), mean difference in lesion size in mm. Five trials (9%) 
used more than one scale to measure repigmentation. 
In total, repigmentation was measured using 48 
different scales in 54 eligible trials. Although 30% of the trials 
used quartiles (16/54), 14 different scales were created 
including differences in the definition of quartiles and the 
names of the corresponding categories. For example, Kumaran 
et al (2006) and Bhatnagar et al. (2007) ERWKXVHGWKH³-
24%; 25-50%; 50-75%; 76-´TXDUWLOHVEXWRQHWULDO 
(Kumaran et al., 2006) reported moderate improvement as 
25-50% repigmentation and the other (Bhatnagar et al., 2007) 
as 50-75% repigmentation of vitiliginous lesions. The 
definition of excellent repigmentation or success varied from 
trial to trial and included values fURP³DQ\UHSLJPHQWDWLRQ´WR
100% repigmentation of vitiliginous lesions. 
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Trials assessed repigmentation by combination of clinical 
assessment and other methods such as digital images, paper 
tracing, planimetry (29/54; 54%) or clinically only (17/54; 
31.5%). Eleven percent of trials (6/54) used only objective 
methods in assessing repigmentation such as digital images, 
planimetry, and image analysis of reflected UV photographs.  
Only two trials (3.7%) incorporated patient assessed 
repigmentation.  
3.3.1.2 Pattern of repigmentation and colour matching 
Pattern of repigmentation was reported in 17% (9/54) of 
trials. This was usually briefly mentioned in the discussion 
section or the results section only. Perifollicular and 
peripheral/perifollicular patterns were mentioned in 4% (2/54) 
and 9% (5/54) of the trials respectively. Four percent of the 
trials reported all patterns (perifollicular, marginal and diffuse) 
of repigmentation (Table 3.2). 
Change in colour (colorimetry) and colour matching of 
vitiliginous lesions was assessed in 5.5% (3/54) and 2% (1/54) 
trials respectively. These were assessed by either clinicians 
only (Bhatnagar et al., 2007; Tegta et al., 2006) or 
combination of clinical assessment and photographs (Yones et 
al., 2007) or by using digital images (Sanclemente et al., 
2008). Patient assessment of colour matching was not 
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included in any of the trials (Table 3.3). Response to the 
treatment in light vs. dark skin types was reported in one trial 
(2%) and was measured clinically.
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Table 3.2 Scales used to measure repigmentation in Randomised Controlled Trials for the treatment of vitiligo
from 1967 to 2009
Scale used to
measure
repigmentation
Details Outcome assessor/Methods of assessment
Grades Grades: 0-3 0=None; 1=Regular; 2=Good; 3-Excellent (Cestari et al., 2001) Patient
0=None; 1= up to 25%; 2= 25-50%; 3= 51-100% (Cestari et
al., 2001)
Clinically
0=none; 1+=minimal follicular; 2+=follicular; 3+=above 50%
follicular/confluent repigmentation (Schallreuter et al., 2002)
Clinically, digital images
0=none; 1= <50% (moderate); 2= 50-80%(good); 3= >80%
(excellent) (Leone et al., 2006)
Clinically
Grades: 0-4 0=No change; 1= 1-25%; 2= 26-50%; 3= 51-75%; 4= 76-
100% (Asawanonda et al., 2008)
Digital images
Presented in the article only: Initial=0-25%; complete=75-100%
(Ermis et al., 2001)
Clinically
Scale used to
measure
repigmentation
0=No change;
(good)= 51-75
0=No response
(marked)= 50-
Grades: 0-5 0=0%, 1=1-5%,
(Hofer et al., 2
Points: 0-11 0=none; 1=up
9=8.1-10mm;
VASI Vitiligo Area
Scoring Index
(VASI)
Quantitative pa
Quartiles Percentage
quartiles
Minimal or no
25-50%; mark
marked or com
Bhatnagar et a
Poor/minimal r
good or marke
response:76-1
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Details Outcome a
1 (poor)= 1-25%; 2 (moderate)= 26-50%; 3
%; 4 (excellent)= 76-100% (Casacci et al., 2007)
Clinically, pho
; 1 (minimal)= 1-24%; 2 (moderate)= 25-50%; 3
75%; 4 (complete)= 100% (Kawalek et al., 2004)
Clinically, pho
2=6-25%. 3=26-50%, 4=51-75%, 5=76-100%
005)
Clinically, dig
to 2mm; 3=2.1-4mm; 5=4.1-6mm; 7=6.1-8mm;
11=above 10mm (Navarro et al., 2002)
Clinically
rametric score (Hamzavi et al., 2004) Clinically
response: 0-24%; moderate or mild response:
ed or moderate response: 50-75%; excellent,
plete response: 76-100% (Kumaran et al., 2006;
l., 2007; Rath et al., 2008)
Clinically (Ku
al., 2007; Ra
(Kumaran et
(Kumaran et
esponse:0-24%; moderate response:25-49%;
d response:50-74%; excellent/marked or complete
00% (Rodriguez-Martin et al., 2009; Lu-yan et al.,
Clinically (Ro
et al., 2006;
Passeron et a
ssessor/Methods of assessment
tographs
tographs
ital images
maran et al., 2006; Bhatnagar et
th et al., 2008), paper tracing
al., 2006), digital images
al., 2006; Bhatnagar et al., 2007)
driguez-Martin et al., 2009; Lu-yan
Esfandiarpour et al., 2009;
l., 2004), digital images (Lu-yan
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Scale used to
measure
repigmentation
Details Outcome assessor/Methods of assessment
2006; Esfandiarpour et al., 2009; Passeron et al., 2004) et al., 2006; Arca et al., 2006)
L1=0-25%; L2=25-50%; L3=50-75%; L4=75-100% (Procaccini
et al., 1995)
Clinically and photographs (Procaccini et al.,
1995)
Minimal (25%); Moderate (50%); Marked (75%) or complete
(Parsad et al., 1998; Parsad et al., 2003b)
Clinically, photographs, paper tracing, written
describing and measurement (Parsad et al.,
1998; Parsad et al., 2003b)
None: 0%; Poor or minimal response: 1-25%; moderate or mild
response: 26-50%; good or moderate response: 51-75%;
marked or excellent response: 76-100% (Lepe et al., 2003; Tegta
et al., 2006), (Khalid et al., 1995; Yones et al., 2007)
Clinically (Tegta et al., 2006; Lepe et al., 2003;
Khalid et al., 1995), digital images using
morphometry (Lepe et al., 2003), photographs
and planimetry (Yones et al., 2007)
Tertiles/
Quantiles
Percentages Minimal response: 0-24%; mild or moderate response: 25-49 or
50%; moderate or marked or complete response: 50 or 51-
100% (Arca et al., 2006; Reyes et al., 2006)
Clinically (Arca et al., 2006), (Reyes et al.,
2006), digital images (Arca et al., 2006)
Mild or minimal or poor response: 0-24 or 25%; moderate or
good response: 25 or 26-75%; marked or excellent response:
76-100% (Anbar et al., 2008; Lim-Ong et al., 2005; Radmanesh
and Saedi, 2006).
Clinically and planimetry (Anbar et al.,
2008),(Radmanesh and Saedi, 2006), digital
photographs and morphometry analysis (Lim-
Ong et al., 2005)
No response; beginning: 1-25%; good: 25-90%; complete cure: Clinical assessment, photographs
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Scale used to
measure
repigmentation
Details Outcome assessor/Methods of assessment
90-100% (Kandil, 1974)
Absent: 0%; moderate: 1-49%; good: 50-75%; excellent: 76-
100% (Dell'Anna et al., 2007a)
Clinically, photographs
None: 0-50%; good: 51-100% (Farah et al., 1967) Clinically, patient
0%= none; 75%= significant and satisfying; 100%=complete
(Westerhof et al., 1999)
Clinically
Ineffective: worse or no difference; improved: <50%; marked: >
50%; cured:100% (Shi et al., 2008)
Clinically
Deterioration; stable: no changes; partial: 25-40%; incomplete:
40-60%; good: >60% (Siddiqui et al., 1994)
Clinically, photographs
Failure: 0%; poor: 0-40%; moderate: 40-60%; good/very good:
>60% (El-Mofty et al., 2006)
Poor: <30%; fair: 31-50%; good: 51-75%; very good: 76-90%;
excellent: 91-100% (Khandpur et al., 2005)
mm/cm Reduction of
surface area
Pigment spread: millimetres(Barman et al., 2004)
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Scale used to
measure
repigmentation
Details Outcome assessor/Methods of assessment
Mean size of
lesions
Mean size of lesions in centimetres (Cestari et al., 2001)
Increase in
pigmentation of
surface area
0= absence of repigmentation; 1=3 mm; 3=3.1-5 mm; 5=5.1-7
mm; 7=7.1-9 mm; 9=9.1-11 mm; 11= >11mm (Rojas-Urdaneta,
2007)
Clinically and acetate sheets to mark the edges
Percentages Mean percentage
of surface
repigmentation
Mean %: 0-100% (Goldinger et al., 2007; Sanclemente et al.,
2008; Tjioe et al., 2002; Cestari et al., 2001; Lepe et al., 2003;
Westerhof et al., 1999)
Clinically (Goldinger et al., 2007; Sanclemente
et al., 2008; Tjioe et al., 2002),(Cestari et al.,
2001; Lepe et al., 2003; Westerhof et al.,
1999), digital images (Cestari et al., 2001;
Goldinger et a; 2007; Lepe et al., 2003;
Mehrabi and Pandya, 2006; Sanclemente et al.,
2008; Tjioe et al., 2002; Middelkamp-Hup et
al., 2007; Van Geel et al., 2004), digital
morphometry (Sanclemente et al., 2008) and
transparent sheets tracing (van Geel et al.,
2004)
Size of target
lesions
0-100% (Dawid et al., 2006) Planimetry
Change of the %
of the affected
0-100% Clinically (Arca et al., 2006; Radmanesh and
Saedi, 2006; Ruiz Maldonado and Tamayo,
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Scale used to
measure
repigmentation
Details Outcome assessor/Methods of assessment
skin 1975), photographs (Ruiz Maldonado and
Tamayo, 1975) and tracing (Radmanesh and
Saedi, 2006)
Success only 100% repigmentation (Czajkowski, 2004) Clinically
Categories Categories No response; fair response: slight improvement; good response:
increase in size of pigmented spots or decrease in size of lesions;
excellent response: considerable increase in size of pigmented
spots or decrease in size of lesions (Vasistha and Singh, 1979)
Clinically
Clearance of
lesions
Clear/not clear (Sassi et al., 2008) Image analysis of reflected UV photographs
Reduction of at
least 75% of
overall lesions
Reduction of at least 75%; no reduction of at least 75% (Sassi et
al., 2008)
Image analysis of reflected UV photographs
Number of new
lesions
Number of new lesions (Agarwal et al., 2005) Clinically
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Table 3.3 Scales used to measure outcomes other than repigmentation in Randomised Controlled Trials for the
treatment of vitiligo from 1967 to 2009
Outcome Details Method of assessment Trials
1 Depigmentation -1= 1-25%; -2= 26-50%; -3= 51-75%; -4=76-
100% (Asawanonda et al., 2008)
Digital images (Asawanonda et al., 2008) 1
2 Pattern of
repigmentation
Follicular, peripheral, marginal, diffuse (Anbar et al.,
2008; Casacci et al., 2007; Cestari et al., 2001;
Esfandiarpour et al., 2009; Radmanesh and Saedi,
2006; Rodriguez-Martin et al., 2009; Yones et al.,
2007; Kumaran et al., 2006)
Clinically (Kumaran et al., 2006; Anbar et al., 2008; Casacci et al., 2007;
Cestari et al., 2001; Esfandiarpour et al., 2009; Radmanesh and Saedi,
2006; Rodriguez-Martin et al., 2009; Yones et al., 2007), planimetry (Anbar
et al., 2008; Radmanesh and Saedi, 2006) and photographs (Casacci et al.,
2007; Cestari et al., 2001; Esfandiarpour et al., 2009; Rodriguez-Martin et
al., 2009; Van Geel et al., 2004)
9
3 Colour matching of
newly repigmented
lesion to the
surrounding normal
skin
Darker, same, lighter (Bhatnagar et al., 2007; Tegta
et al., 2006)
Clinically (Bhatnagar et al., 2007; Tegta et al., 2006) 2
Excellent, not excellent (not many details given)
(Yones et al., 2007)
Clinically and photographs 1
4 Change in colour
Colorimetry
Commission International de LEclairege L, a, b
system (Sanclemente et al., 2008)
Digital images 1
5 Quality of life DLQI (Yones et al., 2007; Agarwal et al., 2005; Patients 3
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Papadopoulos et al., 2004)
Skindex 29 (Sassi et al., 2008; Middelkamp-Hup et
al., 2007)
2
WHOQOL-BREF questionnaire for quality of life
(Agarwal et al., 2005)
1
6 General health General health questionnaire (Papadopoulos et al.,
2004)
Patients 1
7 Body image Body image dysphoria-situational inventory of body
image dysphoria, body image feelings-body image
automatic thoughts questionnaire (Papadopoulos et
al., 2004)
Patients 1
8 Self-esteem Rosenberg self-esteem scale (Papadopoulos et al.,
2004)
Patients 1
9 Stress Perceived stress scale (Papadopoulos et al., 2004) Patients 1
10 Cessation of spreading
of vitiligo/Disease
activity
Not clear (Parsad et al., 2003b) Clinically, photographs, planimetry, written description and measurement 1
Not clear (one sentence at the discussion section)
(Rath et al., 2008)
Not clear (Rath et al., 2008) 1
Vitiligo Index Disease Activity (VIDA) score (Dawid et
al., 2006; Lim-Ong et al., 2005)
Patients 2
No scale (Papadopoulos et al., 2004) Photographs(Papadopoulos L, 2004) 1
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Positive, stable, deteriorating (Siddiqui et al., 1994) Clinically and photographs 1
Binary scale: stabilised/not stabilised (Dell'Anna et
al., 2007a)
Clinically and photographs 1
11 Clinical Global
assessment
Very severe; severe; more or less severe; not so
severe (Middelkamp-Hup et al., 2007)
Clinically 1
Complete improvement (100%); very much
improved (76-99%); much improved (51-75%);
improved 26-50%); minimal change(1-25%); no
change (Hamzavi et al., 2004)
1
Anchored Horizontal visual analogue scale (Sassi et
al., 2008)
1
12 Patient global
assessment
Visual analogue scale: -5 to +5 (Rodriguez-Martin et
al., 2009)
Patients 1
Visual analogue scale: 0 to 10 (Middelkamp-Hup et
al., 2007; Yones et al., 2007)
2
Complete improvement (100%); very much
improved (76-99%); much improved 51-75%);
improved 26-50%); minimal change(1-25%); no
change (Hamzavi et al., 2004)
1
13 Satisfaction with the
treatment
Visual analogue scale: 0 to 10 (Hofer et al., 2005) Patients 1
Questionnaire (no further details) (Mehrabi and 1
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Pandya, 2006)
Opinion on treatment and side effects questionnaire
(no further details) (Westerhof et al., 1999)
1
Opinion on treatment efficacy and degree of
satisfaction questionnaire. Scale: poor; good;
excellent (Passeron et al., 2004)
1
14 Cosmetic acceptability
of the results
Satisfied/ unsatisfied (Barman et al., 2004) Patients 1
15 Tolerability of the
treatment
Visual analogue scale (Passeron et al., 2004) Patients 1
16 Response to treatment
in light vs. dark skin
types
Descriptive (Middelkamp-Hup et al., 2007) Clinically 1
17 Stability of gained
regimentation and
development of new
lesions
Within 1 year after treatment; Scale: Not clear (Lim-
Ong et al., 2005)
Not clear 1
Within 20 weeks after treatment Categories:
maintained repigmentation; continued to improve;
pigmentation faded; development of new lesions
(Kumaran et al., 2006)
1
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3.3.1.3 Cessation of disease activity  
Thirteen per-cent (7/54) of RCTs measured the cessation 
of spreading of vitiligo during treatment period; only 7% (4/54) 
stated the scale used. 
3.3.1.4 Stability of gained repigmentation 
Four per-cent of the trials (2/54) assessed stability of 
gained repigmentation and development of new lesions.  The 
timescales of the assessment of this outcome were 1 year and 
20 weeks after the completion of the treatment. 
3.3.1.5 3DWLHQW¶VRSLQLRQRQWreatment efficacy 
2QO\RIVWXGLHVUHSRUWHGSDWLHQWV¶RSLQLRQV
regarding treatment efficacy and degree of satisfaction with 
the treatment including cosmetic acceptability of the results. 
In particular, 7.5% of trials (4/54) assessed patient 
satisfaction with the treatment by asking them directly using a 
questionnaire or a visual analogue scale. However details of 
which questions were asked were generally lacking. Cosmetic 
acceptability of the results and patient global assessment were 
monitored in 2% (1/54) and 7.5% (4/54) of trials respectively. 
The latter was measured in 3 different ways (Table 3.3). 
Tolerability of the treatment was briefly reported in one trial 
(2%). 
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3.3.1.6 Quality of life  
Nine per-cent (5/54) of trials assessed quality of life of 
vitiligo patients. Different questionnaires were used: 
Dermatology Life Quality Index (DLQI) (3/54; 5.5%), Skindex-
29 (2/54; 3.7%) and WHOQOL-BREF questionnaire for quality 
of life (1/54; 1.8%). 
3.3.1.7 General health, stress, body image and clinician global 
assessment 
One trial (Papadopoulos et al., 2004) reported several 
patient centred outcomes; stress, body image, self-esteem 
DQGJHQHUDOSDWLHQW¶VKHDOWK&OLQLFLDQJOREDODVVHVVPHQWZDV
measured using 3 different scales in 3 trials (5.5%). 
3.3.1.8 Side effects and harms 
Various side effects and harms such as erythema, 
blistering, graft failure, Koebner phenomenon, 
hyperpigmentation around vitiliginous lesions, were reported 
in 46 trials out of 54 eligible trials (85%). Nine trials 
mentioned that various blood parameters such as full blood 
count, kidney and liver function tests were measured for the 
purpose of monitoring possible treatment side effects only and 
therefore were included in this category of outcomes. Side 
effects and harms were generally reported briefly in the results 
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or discussion section of the article with limited information on 
frequency or severity. 
3.3.1.9 Specific blood, skin parameters and other outcomes 
Histopathology of vitiliginous lesions (3/54; 5.5%), T-
lymphocytes and cytokines (3/54; 5.5%); concentration of 
epidermal H2O2 (1/54; 2%), catalase activity and lipid 
saturation (1/54; 2%) were measured as an indicator of 
effectiveness of compared treatment. 
Number of treatments to gain repigmentation, 
cumulative dose and time to suction blister formation were 
sometimes reported in trials where relevant to delivery of the 
intervention (Table 3.1). 
 
3.3.2 Survey of the most desirable outcomes for vitiligo 
identified by patients and clinicians  
Eighty seven percent (401/461) of vitiligo PSP 
participants suggested at least one outcome (response rate 
87%). 
In total, 438 suggestions were made and 23.5% 
(103/438) of these were excluded as non-relevant, such as 
questions on inheritance and trigger factors for vitiligo. 
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Of the remaining 335 suggestions, 68% of responses 
were from patients, 25% from clinicians and 7 % unknown.  
More women responded than men (53% women; 30% men 
and 17% did not specify), and most were aged 30-60 years 
old (½\HDUV-\HDUV¾\HDUVDQG7% 
did not specify). 
The most popular outcome amongst all responders was 
repigmentation of vitiliginous lesions (68%), followed by 
cessation of spreading of the disease (15%), quality of life of 
vitiligo patients (6%), maintenance of repigmentation (4%) 
and other outcomes such as camouflage effectiveness and 
depigmentation. 
3.3.2.1 Repigmentation of vitiliginous lesions 
6WDWHPHQWVVXFKDV³FRVPHWLFDOO\DFFHSWDEOH
UHSLJPHQWDWLRQUDWKHUWKDQSHUFHQWDJH´³QRUPDOORRNLQJVNLQ´
³-UHSLJPHQWDWLRQ´DQG³Tuick and long lasting ( at 
least 2 years) were made by survey responders. 
Repigmentation on visible areas such as face and hands was 
also considered important (Figures 3.1 and 3.2). 
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Figure 3.1 Desirable outcomes for patients 
 
Figure 3.2 Desirable outcomes for clinicians 
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3.3.2.2 Cessation of spread of vitiligo 
Nineteen percent of patients found cessation of the 
disease important compared to only 5% of clinicians (Figures 
3.1 and 3.2). 
3.3.2.3 Quality of life 
Nearly equal percentages of patients (9%) and clinicians 
(8%) found the quality of life of vitiligo patients an important 
RXWFRPH6WDWHPHQWVVXFKDV³WRUHGXFHWKHVWUHVVDQG
embarrassment, psychological impact, support, coping 
strategies and self-confidence, psychological support for 
children wLWKYLWLOLJR´ZHUHUHSRUWHG)LJures 3.1 and 3.2). 
Other submissions included depigmentation, camouflage 
improvement. 
 
3.4 Discussion 
Well-designed clinical trials are a fundamental aspect of 
evidence-based medicine. Relevant and reliable outcomes play 
a crucial role in the correct interpretation and comparison of 
the results of different treatment modalities (Charman et al., 
2003). Lately, it has been increasingly recognised that 
outcome measures in trials should be relevant to patients and 
clinicians (COMET, 2010; Tugwell et al., 2007). However, no 
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attempts have been made, either by researchers or by 
pharmaceutical companies, to standardise outcome measures 
for the treatment of vitiligo. 
Recently, it has been reported that 85% of research 
funding is wasted across all aspects of the research cycle 
(Chalmers and Glasziou, 2009). Three of the four sources of 
waste are closely related to the outcomes used in the trials: 
important outcomes are not assessed; published research fails 
to set the study in the context with all previous similar 
research and over 50% of planned study outcomes are not 
reported (Chalmers and Glasziou, 2009). 
The majority of the trials in the systematic review 
reported repigmentation, but this was measured using 48 
different scales. In total, 25 different outcomes were reported 
in 54 trials. Patients and clinicians put greatest emphasis on 
repigmentation, quality of life, cessation of spread of the 
disease and maintenance of gained repigmentation. However 
cosmetically acceptable repigmentation as assessed by 
patients, rather than percentage of repigmentation per se, 
should be measured where possible. Whilst it is encouraging 
that a clear candidate for a core outcome to be included in all 
clinical trials on vitiligo is repigmentation, with so many 
different ways of assessing treatment results, it will never be 
possible to perform a meaningful meta-analysis of vitiligo trials 
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until these issues have been resolved. Urgent action is 
required, if the field of vitiligo research is to move forward. 
It is also disappointing that the definition of successful 
treatment or excellent repigmentation is unclear, and that 
patient involvement in assessing the success of treatments or 
quality of life is so limited. 
To my knowledge, this study is the first to systematically 
summarise outcomes reported in RCTs of vitiligo treatments, 
and to compare these outcomes with the results of qualitative 
work amongst patients and clinicians to establish the 
outcomes of importance to them. 
The survey responders included patients with vitiligo, 
their carers and parents, dermatologists and other healthcare 
professionals with an interest in vitiligo. Hence, the proposed 
outcomes reflect a broad spectrum of views. 
A convenience sample of RCTs included in the updated 
Cochrane systematic review was chosen based on resources 
and time limitations. It is possible, that more recent trials 
have been more consistent in including patient-reported 
outcomes and quality of life scales in line with recent 
recommendations (Gonzalez et al., 2011). 
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Amongst the huge number of outcomes that have been 
reported in the RCTs to date, it is difficult to identify precisely 
which outcomes should be measured in vitiligo trials.  
Initial attempts have been made to create a consensus 
in the way that vitiligo is assessed. An innovative scoring tool 
was proposed in 2007 by the Vitiligo European Task Force; 
however, this had not been used in the randomised controlled 
trials included in this review. This scoring system combines the 
three dimensions of the disease: extent, staging and 
spreading and takes into consideration the presence of white 
hair and the body sites of vitiliginous lesions (Taieb and 
Picardo, 2007). 
Recent guidelines for designing and reporting clinical 
trials on vitiligo have suggested that patient-centred outcomes 
should be incorporated into the design of future trials of 
vitiligo treatment along with quality of life, percentage of 
repigmentation, permanence of gained repigmentation and the 
arrest of the progression of the disease (Gonzalez et al., 2011). 
To overcome the issue of different body sites responding 
differently to treatments, it has been suggested that studies 
perform stratified analyses based on body sites (Gonzalez et 
al., 2011) and that other important clinical parameters should 
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be collected such as resistance to previous treatment and 
presence of leukotrichia.  
Although, quality of life has been reported in only 9% of 
trials, it is consideUHGDQLPSRUWDQWRXWFRPHIURPDSDWLHQW¶V
point of view (19%) and was also proposed as a primary 
outcome in the guidelines for designing and reporting clinical 
trials for vitiligo (Gonzalez et al., 2011).  
Recently published revised international classification of 
vitiligo and definition of stabilisation of the disease 
recommends that disease stability is best assessed based on 
the stability of individual lesions rather than the overall 
stability of the disease, as the latter is difficult to define 
precisely and reliably (Ezzedine et al., 2012). Therefore the 
cessation of spreading of vitiligo is relevant to individual 
lesions as well as whole body or systematic treatments. 
It has been reported that more research is needed into 
the establishment of the definition of successful 
repigmentation as well as methods of assessment of the 
proposed outcomes (Gonzalez et al., 2011). 
I believe that the previously proposed outcomes, in 
combination with the findings of this review and survey are a 
good starting point for creating a consensus on a core 
outcome set for vitiligo trials. However, the questions of what 
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PDNHV³FRVPHWLFDOO\DFFHSWDEOH´UHSLJPHQWDWLRQ³ZKDWVFDOH
WRXVH´DQG³ZKRVKRXOGDVVHVVWKHVHRXWFRPHV´VWLOOUHPDLQ
unanswered and will require further research.  
Meanwhile, the following outcomes should be clearly 
reported in all future trials for the treatment of vitiligo (Table 
3.4). 
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Table 3.4 Proposed core outcomes for the trials on treatment of vitiligo
Proposed
outcomes
Example of scale
Assessors/method of
assessment
Comments
Repigmentation % quartiles: 0-24%; 25-49%; 50-
74%; 75-100%
Objective means such as
planimetry, coloritmetry,
digital photographs, UV
photographs
The method of assessment will depend upon its availability
and appropriate training of personnel.
Cosmetically
acceptable
repigmentation
Visual analogue scale (bad, fair,
good, excellent)
Patient This will take account of the colour match of the newly
repigmented lesions to the surrounding normal skin including
hyperpigmentation around the lesions if applicable
Global assessment Visual analogue scale: Complete
improvement; very much
Patient and clinician A unified combined scale should be used by both patients and
clinicians, which would be quick and easy to use in both
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Proposed
outcomes
Example of scale
Assessors/method of
assessment
Comments
of the disease improved; much improved;
improved; minimal change; no
change (Hamzavi et al., 2004))
clinical setting and research environment.
Quality of life Skindex-29 Patient Concerns have been recently reported regarding the use of
DLQI in monitoring patients with mild to severe psoriasis and
atopic dermatitis (Twiss et al., 2012; Fernandez-Penas et al.,
2012).
Maintenance of
gained
repigmentation
2 years follow-up after completion
of the treatment (Whitton et al.,
2010)
Patient and clinician It is well known that repigmentation of vitiliginous lesions can
take months and that depigmentation can recur; therefore it
is important to assess maintenance of gained repigmentation
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Proposed
outcomes
Example of scale
Assessors/method of
assessment
Comments
when weighting the treatment benefits against the harms.
Cessation of
spread of the
disease
Vitiligo Disease Activity (VIDA)
score (Dawid et al., 2006; Bhor
and Pande, 2006; Lim-Ong et al.,
2005)
Patient and clinician Cessation of spreading of the disease is an important
outcome due to the unpredictable nature of vitiligo, which
can be devastating and distressing for patients. Stabilisation
of the disease until repigmentation occurs was reported as a
realistic measure of outcome (Gonzalez et al., 2011).
Side effects and
harms
Descriptive. Should also include
convenience of the treatment from
the patients perspective
Patient and clinician Side effects and harms of an intervention should be clearly
reported in the results section with relevant frequencies.
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Finally, following my presentation of the findings of the 
systematic review of outcome measures for vitiligo and a 
survey of most desirable outcomes amongst patients and 
clinicians at the International Pigment Cell Conference 2011, 
(IPCC 2011, France), I proposed the inclusion of establishment 
of a core outcomes set for vitiligo into the agenda of the 
International Federation of Pigment Cell Societies (IFPCS).  
The next step was to undertake an international 
consensus amongst researchers, clinicians and patients on the 
core outcomes and unified scales to measure these.  
The initiation meeting to establish core outcomes set for 
vitiligo was held during the 21st European Academy of 
Dermatology and Venereology Congress (EADV), in September 
2012. I have been appointed as a leader of this international 
consensus and am in the process of initiation a three-round e-
Delphi exercise to establish the core outcomes set. 
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CHAPTER 4: PILOT TRIAL OF HOME 
INTERVENTION OF LIGHT THERAPY FOR 
VITILIGO (HI-LIGHT TRIAL) 
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Abstract  
Background 
Hand-held NB-UVB units are portable and light weight 
devices. Currently in the UK, phototherapy is usually reserved 
for widespread vitiligo and requires frequent hospital visits. 
Some evidence exists that treating vitiligo early may enhance 
the chance of successful repigmentation. Early treatment of 
limited vitiligo may be a promising approach. 
Methods 
This pilot trial determined the feasibility of conducting a 
large multi-centre RCT involving hand-held, home 
phototherapy. The primary objective was to establish the 
proportion of eligible participants and their willingness to be 
randomised. Secondary objectives included preparing an 
educational package on how to use the intervention, to deal 
ZLWKSRVVLEOHVLGHHIIHFWVHVWDEOLVKLQJSDUWLFLSDQWV¶DGKHUHQFH
to the treatment and testing the primary outcomes for the 
main trial (repigmentation, quality of life, cessation of spread). 
This was a three arm placebo-controlled, parallel trial. 
Two devices were tested: Group A-active Dermfix; Group B-
active Waldmann; Group C-placebo Dermfix. Twenty nine 
participants were randomised and treated for four months with 
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NB-UVB at home. Patients received training on the baseline 
visit. Outcomes were assessed on baseline and after 16 weeks 
of treatment. Patients and investigators were blinded.   
Results 
Recruitment was completed in three instead of the 
anticipated six months. Response rate for primary care and 
secondary care were 40% and 79% respectively. We identified 
54/97 (55.6%) eligible patients but were able to allocate only 
29 due to limited resources available. Ninety per cent (25/29) 
of patients adhered to the treatment. Eleven out of seventeen 
patients (65%) in the active groups had some degree of 
repigmentation, especially on the face and neck. Both devices 
have similar characteristics including output pre and post-trial 
and acceptability to participants. 
 
Conclusions 
The pilot trial showed that vitiligo patients are keen in 
participating in trials of home light therapy. The educational 
package was comprehensive and suitable for implementation 
at home. 
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4.1 Introduction 
In chapter 1 of this thesis, I have described the 
epidemiology, aetiology of vitiligo and the major impact on the 
quality of life that vitiligo has on its patients. Currently, there 
is lack of firm clinical recommendation for the treatment of 
vitiligo and a great need for a large well conducted trial on 
vitiligo treatments (Whitton et al., 2010). 
In chapter 2, the vitiligo Priority Setting Partnership (PSP) 
identified the Top 10 treatment uncertainties, in order to steer 
the international research agenda on topics important to 
patients and clinicians. Four of these treatment uncertainties 
included phototherapy (Table 2.5).  
In this chapter, I describe a pilot, double-blind, 
randomised, controlled, multi-centre trial of hand-held narrow 
band-ultra violet light B (NB-UVB) phototherapy for the 
treatment of focal or early vitiligo at home. This pilot trial was 
used to inform the design and conduct of a national, multi-
centre randomised controlled trial (RCT) for the treatment of 
vitiligo. 
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4.1.1 Current clinical practice for the treatment of 
vitiligo in the UK 
In the UK, vitiligo patients are treated in both primary 
and secondary care. This is a chronic condition that requires 
long-term treatment. Patients can experience periods of rapid 
spread, and periods when the vitiligo is relatively stable 
(Gawkrodger et al., 2008). In order to induce remission, 
treatment is often given over periods of several months. 
Current British Association of Dermatologists (BAD) clinical 
guidelines for the diagnosis and management of vitiligo, 
recommend NB-UVB, tacrolimus and topical steroids 
(Gawkrodger et al., 2008).  
In the UK, NB-UVB is almost exclusively available in 
secondary care and most often used for widespread vitiligo. 
It requires regular visits to the hospital (usually three times 
per week for up to 12 months or 200 treatment sessions) 
(Gawkrodger et al., 2008).  
Narrow-band refers to a specific wavelength of 
ultraviolet (UV) radiation, 311 to 312 nm. Currently, there are 
various devices available on the market for the delivery of NB-
UVB: whole body units, hand and feet units and hand-held 
(targeted) units. The choice of the devices is usually based on 
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the size and location of the lesions and the percentage of the 
affected body surface (Ibbotson et al., 2004).  
The lamps used in all units, including the hand-held 
devices, are TLO1 i.e. the same as hand/feet units and whole 
body units.  Hospital NB-UVB usually involves whole body 
cabinets suitable for extensive, generalised vitiligo only i.e. 
large or multiple lesions. During the session, the participant 
goes into a specially designed cabinet containing fluorescent 
light tubes (whole body units). She/he stands in the centre of 
the cabinet, undressed except for underwear, and wears 
protective goggles. Usually the whole body is exposed to the 
UVB for a short time (seconds to minutes). NB-UVB is also 
used in the treatment of many other skin conditions including 
psoriasis and eczema.  
The hand-held NB-UVB unit, is a portable and light 
weight NB-UVB device, which is slightly larger than a usual 
hairbrush (Picture 4.1).  
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Picture 4.1 Hand-held NB-UVB devices (A) Waldmann device and (B) 
Dermaray device 
The hand-held device is held above any small area of the 
skin (10-12cm x 4-6.5 cm) and spacers are provided in order 
to standardise the distance from the skin. The lamp is held still, 
above the vitiliginous lesion. If the size of the lesion is bigger 
than mentioned above i.e. 10-12 cm X 4 cm, patients (or their 
parent or legal guardian) move the lamp slowly, above the 
vitiliginous area in circular movements. Hand-held NB-UVB 
units are suitable for small lesions, making phototherapy 
available for patients with limited disease. 
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Recently, a new European Guideline for vitiligo was 
introduced, suggesting early treatment of small lesions of 
recent onset and childhood vitiligo with combination of 
phototherapy and topical agents (Taieb et al., 2013); however 
suitable facilities and equipment are needed, if this new 
guideline is to be implemented in the UK. 
Hand-held phototherapy units are currently used in 
Ninewells Hospital (Dundee, Scotland) for the treatment of 
psoriasis of the scalp mainly and in St. Woolos Hospital 
(Newport, Wales). Both hospitals have an international 
reputation for research into phototherapy and provide 
excellent phototherapy services.  Hand-held phototherapy 
units have been trialled there as a way of meeting the needs 
of their patients due to the large geographical area covered.  
Currently, there are several manufacturers of hand-held 
phototherapy units with the appropriate CE marking (IIb 
medical device) such as Waldmann and Androv. All have 
similar output as they use the same TLO1 bulb and are 
licensed to treat various skin conditions such as psoriasis of 
the scalp, vitiligo, and eczema. Hand-held phototherapy units 
are a new and potentially effective treatment for isolated areas 
of the body. Although no formal trials of the effectiveness of 
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this type of treatment have been conducted, participants have 
reported benefit (Yule, 2005). 
4.1.2 Home phototherapy  
Home phototherapy using whole body units is available 
for the treatment of other dermatological conditions such as 
psoriasis (Nolan et al., 2010). A recent, randomised, controlled 
trial comparing home (whole body units) versus hospital NB-
UVB phototherapy for mild and severe psoriasis concluded that 
home phototherapy is equally effective and implies no 
additional safety hazards compared to hospital phototherapy. 
Most of the participants said they would prefer future 
phototherapy at home over hospital. Home phototherapy 
lowered the burden of the treatment and improved 
SDUWLFLSDQWV¶TXDOLty of life (Koek et al., 2009).  
Similarly, a small, retrospective questionnaire study for 
the treatment of non-segmental vitiligo showed participant-
reported outcomes of home and outpatient NB-UVB therapy, 
as comparable, with similar repigmentation and occurrence of 
side-effects (Wind et al., 2010). In another questionnaire 
study that surveyed psoriasis, vitiligo, atopic dermatitis and 
mycosis fungoides, participants reported that all participants 
found home phototherapy to be effective, and agreed to 
continue, repeat and recommend it to others. The home 
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phototherapy units used in this study were hand/feet units and 
whole body units (Haykal and DesGroseilliers, 2006).  
Although, there are currently no studies evaluating 
hand-held NB-UVB devices for vitiligo; trials on the 
effectiveness and safety of these devices on scalp psoriasis at 
home, showed that this treatment is effective, well tolerated, 
easy to use and safe for the treatment of psoriasis (Dotterud 
and Braun, 2000; Caccialanza et al., 1989).  
4.1.3 NB-UVB phototherapy and carcinogenicity 
The issue of how great is the risk of carcinogenicity of 
NB-UVB is still unclear as there is no good evidence to date. 
The information provided below, is a summary of existing 
evidence as well as recommendations of the British Association 
of Dermatologists (Gawkrodger et al., 2008) and the Photonet 
network (Managed Clinical Network (MCN) for Phototherapy) 
NHS Scotland. 
Three studies, one with a very small number of 
participants (Weischer et al., 2004), and two others with 
limited follow-up (Man et al., 2005; Hearn et al., 2008) were 
unable to detect any definite increased risk of skin cancer 
following NB-UVB phototherapy. Few studies addressing the 
issue of possible carcinogenicity of broad-band UVB have been 
conducted but the overall impression has been that any 
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increased risk of skin cancer is low (Studniberg and Weller, 
1993). A larger study on 1,380 participants, also showed that 
UVB remains a relatively low-risk treatment for psoriasis (Lim 
and Stern, 2005). 
The adjusted (taking into account known risk factors, 
including PUVA exposure) incidence rate ratio for squamous 
cell carcinoma for >300 compared to <300 UVB treatments, 
was estimated at 1.37 (95% CI 1.03 to 1.83). Whether or not, 
the risk with narrow-band UVB is lower or higher than with 
broad-band UVB is not known (Photonet, 2010).  
A recent study, performed on 1,514 participants with 
vitiligo and 2,813 participants with no vitiligo, showed that 
there is a mutually exclusive relationship between 
susceptibility to vitiligo and susceptibility to melanoma i.e. 
vitiligo patients may have protection against melanoma (Jin et 
al., 2010). However, there are no trials performed on the risk 
of carcinogenicity of NB-UVB phototherapy on vitiligo patients 
and the consensus is made mainly on data from psoriasis 
patients.  
The BAD guidelines for diagnosis and management of 
vitiligo, advise that in view of the greater susceptibility of 
vitiliginous skin to sunburn and possible photo-damage (due to 
absence of melanin), it is advised that safety limits for NB-UVB 
Page 181 of 338 
for the treatment of vitiligo are more stringent than those 
applied to psoriasis, with an arbitrary limit of 200 treatments 
for skin types I±III. This could be higher for skin types IV±VI 
at the discretion of the clinician and with the consent of the 
participant (Gawkrodger et al., 2008). However, this limit is 
based mainly on specialist consensus and more research is 
needed to establish the optimum number of treatment 
sessions as well as maintenance regimen for vitiligo. 
4.1.4 Existing evidence behind phototherapy treatments 
for vitiligo  
NB-UVB is considered to be more effective light therapy 
for the treatment of vitiligo compared to PUVA (Yones et al., 
2007). Twelve trials compared NB-UVB as monotherapy to 
combination of NB-UVB with other agents (Whitton et al., 
2010). The Cochrane systematic review concluded that the 
light combination interventions were superior to 
monotherapies. Some form of light therapy is probably needed 
in order to induce the development and proliferation of the 
pigment cells, hence repigment the skin.  However, larger 
studies are needed in order to provide stronger evidence for 
the many combination interventions that have shown promise 
in treating vitiligo (Whitton et al., 2010). 
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Two studies have assessed the combination of ultraviolet 
light and topical corticosteroids (TCS) in treating vitiligo 
(Westerhof et al., 1999; Lim-Ong et al., 2005). Other studies 
have used a combination of these two treatments with other 
interventions (e.g. surgical treatments such as skin grafting) 
but the complexity of these multiple interventions make the 
findings less relevant. Many other studies have been published 
that assess combination treatments (including other light 
sources such as laser) with TCS, but again these combinations 
are sufficiently dissimilar to the proposed intervention in this 
pilot trial to limit their relevance. For example, the 308nm 
excimer light and excimer laser investigated in some of these 
studies has a similar wavelength to the NB-UVB, but the other 
properties of these light sources are very different from NB-
UVB. A further update of the Cochrane review is currently 
underway, but this has not identified any other studies 
assessing the specific combination of UV light and TCS.   
Previous studies, carried out to assess the effect of a 
combination of TCS and ultraviolet light, have considerable 
limitations. A trial conducted by Westerhof et al (1999) 
compared the combination of ultraviolet A light therapy and 
fluticasone propionate (a potent TCS) with mono-therapy, and 
showed evidence of improved pigmentation with combination 
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treatment. However, UVA is less widely used in recent years 
due to increased carcinogenicity compared to UVB.  
Lim-Ong et al (2005) showed that a combination of 
clobetasol propionate (a superpotent TCS) and NB-UVB 
produced improved repigmentation relative to mono-therapy, 
but this trial recruited only 25 patients; five of whom did not 
complete the study. The dropout rate for this study was 20% 
(inconvenience of the hospital visits was cited as the main 
reason for this) (Lim-Ong et al., 2005).  
Another study by Kroon et al in Amsterdam (trial 
registration: NCT01246921) assessing NB-UVB both alone and 
in combination with fluticasone propionate (a potent TCS) has 
recently been completed but final data are not yet available. 
This trial used full-body NB-UVB cabinets, as opposed to the 
hand-held devices to be used in this trial and aimed to recruit 
around 50 patients.  
Recently, some evidence has emerged that, early 
treatment of generalised vitiligo may enhance the chance of 
successful repigmentation (Hallaji et al., 2012). An open, 
uncontrolled study on 63 patients, 26 patients with recent (up 
to 4 years duration) and 37 patients with long standing 
disease (greater than 4 years duration), found statistically 
significant difference in overall response between the two 
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groups. Good to excellent response (50-100% repigmentation) 
was noted in 61.5% of patients with recent vitiligo compared 
to 27% of patients in long standing vitiligo group (Hallaji et al., 
2012). In addition, 2 case reports suggested that even acral 
vitiliginous areas, usually the most resistant body areas to any 
therapy, can be markedly improved by phototherapy if they 
have recent onset (up to three months duration) (Lee et al., 
2010a). Finally, another 2 case reports, showed that recent 
(up to 5 weeks duration) vitiliginous lesions on the face were 
successfully treated with oral prednisolone and topical 
tacrolimus (Lee et al., 2010b). 
In early stages of vitiligo (Chapter 1), some melanocytes 
are still present and functioning, providing a possible 
explanation for the results of the above described research. 
More studies are needed into the treatment of recent onset 
vitiliginous lesions (Lee et al., 2010a; Lee et al., 2010b). 
4.1.5 The link between the Top 10 uncertainties and this 
pilot trial 
The following four treatment uncertainties for vitiligo 
(out of the Top 10) refer to light therapy:  
x Which treatment is more effective for vitiligo: 
calcineurin inhibitors or light therapy? (3rd  uncertainty)  
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x How effective is UVB light therapy when 
combined with creams and ointments in treating vitiligo? 
(4th uncertainty) 
x Which treatment is more effective for vitiligo: 
steroid creams or light therapy? (8th uncertainty)  
x How effective is pseudocatalase cream 
(combined with brief exposure to UVB light) in treating 
vitiligo? (10th uncertainty) 
Alongside the Top 10 treatment uncertainties, other 
important general themes to be considered when designing a 
trial for vitiligo are 1) the effectiveness and safety of vitiligo 
treatments for children and 2) the optimal timing to treat 
(early vs. late) vitiligo (Table 2.6) (Eleftheriadou et al., 2011). 
It is clear from the above that the evaluation of NB-UVB, for 
both children and adults is of great interest and importance 
amongst patients and clinicians. 
Further evaluation of NB-UVB, both as combination 
therapy with topical agents as well as monotherapy, is needed. 
This would be feasible and more acceptable by using hand-
held devices since topical treatments are already routinely 
used for focal disease, limited to a few small patches and/or 
early disease. Therefore, a pilot trial on home hand-held NB-
UVB phototherapy would assist future research into the 
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treatment of vitiligo, based on the topics of importance for 
patients and clinicians (Eleftheriadou et al., 2011). 
4.1.6 Significance of proposed pilot trial on home hand-
held phototherapy for vitiligo 
There are several benefits of using hand-held devices at 
home such as (Mysore, 2009): 
x Reduction in attendance at hospital. 
Traditionally, patients receiving NB-UVB treatment 
would be required to attend hospital 2-3 times per week. 
x Sparing of uninvolved skin as only 
vitiliginous skin is exposed to NB-UVB. 
x Cheaper cost and less opportunity cost for 
patients such as travelling costs. 
x Treatment can be provided at an early stage 
of their disease, when the intervention might be more 
effective. Whole body NB-UVB is normally limited to 
patients with extensive disease (Gawkrodger et al., 
2008). 
Should a hand-held device prove to be effective and safe 
for the treatment vitiligo at home, this could be an important 
addition to the treatment options available to participants with 
limited and/or early disease such as on the face, hands, ears, 
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lips, or early stages when only few patches are present. Also 
hand-held devices could be a suitable treatment option for 
patients wishing to treat visible areas of vitiliginous skin only 
such as face.  
Feedback from patients (via the Vitiligo Society UK and 
the Vitiligo Support International) and healthcare professionals 
from the UK and other European countries also suggests that 
patients with vitiligo are currently buying these hand-held NB-
UVB units for home use, and are using them in an 
unsupervised way. Questions such as how far away to hold the 
unit, how long to treat each area, whether the areas around 
the vitiligo should be covered/masked in some way, and how 
long before results are seen are persistently being asked 
(personal communication). 
 
4.2 Objectives 
The main aim of this pilot trial is to determine the 
feasibility of conducting a subsequent definitive randomised 
controlled trial (RCT) looking into the effectiveness and safety 
of home hand-held NB-UVB phototherapy units both compared 
to and in combination with a topical treatment for early or/and 
focal vitiligo.  
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The primary objective of this pilot trial is: 
x To establish the proportion of eligible participants 
and their willingness to be randomised to home NB-UVB.  
The secondary objectives are: 
x To HVWDEOLVKSDUWLFLSDQWV¶ adherence and 
satisfaction in using home phototherapy.  
x To assess success of blinding of both participants 
and outcome assessors by using an identical placebo 
unit.  
x To establish possible short term side effects i.e. if 
the device is suitable for home use with limited medical 
supervision. 
x To manualise the treatment intervention (i.e. 
prepare a training package educating participants in how 
to use the intervention and how to deal with possible 
side effects). 
x To define and test the primary and secondarily 
outcome measures and the methods of data collection 
for the main RCT. 
This pilot trial did not aim to answer the question of 
whether the hand-held phototherapy devices are effective for 
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repigmentation and cessation of the spread of vitiligo or seek 
to change the CE authorisation for each device used.  
4.2.1 Ethics approval 
This trial was approved by the National Research Ethics 
Service (NRES) committee of East Midlands (REC reference: 
11/EM/0031) and registered with the clinicaltrials.gov. The 
trial registration number is ISRCTN: NCT01478945. This trial 
was conducted in accordance with the ethical principles that 
have their origin in the Declaration of Helsinki, 1996; the 
principles of Good Clinical Practice, and the Department of 
Health Research Governance Framework for Health and Social 
care, 2005. 
This study involved a CE-marked phototherapy unit that 
is being used within its normal licensing authorisation. As such, 
it did not require MHRA approval. 
 
4.3 Methods 
4.3.1 Trial configuration  
This was a pilot, double blind, multi-centre, parallel 
group randomised controlled trial (RCT) of hand-held NB-UVB 
phototherapy for the treatment of focal or early vitiligo at 
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home. The trial was designed to establish the feasibility of 
conducting a large scale RCT. The acronym for this trial was 
HI-Light trial for vitiligo (Home Intervention of Light therapy 
trial for vitiligo). 
Overall duration of the trial was seven months: 
recruitment period lasted three months (1st of March to 31st of 
May) and treatment period lasted four months (until 31st of 
September). This treatment period was chosen due to time 
limitation for this pilot; therefore this is unlikely to be 
sufficient to achieve meaningful treatment response. 
Participants were recruited from both primary and 
secondary care in Nottingham and Leicester. Mansfield 
community hospital and local GP practices (Nottingham and 
Leicester) were used as patient identification centres along 
with direct advertising to participants through the Vitiligo 
Society and the Centre of Evidence Based Dermatology 
(CEBD). Participants were randomly allocated to Group A 
(active Dermfix 1000), Group B (active Waldmann) and Group 
C (placebo Dermfix) in a 1:1:1 ratio. The allocation ratio to the 
active or placebo group was 2:1 (Figure 4.1). 
This trial configuration was chosen as it reflected the 
SDUWLFLSDQWV¶OLNHO\DOORFDWLRQWRDFWLYHDQGSODFHEo groups in 
the main RCT, as the latter is most likely to be a three arm or 
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a factorial trial involving the use of NB-UVB in combination 
with topical treatment. 
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Figure 4.1 Flowchart of the pilot Hi-Light trial 
configuration 
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4.3.2 Participants, settings and outcomes 
4.3.2.1 Recruitment and patient identification strategies 
Recruitment into the trial took place in Nottingham, 
4XHHQ¶V0HGLFDO&HQWUH40&DQG7UHDWPHQW&HQWUH7&
and Leicester, Leicester Royal Infirmary (LRI). Mansfield 
community hospital and local GP practices (Nottingham and 
Leicester) were used as participant identification centres 
(PICs).  
3DWLHQWV¶LGHQWLILFDWLRQFHQWUHVZHUHDVNHGWRUXQVHDUFK
into their database and identify potential participants with 
diagnosis of vitiligo who were five years old or older i.e. to use 
only the above mentioned two criteria rather than all the 
inclusion/exclusion criteria of the trial. Primary Care Research 
Networks (PCRN) in both Leicester and Nottingham were 
involved. We focused on GP practices that were within 15 
miles of the two recruitment centres (QMC and LRI). These 
included GP practices in Nottingham City, Nottingham county 
(southern part), Derby city, Derby county (southern part), 
Leicester city and Leicester/Rutland PCTs. Participants were 
only included in the trial if they were willing to travel to either 
Nottingham or Leicester-where the research teams were based. 
The principal investigators of both recruiting centres (Dr 
Jane Ravenscroft and Dr Anton Alexandroff) were aware of this 
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pilot trial from the starting point of the development of the 
protocol (September 2011). Hence, they compiled a list of 
prospective vitiligo patients, who were willing to be informed 
about the trial. 
The initial approach letter for potential participants 
identified in secondary and primary care was sent from their 
clinical care team in the first instance and included brief 
information about the trial and a reply slip (Figure 4.1). 
Adverts were placed on the website of the UK Dermatology 
Clinical Trials Network (UK DCTN), the Centre of Evidence 
Based Dermatology and patient support group, the Vitiligo 
Society UK. In the event of the number of participants 
identified by using the above means was not sufficient, our 
research team was prepared to also place adverts in local 
newspapers and radio, targeting black and ethnic minorities. 
Finally, posters were placed in the dermatology departments 
of recruitment sites. A dedicated website 
(www.vitiligostudy.org.uk) was available for the purpose of 
this trial.  
The following criteria were used to identify suitable 
participants for this trial: 
Inclusion criteria 
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1. Participants with a diagnosis of vitiligo confirmed 
by a dermatologist. Participants with focal disease, less 
than 25% of body surface area.  
2. Age: children and adults (no upper age limit). 
&KLOGUHQDJHG\HDUVRIDJHZHUHHOLJLEOHDVORQJDV
they were mature enough to understand that the eyes 
must be kept closed, and to remain still for the duration 
of treatment sessions.  
3. No therapy for vitiligo in the previous two weeks 
and no other vitiligo treatment during the trial other 
than as per trial protocol. 
4. Participants with both spreading and stable disease 
5. Participants able to give informed consent (or their 
parents/legal guardians). 
Participants were instructed to treat all their vitiliginous 
lesions; however for the purpose of the trial, up to three 
representative lesions were chosen by the research nurse and 
patient, preferably on three different anatomical areas e.g. 
face, hand, and leg, in order to assess treatment response and 
trial logistics at different body sites. Only representative 
lesions were included in the analysis.  If there were any 
lesions that participants did not want to treat, such as on non-
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exposed sites or areas difficult to reach, e.g. back, this was 
agreed with the research nurse at the beginning of the trial.  
The body surface area was estimated and recorded using 
the rule of nine (Chapter 1, page 47, VEFT vitiligo scoring and 
evaluation form) by calculating the affected area as a 
percentage of the whole body i.e. face and neck, upper limbs 
as 9% of the whole body surface each, 18% for the lower 
limps and anterior trunk each and 1% each for genitals, each 
palm and the back of each hand. 
Exclusion criteria  
1. Segmental vitiligo 
2. Universal vitiligo 
3. Previous history of skin cancer 
4. Recent or concurrent radiotherapy 
5. Photosensitivity 
6. Use of immunosuppressive or photosensitive drugs 
7. Pregnant or lactating women 
8. Any major medical co-morbidities  
9. Patients with vitiligo limited to the genitalia only, 
as these areas would not be suitable for phototherapy. 
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4.3.2.2 Informed consent 
All participants (or their parent/legal guardian if a 
participant was under the age of 16) provided written 
informed consent before they entered the trial. In addition to 
the main trial consent form, an additional consent form was 
signed on completion of the NB-UVB training session to 
confirm that the training took place and that participants (or 
their parents / legal guardians) understood how to use the 
devices during the trial. Once the consent forms were signed, 
a letter was VHQWWRWKHSDUWLFLSDQW¶V*3 informing them about 
their recruitment in the trial. 
4.3.2.3 Outcomes  
The primary outcome measure of interest for this pilot 
trial was the proportion of eligible participants with vitiligo who 
were willing to be randomised. This is the most critical 
component of the success of any future trial examining the 
effectiveness of hand-held NB-UVB for the treatment of vitiligo.  
The secondary outcomes were designed to further 
facilitate the design of a larger, controlled multi-centre trial: 
x Number of participants accepting the initial 
invitation to participate 
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x Proportion of participants fulfilling trial eligibility 
criteria 
x Proportion of participants adhering to the 
treatment protocol 
x Proportion of participants who were satisfied with 
the treatment and the Dermfix units in groups A and C 
and the Waldmann units in group B. 
x Proportion of participants for whom the blinding of 
the assessor was maintained 
x Proportion of participants for whom the blinding of 
the allocated group (active or placebo) was maintained  
x Percentage of missing data and withdrawal rates 
x Incidence of NB-UVB short term adverse events 
x Outcome measures for the main large trial were 
also tested: 
o Repigmentation rate of vitiliginous lesions 
presented in percentage of repigmentation 
quartiles: negative-0%, 1-24%, 25-49%, 50-74%, 
75-100%. Size of each representative lesion was 
traced by using skin mapping technique at baseline 
and week 16 visits. ConvaTec transparencies were 
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used to trace the lesions. These were later 
transferred onto clear film sheets and scanned. 
Scanned lesions were measured by using a freely 
available software for analysis and measurements 
of digital images, the ImageJ 1.47d (Image 
processing and analysis in Java by the National 
Institute of Health, USA; http://imagej.nih.gov/ij) 
o Cessation of spreading of vitiligo. Disease 
activity, both overall as well as for each 
representative lesion separately, was assessed on 
the baseline and the 16 week visits. In particular, 
patients were asked if they had noticed any new 
vitiligo lesions appearing or spreading of old ones 
during the past year. The same question was 
asked for each representative lesion i.e. whether 
the lesion in question was stable, spreading or 
spontaneously repigmenting during the last 12 
months.  
o Impact on the quality of life of participants. 
This was assessed using Dermatology Life Quality 
Index (DLQI) for adults (Finlay and Khan, 1994) 
and Children Dermatology Life Quality Index 
(CDLQI) (Lewis-Jones and Finlay, 1995) for 
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children on baseline and week 16 hospital visits. 
DLQI and CDLQI estimate the effect of a disease 
on patients quality of life i.e. the larger the score 
the bigger the HIIHFWLVRQSDWLHQW¶VOLIH-1 = no 
effect at all; 2-5 = small effect; 6-10 = moderate 
effect; 11-20 = very large effect; 21-30 = 
extremely large effect). Therefore, reduction in 
DLQI and CDLQI scores are interpreted as 
satisfaction with the treatment. 
o Global improvement in disease assessed by 
participants and researchers. The patient, research 
nurse and the independent outcome assessor, 
were asked at week 16 hospital visit, to rate the 
RYHUDOOFKDQJHVLQSDWLHQW¶VYLWLOLJR³+RZZRXOG
you rate the overalOFKDQJHVLQSDWLHQW¶VYLWLOLJR"´
using a 5 point Likert-scale (much worse; a bit 
worse; no change; a bit better and much better). 
o Participant-defined outcome questionnaire 
for vitiligo3DWLHQW¶V%HQHILW,QGH[3%, (Augustin 
et al., 2008) (Chapter 1, page 52). PBI was 
FDOFXODWHGRQWKHEDVLVRIWKHSDWLHQW¶VGHILQHG
need questionnaire completed at baseline and the 
SDWLHQW¶VEHQHILWTXHVWLRQQDLUHFRPSOHWHGDWZHHN
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16 visit. The needs prior to therapy and the 
benefits achieved by therapy were converted to a 
weighted index value, the PBI. Its values range 
from zero (no benefit) to four (maximum benefit) 
(Augustin et al., 2008). 
o Satisfaction with response, including 
cosmetic acceptability of the results. Satisfaction 
with the treatment response was assessed by 
asking participants to rate how satisfied they were 
DIWHUWKHFRPSOHWLRQRIWKHWULDO³+RZVDWLVILHGDUH
\RXZLWKWKHWUHDWPHQW"´,QDGGLWLRQSDWLHQWV
and research nurses were asked to rate the colour 
match of each representative lesion as bad, good, 
fair or excellent ³3OHDVHUDWHWKHFRORXUPDWFKRI
\RXURU\RXUSDWLHQW¶VYLWLOLJRSDtches following 
light treatment´DWweek 16 appointment. 
 
4.3.3 Trial procedures 
4.3.3.1 Pre-trial contact (telephone call/ email) (Figure 4.1; 
Table 4.1 and 4.2) 
On receipt of a potential participant¶s contact details 
(either in response to approach letter, or through advertising), 
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an age-appropriate information sheet was sent and a member 
of the research team based at the co-ordinating centre, made 
contact, either by telephone or e-mail. An overview of the trial 
was given and provisional eligibility was established. If the 
participant was potentially eligible and willing to attend for a 
screening visit, an appointment with a research nurse and a 
dermatologist was made, at the closest participating hospital. 
4.3.3.2 Screening / randomisation / educational visit 
During this visit the participant (or their parent/legal 
guardian) was given the opportunity to discuss the trial further, 
with a member of the trial team and answer any questions 
they might have had.  
The initial trial visit took approximately 1.5-2 hours and 
included the following activities: 
x Informed consent. 
x Confirmation of diagnosis and suitability for NB-
UVB treatment by a dermatologist. 
x Confirmation of other eligibility criteria. 
x Confirmation of vitiliginous lesions to be treated 
and assessed. 
x Collection of outcomes and baseline data. 
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x Conduction of Minimum Erythema Dose (MED) test 
LQRUGHUWRHVWDEOLVKSDUWLFLSDQW¶VWUHDWPHQWSODQpage 
209 for MED test methods). 
x Training session on how to use the UVB devices, 
how to complete the treatment diary and what to do in 
case of side effects (page 216). 
4.3.3.3 Baseline visit  
Participants returned to the hospital the following day 
and their MED results were read. MED results were recorded in 
WKHSDUWLFLSDQWV¶QRWHV,IDSDUWLFLSDQWIDLOHGWRUHWXUQDIWHU
hours for the results of the MED test, then the starting dose 
for their skin type, determined by a dermatologist was used. 
The start date of the treatment was confirmed with the 
participants, by taking into consideration the two weeks 
washout period, in case the participant was on any treatment 
for vitiligo. Participants were given their home UVB device 
(boxed and sealed in order to protect blinding of the research 
nurse).  
4.3.3.4 Scheduled Interim Follow-up visits and Telephone calls 
Interim follow-up contact with the participant was 
scheduled as follows: 
x 7 days (telephone call) 
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x Week 2 (telephone call) 
x Week 8 (2 months) (face-to-face visit at clinic) 
x Week 12 (3 months) (telephone call) 
x Week 16 (4 months) (face-to-face visit at clinics) 
These follow-up contacts enabled the trial team to 
answer any questions and to address any areas of concern the 
participants had and provided support and reassurance for the 
participants, if needed.  
During the follow-up contacts (telephone calls and face-
to-face visits), all the participants were asked about adherence 
to their treatment plan and reminded about the correct use of 
hand-held phototherapy. 
4.3.3.5 Week 8 clinic visit 
The 8 week face-to-face visit was conducted at the 
hospital and relevant outcomes were measured (Table 4.1). 
4.3.3.6 Final Trial visit at 16 weeks 
 At this visit, the following trial procedures were carried 
out: 
x Participants were clinically examined and 
outcomes recorded by both their usual research nurse 
and by an independent assessor. This was done 
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primarily in order to test the feasibility of the blinding of 
the outcome assessor for the main RCT.  
x Assessment of success of blinding was achieved by 
asking the research nurse and participants to guess the 
group to which the latter had been allocated (active 
Group A and B or placebo group C). 
x Assessment of the secondary outcomes, such as 
re-pigmentation rate of representative vitiligo lesions, 
cessation of spread of vitiligo, impact on the quality of 
life, global improvement and short term side effects of 
phototherapy. Participants were asked to score their 
satisfaction with the treatment and global improvement 
in their vitiliginous lesions based on digital images taken 
on the baseline hospital visit. 
x Adherence to the phototherapy regimen was 
assessed through the SDUWLFLSDQWV¶GLDULHV 
x Participants were asked for their opinion on their 
participation in the trial. Issues that were addressed, 
included acceptability of the intervention, reasons for 
non-adherence and any suggestions of how the trial 
FRXOGEHLPSURYHGIURPDSDUWLFLSDQW¶VSHUVSHFWLYH$OO
the participants were asked if they would like to join the 
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Centre of Evidence Based Dermatology mailing list in 
order to be contacted regarding future research. 
Participants, who were in the placebo group, were 
offered the opportunity to use the active device at home for 
further four months if they wished. 
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Table 4.1 Summary of Hi-light trial schedule and procedures which took place during each visit
Pre-trial
contact
Screening/
enrolment/
educational visit
Baseline
visit
Follow-up telephone calls
(Weeks 1, 2, 6 & 12)
Follow-up
face-to-face visit
(Week 8)
Final trial visit
(Week 16)
Discuss trial-pre-screening ¥ ¥
Obtain informed consent ¥
Check eligibility Including MED test Randomisation ¥
MED test results ¥
Outcomes assessment ¥ ¥ ¥
Education on hand-held devices including how to
deal with side effects, detailed treatment schedule
¥ ¥
Assessment of phototherapy short-term side
effects
¥ ¥
Discuss trial progress and any skin problems ¥ ¥ ¥
Discuss adherence to the treatment regimen and
satisfaction with the device
¥ ¥ ¥
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Table 4.2 Summary of Hi-Light trial schedule and duties of each member of research team
Dermatologist CLRN nurse/staff Trial manager (Dr Viktoria
Eleftheriadou)
Central CLRN
Administrator
Pre trial x Provide info about
the trial by
telephone/email
x Provide info about the trial by
telephone/email
x Pre-eligibility check over the
phone
x Provide info about the trial
x Pre-eligibility check over the
phone
x Advertising and publicity
Screening/
Randomisation/education
visit
x Confirm diagnosis
x Confirm participants
skin type
x Issue prescription for
phototherapy
x Provide info about
the trial and obtain
informed consent
x Data collection
x Educational session
on how to use the
devices
x Perform MED test
x Provide info about the trial and
obtain informed consent
x Data collection
x Educational session on how to
use the devices
x Perform MED test
x Randomisation
x Package hand-held
phototherapy units ready for
distribution according to
randomisation schedule
Baseline visit x MED test results x MED test results x MED test results
Follow-up telephone calls x Conduct telephone
follow-ups including
book appointments
x Coordinate appointments and
follow-up calls at all recruitment
x Conduct telephone follow-ups
and coordinate appointments at
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as appropriate
x Refer to
dermatologist if
necessary
sites
x Refer to dermatologist if
necessary
sites
8 weeks visit x Take digital images of
vitiliginous lesions
x Conduct outcome
assessment
x Monitor adherence
x Monitor side effects
and refer to
dermatologist if any
concerns
x Take digital images of vitiliginous
lesions
x Conduct outcome assessment
x Monitor adherence
x Monitor side effects and refer to
dermatologist if any concerns
16 weeks visit x Conduct blinded
outcome assessment*
x Take digital images of
vitiliginous lesions
x Monitor adherence
x Monitor side effects
Conduct outcome
assessment
x Conduct blinded
outcome
assessment*
x Take digital images of vitiliginous
lesions
x Monitor adherence
x Monitor side effects
x Conduct outcome assessment
x Conduct blinded outcome
assessment*
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Overall care x Provide medical cover
for any adverse events
that require medical
attention
x Be the first point of
contact for serious
adverse events for out
of hours or weekends
(on-call dermatology
SpR)
x Provide medical cover
if needed for any
adverse events that
require medical
attention
x Trial manager duties i.e. be the
first point of contact and
coordinate all the recruitment
sites, ensure the appointments
are booked, the CRFs are up to
date, photos are taken
x Be the first point for contact for
participants and investigators
regarding the trial configuration
and conduction
x Provide medical cover if needed
for any adverse events that
require medical attention
x Be the first point of contact for
side effects or advice on how to
use the device or deal with side
effects (from 9:00 to 17:00
Monday to Friday)
x Refer to dermatologist or nurse
if needed for review
*A dermatologist or a research nurse was able to act as an independent outcome assessor only for patients, he (she) did not assess at baseline, week 8 or any unscheduled
telephone calls or visits. In other words, the independent assessor should have not had any previous contacts with the patient during the trial except baseline visit in order
to remain blinded.
Page 211 of 338 
4.3.3.7 Unscheduled and emergency calls/visits 
Participants were asked to record any side effects in 
their diaries and contact the co-ordination centre for advice if 
needed, at any point during the trial. If the participant 
developed any side effects such as redness, dry skin, burn, 
blister, cold sores etc., they were asked to call the central 
administrator first, who then arranged for them to see a 
dermatologist if needed. 
Participants were also given the contact details of their 
local hospital, which they were instructed to contact if they 
needed advice out of hours or over the weekend, regarding 
side effects. The on-call dermatology SpR (who was briefed in 
advance about the study) provided advice over the telephone 
or asked the participant to attend the dermatology department 
if needed.  
4.3.3.8 Withdrawal  
If a participant wished to withdraw from the trial, they 
were asked to attend for a final trial (withdrawal) visit. At this 
visit, the same procedures as for the final trial visit at four 
months were carried out, if the participant was willing to 
attend. If the participant was not willing to attend, then as a 
minimum, the trial team attempted to establish the reason for 
withdrawal by a telephone interview. The device had to be 
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returned to their local hospital or, if this was not feasible, sent 
back by recorded delivery.  
4.3.3.9 Criteria for terminating the trial 
This was a pilot trial to explore the logistics of the 
definitive main RCT. It involved CE-marked phototherapy units 
that were being used within their normal licensing 
authorisation. As such, this trial had a very low risk. However, 
if severe adverse effects, associated with the unit, would have 
occurred frequently, the study would have been terminated. 
 
4.3.4 Trial management 
The trial was co-ordinated from the Centre of Evidence 
based Dermatology, by the Trial Manager (myself). A Trial 
Management Group (TMG), which included me, Professor 
Hywel Williams, Dr Kim Thomas, Dr Jane Ravenscroft, Dr 
Robert Dawe, Mrs Maxine Whitton and Dr Jonathan Batchelor, 
held two teleconferences, every three months depending on 
the requirements of the trial as it progressed. The trial was 
supported by two part-time CLRN nurses in Nottingham and 
one in Leicester. 
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This small pilot trial and so both the Data Monitoring 
Committee (DMC) and the Trial Steering Committee (TSC) was 
not deemed necessary.  
The Chief Investigator had overall responsibility for the 
study and oversaw all study management with a trial manager 
(myself) responsible for the day to day running of the study. 
 
4.3.5 Data collection 
Each participant was assigned a trial identity code 
number, allocated at the pre-screening stage, for use on the 
case report forms (CRFs), other trial documents and the trial 
database. The database also used the initials of the participant 
and their date of birth. CRFs were treated as confidential 
documents and held securely in accordance with Data 
protection regulations. A separate confidential record was kept 
RIWKHSDUWLFLSDQW¶VQDPHGDWHRIELUWKORFDOKRVSLWDOQXPEHU
or NHS number, and Participant Trial Number (the Participant 
Screening and Enrolment Log), to permit identification of all 
participants enrolled in the trial, in case additional follow-up 
was required. CRFs were restricted to those personnel 
approved by the Chief or local Principal Investigator and 
UHFRUGHGRQWKHµ6LWH'HOHJDWLRQ/RJ¶ 
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All trial staff and investigators endeavoured to protect 
WKHULJKWVRIWKHWULDO¶VSDUWLFLSDQWVWRSULYDF\DQGLQIRUPHG
consent, and adhered to the Data Protection Act, 1998. The 
CRFs were held securely, in a locked room and locked cabinet 
both centrally, at the Centre of Evidence Based Dermatology 
(CEBD), and locally, at the relevant hospital. Access to the 
information was limited to the trial staff and investigators and 
relevant regulatory authorities if needed.  
The database was designed specifically for this trial (IT 
expert-Graham Watson). Once the paper CRFs were completed 
by the research nurse, they were then faxed over to the CEBD 
and entered onto the database by the co-ordination centre 
administrator. A sample of CRFs (10%) was checked for 
verification of all entries made, by the trial manager (VE). All 
electronically held data, including the trial database were held 
securely and password protected. Electronic data was backed 
up every 24 hours to both local and remote media in 
encrypted format.  
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4.3.6 Intervention 
4.3.6.1 Hand-held devices 
In the introduction section of this chapter, I outlined the 
basic characteristics of hand-held devices. These units are CE-
marked and are being used within their licensing agreement. 
In this trial I explored two different hand-held NB-UVB 
devices, Dermfix 1000 NB-UVB and Waldmann NB-UVB 109, 
with the same output, but a few differences such as the size of 
treatment area, weight of the unit and cable length (Table 4.3).  
By doing this I was able to monitor and assess which of the 
two units was best tolerated in WHUPVRISDUWLFLSDQWV¶
satisfaction and minimisation of side effects, if any. The 
information gathered assisted in the choice of device for the 
main RCT.  
Finally, I have also identified another hand-held NB-UVB 
device with various automated features such as treatment 
regimen based on skin type, dose reduction in case of side 
effects and calculation of total treatment sessions and total 
exposure time. However, this device is not approved for use in 
Europe yet. 
Group A participants were using Dermfix 1000 NB-UVB 
(device A), Group B participants were using Waldmann NB-
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UVB 109 (device B) and Group C received a placebo Dermfix 
1000 NB-UVB (device C).  
Both devices (A and B) are phototherapy lamps with an 
on/off switch and an external digital timer. The user of each 
device had to follow the written treatment plan, set and re-set 
the timer each time manually and keep an accurate diary of 
exposure times and post treatment side effects.  
 
Table 4.3 Characteristics of various hand-held NB-UVB      
(311 nm) devices freely available for sale on the internet 
Features Dermfix 
1000 NB-
UVB by 
Androv 
Waldmann NB-
UVB 109 
Dermaray UV 109 
  
 
Digital timer External 
³NLWFKHQ
WLPHU´ 
Needs manual 
resetting prior 
each 
treatment 
session 
([WHUQDO³NLWFKHQ
WLPHU´ 
Needs manual 
resetting prior 
each treatment 
session 
Integrated automated timer 
Calculates automatically 
treatment time based on 
SDWLHQW¶VVNLQW\SH 
Automatic 
treatment 
plan 
No  No  Yes 
Automatically reduce dose 
in case of side effects o 
Integrated 
diary 
No  
Patients must 
keep diaries: 
lesion name, 
No 
Patients must 
keep diaries: 
lesion name, 
Yes 
Able to store up to 32 
lesions for each patients, 
automatically calculate 
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treatment 
time and side 
effects 
treatment time 
and side effects 
treatment time based on 1) 
treatment session and 2) 
side effects from previous 
treatment session  
Safety 
features from 
overexposure 
Spacer 
(plastic teeth) 
Spacer (plastic 
teeth) 
Spacer (plastic teeth) 
Automatically switch off 
after each treatment 
session. 
Other alerts ( i.e. lamp not 
hold correctly or if used a 
next day rather than the 
day after next of the 
previous treatment) 
Power supply Has to be 
connected to 
the socket all 
the time 
Has to be 
connected to the 
socket all the time 
Rechargeable battery (or 
connected to the socket) 
Compliance 
monitoring 
n/a n/a Stores total treatment 
session number and total 
exposure time.  
Weight Light  More heavy 
compared to other 
two 
Light 
Treatment 
window 
shape and 
size 
Oval  
12 X 6.5 cm 
Rectangular  
10 X 4 cm 
Rectangular 
10 X 6 cm 
Price £165 £256 
 
$ 695 
 
CE marking Class IIb 
medical 
device 
Class IIb medical 
device 
Class I TGA (Australia) and 
CE medical device i.e. not 
licenced for medical use in 
Europe yet 
 
The placebo device used (C), was identical to the active device 
Dermfix 1000, with the only difference, being that a special 
plastic cover which blocked the emission of NB-UVB rays was 
used, instead of the standard cover used on the active devices. 
Both covers (on active and placebo units) were visually 
identical. 
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4.3.6.2 Treatment plan 
Each participant received a personalised treatment plan 
according to his/her Fitzpatrick skin type. There were four 
treatment plans available: skin type I, II, III and IV-VI (Table 
4.4). Each plan included treatment times per session for the 
first 60 sessions i.e. until the maximum exposure time (MET) 
was reached (Table 4.4). 
 
Table 4.4 Summary of treatment schedule according to the 
participants skin type 
Skin 
Type 
Starting 
time 
Exposure time 
+20% of 
treatment 1 
Exposure time 
-20% of 
treatment 1 
Maximum 
exposure 
time (MET) 
Total 
duration 
I 15 sec +3 seconds -3 seconds 3 min 4 months 
II 20 sec +4 seconds -4 seconds 4 min 4 months 
III 25 sec +5 seconds -5 seconds 5 min 4 months 
IV 30 sec +6 seconds -6 seconds 6 min 4 months 
V 30 sec +6 seconds -6 seconds 6 min 4 months 
VI 30 sec +6 seconds -6 seconds 6 min 4 months 
 
At the screening/randomisation/educational visit, the skin type 
for each participant was established by 1) a dermatologist 
(criteria for Fitzpatrick skin type table 4.5) and 2) a Minimal 
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Erythema Dose (MED). During the MED test, the skin was 
exposed to 10 doses of NB-UVB. The test was performed by 
using Durham UVB erythema test device (Hybec MED tester), 
a portable device which is the same size as the hand-held NB-
UVB lamps. The device has 10 apertures with different grid 
densities, which determined the dose of light emitted (Picture 
4.2). The MED test was performed on inner surface of the 
SDUWLFLSDQW¶VIRUHDUP:HDLPHGWRSHUIRUPWKHWHVWRQVNLQ
affected by vitiligo, however normal skin was used, if the 
above mentioned area was not affected by vitiligo or the patch 
was not big enough. Participants were required to return the 
following day for reading of the MED test result (Picture 4.2). 
 
Picture 4.2 (A) Durham UVB erythema test device by Hybec (B) Picture 
showing skin after a Minimal Erythema Dose test 
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Manufacturers of the devices suggest a treatment plan 
DFFRUGLQJWRWKHSDWLHQW¶VVNLQW\SHGHWHUPLQHGE\VWDQGDUG
criteria (Table 4.5) for Fitzpatrick skin type, rather than the 
results of the MED test. In order to test the suitability of the 
treatment plan provided by the manufacturers, I compared the 
results of the MED test determined skin type and the 
dermatologist recorded skin type. This was important in order 
to determine whether or not the MED test was necessary for 
the future RCT, or whether dose based on a dermatologist 
recorded skin type alone was safe and effective.   
 
Table 4.5 Criteria for Fitzpatrick skin types 
I Always burns, never tans 
II Usually burns, tans less than average (with difficulty) 
III Sometimes mild burn, tans about average 
IV Minimally burns, tans more than average (with ease) 
V Rarely burns, tans profusely 
VI Never burns, tans profusely 
 
Based on the average MED for various skin types 
(Palmer et al., 2006) (Figure 4.2), the initial dose (treatment 
session 1) was approximately ¼ of the dose causing erythema 
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for example, for skin type I, the median MED is 200 mJ/cm2 
and the dose that a participant with the same skin type 
received was 54 mJ/cm2 (Table 4.5). 
 
Figure 4.2 Median MED (in mJ/cm2) for each Fitzpatrick 
skin type compared to initial treatment doses in this trial. 
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Table 4.6 Summary of the Minimal Erythema Dose (MED) test 
results (in J/cm2) in correspondence to the phototherapy 
treatment plan prescribed. 
Dosage in J/cm2 0.50 
MED 
tester 
aperture 
MED 
performed 
on normal 
skin 
(J/cm2) 
Treatment 
regimen 
according to 
MED normal 
skin 
MED 
tester 
Aperture 
MED 
performed 
on vitiligo 
skin(J/cm2) 
Treatment 
regimen 
according to 
MED vitiligo 
skin 
Open 0.5 
)LW]SDWULFN¶V
skin type  
4-6 
Open 0.5 
)LW]SDWULFN¶V
skin type  
4-6 
2 0.45 
FLW]SDWULFN¶V
skin type  
4-6 
2 0.45 
)LW]SDWULFN¶V
skin type  
4-6 
3 0.38 
)LW]SDWULFN¶V
skin type 3 
3 0.38 
)LW]SDWULFN¶V
skin type  
4-6 
4 0.31 
)LW]SDWULFN¶V
skin type 2 
4 0.31 
)LW]SDWULFN¶V
skin type  
4-6 
5 0.24 
)LW]SDWULFN¶V
skin type 1 
5 0.24 
FitzSDWULFN¶V
skin type  
4-6 
6 0.18 
)LW]SDWULFN¶V
skin type 1 
6 0.18 
)LW]SDWULFN¶V
skin type 3 
7 0.15 
)LW]SDWULFN¶V
skin type 1 
7 0.15 
)LW]SDWULFN¶V
skin type 2 
8 0.13 
)LW]SDWULFN¶V
skin type 1 
8 0.13 
)LW]SDWULFN¶V
skin type 1 
9 0.10 
)LW]SDWULFN¶V
skin type  1 
9 0.10 
)LW]SDWULFN¶V
skin type  1 
10 0.08 
)LW]SDWULFN¶V
skin type 1 
10 0.08 
)LW]SDWULFN¶V
skin type 1 
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Table 4.7 Example of 
individualised treatment plan for 
skin type I for the first five 
sessions (see Appendix for 
treatment schedules for all skin 
types) 
 
If the starting dose suggested in the table 4.6 was more 
than the MED for the individual participant, the protocol was 
adjusted i.e. the treatment plan prescribed was approximately 
50% of the MED test results,  performed on vitiliginous skin or 
approximately 25% of the MED test results performed on 
normal skin. In case the MED test results were unreadable, 
skin type recorded by the dermatologist was used as a 
JXLGDQFHWRGHWHUPLQHSDUWLFLSDQW¶VWUHDWPHQWSODQ 
By performing the MED tests and by using cautious 
treatment plan times, the safety of the trial participants was 
ensured (Palmer et al., 2006).  
4.3.6.3 Treatment plan and erythema  
The treatment was self-administered by the participants 
or their carers on alternate days i.e. participants were advised 
to undergo treatments at least three times a week and no 
Skin type I  Treatment time 
Treatment 1 15 sec 
Treatment 2 18 sec  
Treatment 3 21 sec 
Treatment 4 24 sec 
Treatment 5 27 sec 
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more than four times a week but never on consecutive days. 
The initial time of exposure on vitiliginous lesions 
corresponded to the starting time on the table 4.6 as above. 
For each treatment session, the exposure time was 
incremented by 20% of the treatment 1 time (Table 4.4 and 
4.7). Participants continued to increase their exposure time if 
they did not have any erythema reactions, until the maximum 
exposure time (MET) (Table 4.4) was reached. Once the MET 
was reached, the exposure time of all consecutive treatment 
session remained the same i.e. equal to the MET. 
In case of a Grade 1 erythema (settles within a day; 
NOT painful), participants were instructed to decrease the 
exposure time by 20% of treatment 1 time e.g. if the 
participant experienced grade 1 erythema after the 3rd 
treatment ( 21 seconds), she/he administered 18 seconds 
rather than 24 on the day of treatment four (Table 4.7). 
In the case of a Grade 2 erythema (lasts for around two 
days. NOT painful), the participant missed a treatment day 
and was instructed to decrease the exposure time by 20% of 
the treatment 1 time e.g. if after treatment session three on 
Monday, the participant developed a Grade 2 erythema, 
he/she missed the next treatment day on Wednesday and 
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continued on Friday with decreased time exposure as per 
treatment two i.e. 18 sec. 
In the case of a Grade 3/4 erythema (very red, like 
sunburn, lasts for two ± three days, hot and painful, with 
possible blistering), the participant was instructed not to treat 
vitiliginous lesions and to seek medical advice from the 
research team. If this occurred, participants were instructed to 
stop treatment and to seek medical advice.  
The following instructions relating to missed treatments 
that are NOT due to erythema reaction were given to the 
patients: 
1) One or two missed treatments: administer exposure 
time decreased by 20% of treatment 1 time i.e. same as per 
erythema Grade 1. 
2) Three treatments or more missed: contact the 
research team for advice.  
 
4.3.7 Training sessions 
4.3.7.1 Training sessions for research staff 
Before the initiation of the trial the research nurses 
attended four training sessions on: 
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x How to deliver face-to-face training session 
to the participants of the trial. The session was 
delivered by both me and a phototherapy nurse 
from Dundee (Mrs Susan Yule). This session 
included a role play with a volunteer psoriasis 
patient, member of the Centre of Evidence Based 
Dermatology (CEBD) patient panel. 
x How to measure outcomes, complete the 
appropriate CRFs and conduct the 
screening/randomisation/educational, baseline, 
week 8 and week 16 hospital visit training during 
the trial (three sessions). I organised and 
delivered these sessions. These sessions also 
included MED test training, reminder on what and 
how to advice the participants in case of side-
effects during the trial and how to reduce the 
treatment times. A detailed guidance manual with 
all the above covered information was also given 
to the research nurses (see appendix). 
Finally, the co-ordination centre administrator was also 
trained on how to provide information about the trial to the 
potential participants and pre-screen them over the telephone, 
how to complete the relevant follow-up calls CRFs and how to 
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provide guidance to the participants on possible side effects. 
The above training was performed by me. 
4.3.7.2 Training session for participants 
During the screening/randomisation/educational hospital 
visit, each participant received a one-to-one training session 
with a member of the research team (either by me or a 
research nurse) on how to self-administer phototherapy at 
home correctly. The training session lasted between 40 min 
and 1 hour. 
The educational session included the following: 
x Safe operation of the hand-held phototherapy 
device. 
x Accurate recording of treatment i.e. how to fill in 
the treatment diary.  
x Possible short term side-effects of the NB-UVB 
phototherapy and how to deal with them including the 
contact details of appropriate people to contact in case 
of emergency. 
x Correct administration of treatment according to 
the treatment plan, which included adjustment of the 
treatment time according to the erythema response. 
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x A supervised treatment session.  
If the participant was a child, the carer or parent was 
required to accompany him/her during the educational session 
in order to be taught how to administer the treatment at home. 
If the participant or their parent/carer did not demonstrate 
competence in administering treatment, then the training 
programme was extended.  
On completion of the training session, each participant 
ZDVVXSSOLHGZLWKD³SDUWLFLSDQWSDFN´ZKLFKLQFOXGHGD
training manual on how to deal with side-effects and adjust 
treatment times accordingly (see appendix), a treatment diary, 
UV protective goggles, a pair of cotton gloves to be worn 
during each treatment and protect hands from overexposure 
and a copy of consent forms (pre and post training session).  
 
4.3.8 Adherence  
3DUWLFLSDQWV¶DGKHUHQFHWRWKHWUHDWPHQWZDVPRQLWRUHG
by reviewing their treatment diaries. Participants or their 
parent/legal guardian (active and placebo) were asked to 
complete a treatment diary with details of the date of 
treatment, duration of treatment for each lesion and presence 
or absence of any side-effects from the previous treatment 
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session. Participants were instructed to complete their 
treatment diaries accurately and before each treatment 
session. 
During the follow-up telephone calls and the week 8 
hospital visit, participants were reminded to fill out their 
diaries in order to ensure their own safety. 
Adherence was monitored using the following 
parameters: 
x Number of treatment sessions per week i.e. three 
to four.  
x At least one day should be left between 
consecutive treatment sessions. 
x If a treatment session was missed due to side 
effects and the treatment plan was resumed correctly, 
participants were considered compliant with the 
treatment plan. 
x In case of missed sessions due to side effects or 
any other reasons, the treatment time had to be reduced 
correctly, DVSHULQVWUXFWLRQVJLYHQLQWKHSDWLHQW¶V
manual and training session. 
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4.3.9 Output of the hand-held phototherapy units 
During this trial, I collaborated with the Medical Physics 
and Clinical Engineering department of the Nottingham 
University Hospitals NHS Trust, Queens Medical Centre. This 
was necessary in order to 1) conduct the safety testing of the 
devices prior to the trial (as a standard procedure for all NHS 
trials involving devices) and 2) investigate the output of the 
two hand-held devices  used in this  trial in order to assist the 
decision on which one to use in the main trial. 
For the characterisation of these devices, three main 
parameters were measured pre-trial and post-trial for each 
device: 1) device output (both irradiance and integrated dose), 
2) output variation with respect to time and 3) tube spectral 
profile. 
All the testing and measurements were performed and 
provided by Mr Richard Farley-clinical technologist (Radiation 
physicist) of the Medical Physics and Clinical Engineering.  
4.3.9.1 Device output 
In order to determine the variation of the irradiance 
output (mWcm-2) across all the hand-held devices, the 
integrated dose (mJcm-2) was recorded for each one.  It was 
important that the setup was repeated the same for each 
device for both the pre and post-trial measurements. All the 
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irradiance and integrated dose measurements were recorded 
using an International Light Technologies ILT1700 radiometer 
with an International Light Technologies SED005 UVB detector. 
The experimental setup involved using two retort stands 
with clamps to hold the hand-held device and UVB detector in 
a fixed position during the measurements.  The centre of the 
UVB detector was positioned to a reference point for each of 
the hand-held devices.  As both types of hand-held devices 
used comb attachments, the reference point for each device 
was centrally between the 7th and 8th tooth and at the tip of 
the comb attachment for the Waldmann units and centrally at 
the 7th tooth and at the tip of the comb attachment for the 
Dermfix units.   
Both the irradiance output and integrated dose 
measurements were achieved with the devices cold, i.e. they 
had been left to cool for at least 30 minutes before being used 
in order to ensure there was no effect of tube heating. 
Additionally, both the hand-held device and UVB detector were 
covered using a thick black shroud. This was to protect the 
operator from scattered UV radiation and to stop any external 
UV sources contributing to the measurement (i.e. the ceiling 
fluorescent lamps that have UVB mercury lines). 
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The irradiance measurements, involved recording the 
output at several different time points, with the timer started 
from the point of lamp ignition.  The time points included 
measuring at two minutes which correlates with the local 
Quality Assurance (QA) routine testing protocol for TLO1 tubes.  
Additionally, the irradiance was measured at 20s, 50s and 85s 
which related to different treatment times based on the 
treatment plan; there was a further measurement at three 
minutes.  The integration measurements were recorded in 15s 
increments (up to 210 s).  
4.3.9.2 Output variation with time 
Output variation with time measurements were 
performed in order to determine how the output varied during 
treatment and how uniform the output was over time. A 
Bentham double grating spectroradiometer with a Bentham D6 
cosine response diffuser were used to perform the above 
measurements. The experimental setup was the same as the 
device output measurements, but instead the D6 diffuser was 
positioned in front of the UVB devices. The Bentham 
spectroradiometer was set to measure a stationary wavelength 
at 311nm rather than scanning across the UV range. The 
spectroradiometer system was initialised so that it continually 
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measured the irradiance at 311nm for 10 minutes after the 
UVB device lamp ignition, taking a reading every second. 
4.3.9.3 Tube spectral profile 
The final measurements involved recording the tube 
spectral profile of the hand-held devices across a selected 
range (specifically covering the UVB spectrum 280nm-315nm).  
This was performed in a same way as the output variation with 
time described above. The Bentham spectroradiometer was 
set to measure a pre-defined range of 250nm to 450nm, with 
a spectral resolution of 0.5nm. 
The Minimal Erythema Dose (MED) testers used in the 
trial were also tested for output. Irradiance and integrated 
dose measurements were recorded using an International 
Light Technology ILT1700 radiometer with an International 
Light Technologies SED005 UVB detector. 
Dosimetry for each of the hand-held active devices and 
of the MED testers were checked in the same way, so that we 
could be sure, within a reasonable margin of error (up to 20%) 
that 1 Jcm-2 delivered by the MED tester was the same as 
1 Jcm-2 delivered by the hand-held active treatment unit. 
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4.3.10 Statistics and sample size 
4.3.10.1 Statistical analysis 
Demographic characteristics of the participants, 
measures of adherence to the treatment plan and all other 
outcomes data, including outcomes for the main RCT, were 
summarised by descriptive statistics (number[n], mean, 
standard deviation [SD], median, minimum and maximum) or 
frequency tables, stratified by active/placebo groups. 
No formal testing or interim analyses was conducted 
since this was a pilot study to determine answers to questions 
for the definitive trial. No assessment of efficacy was 
performed. Only a few potential likely adverse events were 
envisaged for this pilot study and so all adverse events were 
tabulated by these adverse events categories. All randomised 
participants who participated in at least one treatment and for 
whom at least one post-baseline assessment of the primary 
endpoint was available, were analysed. 
All analyses were performed using Stata SE 11 and MS 
Excel 2007. 
The transparencies of vitiliginous lesions were used to 
assess area of involved skin at each representative lesion. 
Tracings were scanned and analysed using the ImageJ 1.47d 
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(Image processing and analysis in Java by the National 
Institute of Health, USA; http://imagej.nih.gov/ij). 
4.3.10.2 Sample size and justification  
This was a pilot study, with sample size being resource 
driven in terms of available participants in a reasonable time 
frame, for which no formal statistically based sample size 
estimate was applicable.  
For this pilot study, 21 participants (seven participants in 
each group) from two recruitment sites allowed us to compare 
the devices and to measure recruitment rate for each site; it 
also gave a reasonable estimate of the acceptability and 
completeness of the outcome data. 
 
4.3.11 Randomisation and blinding  
4.3.11.1 Randomisation  
The randomisation was based on a computer-generated 
pseudo-random code, using random permuted blocks of 
randomly varying size, created by the Nottingham Clinical 
Trials Unit (CTU) in accordance with their standard operating 
procedure (SOP) and held on a secure University of 
Nottingham server. The randomisation was stratified by the 
recruiting site (Nottingham and Leicester). Only the trial 
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administrator at the co-ordinating centre and the data 
manager at the Nottingham CTU were aware of the allocation 
to active or placebo group. The research nurse accessed the 
treatment allocation for each participant, by means of a 
remote, internet-based randomisation system developed and 
maintained by the Nottingham CTU. The sequence of 
treatment allocations was concealed until all interventions 
were assigned and recruitment, data collection, and all other 
trial-related assessments were complete. In other words, the 
research nurse randomised participants during the baseline 
visit, however the results of the randomisation were only 
visible to the co-ordination centre administrator, who 
subsequently packed all the devices identically. 
4.3.11.2 Blinding  
In order to assess the blinding for the main RCT, 
participants were given their home UVB device boxed and 
sealed in identical packages. At the end of the trial, each 
participant and research nurse, were asked to guess the 
SDUWLFLSDQW¶V group allocation; active or placebo. To ensure 
that blinded outcomes assessment was performed at week 16 
hospital visit, an independent research nurse or clinician 
assessed the representative lesions (Table 4.8). 
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4.3.12 Missing data 
Every effort was made to reduce the proportion of 
missing data through trial quality assurance procedures and 
adherence to standard operating procedures, produced by the 
University of Nottingham.  
Tabulation of missing data and looking for reasons for 
any missing data was performed for this study. This 
information was crucial to find out the main reasons for 
missing data (if any) and then amend the study procedures to 
minimise this loss, in the definitive trial.  
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Table 4.8 Summary of blinding status of participants and 
research team members and possible issues around their un-
blinding 
 Blinding 
status 
Possible issues 
Participants Blinded 
May be compromised if they 
experience side-effects (e.g. redness 
of the skin) or tanning. 
Research nurses / 
trial manager (Dr V. 
Eleftheriadou) 
Blinded 
Potential to become unblinded if 
discussing side-effects with 
participants, and during clinic visits. 
Outcome 
assessment (in 
clinic ± clinician or 
independent 
research nurse) 
Blinded 
An independent research nurse / 
clinician assessed the vitiligo at week 
16 in order to provide blinded 
outcome assessment. Blinding might 
have been compromised if the skin 
was tanned around the lesion. 
Outcome 
assessment (digital 
image assessment 
by independent 
assessor) 
Blinded 
An independent assessor calculated 
the surface area of the vitiligo 
patches. 
Blinding may be compromised if the 
skin is tanned around the lesion. 
Trial administrator 
at the co-ordination 
centre 
Not 
blinded 
Was the main point of contact for 
participants wishing to contact the 
research team, packaged and posted 
the devices to the participants 
according to the randomisation 
schedule, and provided general advice 
on how to deal with minor side-
effects. 
Statistician Blinded  
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4.3.13 Side effects  
For this feasibility trial, only a limited number of known, 
common, short term adverse events that could possibly be 
related to the NB-UVB phototherapy were collected: 
  Erythema  
o Grade 1 erythema (mild) ±barely perceptible 
and resolves within 48 hours 
o Grade 2 erythema (moderate) - well defined 
erythema causing slight manageable discomfort. 
o Grade 3 erythema (severe) well defined 
symptomatic/ painful erythema. 
o Grade 4 (very severe) painful erythema, 
usually with bullae. 
 Blistering 
 Burns  
 Pruritis 
 Perilesional hyperpigmentation 
 Hypersensitivity reactions  
 Cold sores 
 Dry skin 
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The above grading system for erythema is widely used in 
dermatology, however it was not validated. 
The purpose of collecting these was to test the feasibility 
of recording and collecting this information for the main RCT. 
In case of any serious adverse events (if any), these 
were reported to the REC and the Chief Investigator was 
responsible for this. 
A Serious Adverse Event (SAE) was any adverse event 
occurring, that results in any of the following outcomes: 
x Death 
x Inpatient hospitalisation or prolongation of existing 
hospitalisation 
x Persistent or significant disability / incapacity 
x A congenital anomaly or birth defect in the 
offspring of a participant 
x Other medical events may be considered to be a 
SAE if they require medical or surgical intervention to 
prevent one of the outcomes listed in this definition. 
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4.3.14 My personal contribution to this trial 
I played a key role in all phases of this trial.  
4.3.14.1 Pre-trial 
I conceived the idea of conducting a trial on hand-held 
devices, did extensive research on what brands of devices are 
available in the UK, their prices and their licensing 
DXWKRULVDWLRQ$IWHULGHQWLI\LQJWZRVXLWDEOH³FDQGLGDWHV´
Androv and Waldmann, I established working relationship with 
the manufacturers, in order to secure an identically looking 
placebo unit for each device and subsequently choose which 
one was better for this pilot trial. I also negotiated with the 
manufacturers on the purchasing price of the devices, 
arranged their delivery and liaised with the medical physics 
department. 
In addition, I visited the St. Woolos and Ninewells 
+RVSLWDOV¶SKRWRWKHUDS\GHSDUWPHQWV,FROODERUDWHGZLWK'U
Robert Dawe (co-investigator for Hi-Light pilot trial) and Ms 
Susan Yule (phototherapy nurse) during the conduction of this 
trial. In addition, I met Professor Alex Anstey, dermatologist 
and international expert in phototherapy, to share my ideas 
about this trial, gather information on how they perform 
RXWSXWDQGFDOLEUDWLRQPHDVXUHPHQWVDQGSDWLHQWV¶HGXFDWLRQ
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on hand-held devices and what treatment plans they use in 
their clinical practice. 
I wrote the trial protocol, the patient information leaflets 
DQGGHVLJQHGDOOWKH&5)VSDWLHQW¶V and researcher guidance 
manuals and all the rest of the necessary paperwork for this 
trial. Also, I applied for and was granted, all the necessary 
approvals for the trial including ethics, Comprehensive Local 
Research Network (CLRN) support and Primary Care Research 
Network (PCRN) support.   
Finally, I delivered training sessions to the research 
nurses and trial administrators, as mentioned above. 
4.3.14.2 During the trial 
I was extensively involved in all stages of the trial (Table 
4.2) as well as performed the duties of the trial manager. I 
recruited patients in both Nottingham and Leicester and 
supervised the research nurses when they were delivering 
training sessions to the patients. I also developed the idea of 
pre-screening potential participants over the phone, prior their 
attendance to the clinics. Finally, I performed all the final week 
16 visits in Nottingham recruitment centre. 
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4.3.12.3 Post-trial 
I analysed all the vitiliginous lesions transparencies 
(acetate sheets), including repigmentation measurements 
using the ImageJ 1.47d programme (http://imagej.nih.gov/ij) 
and MS office Excel 2010. For the statistical analysis of this 
trial, I performed the majority of the analysis and was also 
advised by a junior CTU statistician, who ran Stata code (Stata 
SE 10). 
 
4.4 Results 
4.4.1 Recruitment and eligibility 
4.4.1.1 Proportion of participants accepting initial invitation to 
participate  
The trial gained all the necessary approvals and started 
recruitment on the 1st of March 2012. Although this was four 
months later than originally anticipated, due to the 
overwhelming response, the trial closed for recruitment in only 
three months, on the 31st of May 2012 (instead of six months). 
In total, 97 people approached us, expressed interest in 
this pilot trial and were subsequently pre-screened either 
completely or partially. People, who expressed interest in the 
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trial were identified through: primary care (28/97; 29%), 
secondary care (38/97; 39%), the Vitiligo Society UK (14/97; 
14.5%), vitiligo newsletter (4/97; 4%), other sources such as 
Google search engine and personal contacts (13/97; 13.5%). 
4.4.1.2 Secondary care 
In total 48 invitation letters with reply slips were sent to 
vitiligo patients, who attended dermatology departments of 
WKH4XHHQ¶V0HGLFDO&HQWUHRIWKH1RWWLQJKDP8QLYHUVLW\
Hospitals (31 patients) and the Leicester Royal Infirmary(17 
patients). We received 38 (response rate=79%) completed 
reply slips from patients, who were willing to be contacted and 
pre-screened by the research team (Nottingham response 
rate=93.5% (29/31), Leicester response rate=53% (9/17)). 
4.4.1.3 Primary care 
Two GP surgeries (one Leicester and one in Nottingham) 
sent 67 invitation letters (Leicester 35 letters and Nottingham 
32 letters) and we received 28 completed reply slips (total 
response rate=40%). It was not possible to calculate the 
response rate per each surgery as the reply slips were not 
identifiable. 
In addition, six more GP practices (three in Leicester and 
three in Nottingham) expressed interest in running the 
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searches and sending invitation letters and reply slips to 
vitiligo patients. However, due to the overwhelming response 
from the secondary care patients, these surgeries were asked 
not to send invitation letters. 
Also, the Vitiligo Society UK sent 74 invitation letters to 
its members who live in Nottingham, Leicester and 
Birmingham. Fourteen patients were interested in the trial 
(response rate=19%). 
Finally, 284 vitiligo newsletters (via email) were sent to 
the participants of the vitiligo PSP informing them about the 
trial. There is a significant overlap between those and the 
Vitiligo Society UK members. 
4.4.1.4 Pre-screening of participants prior baseline hospital 
visit 
In total, 55.6% (54/97) of participants were successfully 
pre-screened and provisionally met the trial eligibility criteria. 
Twenty eight percept of participants were ineligible (27/97) 
and 16.4% (16/97) patients were not fully pre-screened 
(Figure 4.3). Due to the overwhelming response, we were 
forced to notify some of the people who sent us a reply slip 
that we had completed recruiting. Understandably, several 
people, although expressed interest in being informed about 
future trials, were not interested in answering all of the pre-
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screening questions and therefore were only partially pre-
screened.  
Fig.4.3 Summary of recruitment sources into Hi-Light trial 
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Eighty three per cent of eligible participants (45/54) on 
the pre-screening phase were willing to attend the baseline 
visit and be randomised. These were identified through: 47% 
(21/45) secondary care, 22% (10/45) primary care, 13.5% 
(6/45) the Vitiligo Society UK, 4% (2/45) from vitiligo 
newsletter (i.e. participants of vitiligo PSP) and 13.5% (6/45) 
from other sources such as Google and personal contacts.   
Provisionally eligible patients who were not willing to be 
randomised (9/54; 17%) gave the following reasons: concern 
about the risk of burning (2/9; 22%), treatment sounded too 
time consuming (1/9; 11%), inconvenient time period due to 
forthcoming holidays (1/9; 11%), possible allocation to 
placebo group (1/9; 11%). The rest did not specify any 
reasons (4/9; 45%). 
Finally, reasons for exclusion from the trial were: regular 
photosensitive drugs (19/27; 70%), segmental vitiligo (7/27; 
26%), widespread vitiligo (4/27; 1.5%) and known 
photosensitivity (2/27; 7.5%). There were patients with more 
than one exclusion criteria. 
4.4.1.5 Proportion of participants fulfilling trial eligibility 
criteria at baseline hospital visit  
We originally expected to recruit 21 participants into the 
trial. We identified 45, provisionally eligible and willing 
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participants by telephone pre-screening; however due to time 
and financial constrains we were not able to allocate them all 
into this trial. 
Only twenty nine of the 45 potential participants were 
booked to attend for a baseline visit. Potential participants 
ZHUHERRNHGLQWRFOLQLFVRQ³ILUVWFRPH-ILUVWVHUYHG´EDVLV
(5/29) from primary care; 52% (15/29) from secondary care, 
17% (5/29) from the Vitiligo Society, 7% (2/29) from vitiligo 
newsletter and 7% (2/29) from other sources such as Google). 
All participants who attended the baseline visit were 
confirmed eligible and were subsequently randomised into the 
trial (29/29; 100%) (Figure 4.4). In conclusion, 29 
participants with 84 representative lesions were randomised 
into three intervention groups (Table 4.9). 
Table 4.9 Baseline characteristics of participants  
Baseline 
characteristics 
All groups  Active 
intervention   
groups (A+B) 
Placebo 
intervention 
group (C) 
Number of 
participants 
29 19 10 
Age range 
(years) 
5-71 5-71 13-51 
Age mean 
(years); SD 
Adults 
Children 
31.7+/-17.9 
38.6+/-14.8 
10.25+/-3.5 
27.63+/-18.6 
38+/-15.8 
9.9+/-3.6 
39.4+/-13.5 
42.3+/-10.85 
13+/-0 
Sex 15/14 10/9 5/5 
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(Female/Male) 
Ethnicity: 
White British 
Mixed 
Black/Black 
Caribbean 
Indian 
Pakistani 
Asian  
Other ethnic 
group 
 
20/29 (69%) 
1/29 (3.5%) 
2/29 (7%) 
2/29 (7%) 
1/29 (3.5%) 
2/29 (7%) 
1/29 (3.5%) 
 
12/19 (64%) 
1/19 (5%) 
2/19 (11%) 
1/19 (5%) 
1/19 (5%) 
1/19 (5%) 
1/19 (5%) 
  
8/10 (80%) 
None 
None 
1/10 (10%) 
None 
1/10(10%) 
None 
Duration of 
vitiligo (years) 
Mean;+/-
SD(min;max) 
 
12.28+/-9.67 
(min=2; 
max=33) 
 
11.36+/-10.12 
(min=2;max=33) 
 
14.01+/-8.5 
(min=5;max=28) 
Vitiligo activity 
(Overall) 
Stable 
Spreading 
Repigmenting  
 
 
6 
19 
4 
 
 
3 
14 
2 
 
 
3 
5 
2 
BSA% covered 
by vitiligo 
Mean;+/-SD 
(min;max) 
8.83+/-6.19 
(min=2;max=25) 
9.84+/-5.96 
(min=3;max=25) 
6.9+/-6.17 
(min=2;max=21) 
Number of 
lesions  
84 56 28 
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Figure 4.4 Flow diagrams of randomised participants 
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4.4.2 Withdrawals, adherence and satisfaction with the 
treatment  
4.4.2.1 Withdrawals 
Three of 29 participants (10%) withdrew from treatment 
during the 4-month period (two patients (67%) from active 
groups and one patient (33%) from placebo group). Only one 
(3%) participant was lost to follow-up. The reasons for 
withdrawals were that the treatment was too time consuming 
(3%; 1/29) and the lack of improvement in vitiligo (7%; 2/29). 
4.4.2.2 Adherence  
Twenty eight of the 29 diaries (97%) were returned to 
the trial team and analysed.  One diary was never returned to 
our research team as the patient was lost to follow-up during 
the trial. The diaries of the three participants who withdrew 
from treatment were also included in the analysis. 
Twenty five of the 29 (90%) participants adhered to 
treatment i.e. performed treatment for four months. 
Twenty one of the 28 (75%) participants administered 
phototherapy at home three to four times a week and left at 
least one day between consecutive treatment sessions. Six 
participants as instructed, omitted one session due to 
treatment side effects i.e. erythema grade 2, resumed their 
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treatment plan correctly and were deemed adherent to the 
treatment plan. 
Seven participants (25%) did not follow the treatment 
plan as instructed. The following mistakes made were: 1) no 
treatment time reduction was made, following a missed 
treatment session and no reason for the missed session was 
noted (6/28; 21%) and 2) incorrect time reduction following 
one week missed sessions due to chickenpox (1/28; 4%). 
When asked at the end of the trial, if the training 
received during the baseline visit was adequate and whether it 
was easy to decide on the grade of erythema, 100% (28/28) 
and 90% (25/28) replied positively respectively. The rest 10% 
ZHUHQ¶WVXUHLIWKH\FRXOGHDVLO\GHcide on the 
erythema grade. 
4.4.2.3 Satisfaction with the treatment 
7ZHQW\HLJKWSDUWLFLSDQWVUHSOLHGWRWKHTXHVWLRQ³+RZ
VDWLVILHGDUH\RXZLWKWKHWUHDWPHQW"´E\FRPSOHWLQJWKHHQG
of study questionnaire (96.5%).Participants in the active 
groups were more likely to be satisfied with their treatment 
than participants allocated to placebo group (31.5% versus 
20%) (Table 4.10). 
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Table 4.10 Proportion of participants satisfied with the 
treatment     
Satisfaction with the 
treatment 
Active 
groups 
(N=19) 
Placebo group  
(N=10) 
 
Total (N=29) 
Very dissatisfied 5 (26%) 1 (10%) 6 (20.7%) 
Somewhat dissatisfied 1(0.5%) 2 (20%) 3 (10.3%) 
Neutral 6 (31.5%) 5 (50%) 11 (37.9%) 
Somewhat satisfied 6(31.5%) 2 (20%) 8 (27.6%) 
Very satisfied 0 (0%) 0 (0%) 0 (0%) 
Missing  1 (0.5%) 0 (0%) 1 (3.4%) 
 
When asked whether they would use the hand-held 
device again, 68% (19/28) of participants answered positively, 
ZHUHQ¶WVXUHDQGVDLGQR 
When asked whether they would recommend the device 
to others, the results were similar to the previous question: 64% 
(18/28) said yes; 28% (8/28) said maybe and 8% (2/28) said 
no. 
Both devices (Dermfix and Waldmann) received the 
following similar positive comments: easy to use, portable and 
compact, convenient to operate at home instead of coming to 
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the hospital. Additional positive comments on Dermfix devices 
were regarding their convenient size. 
Negative comments about both devices were mainly 
about inconvenience of spacers (plastic teeth) and lack of 
treatment response. 
 
4.4.3 Success of blinding  
Overall, 30% (8/27) of participants and 40% (11/27) of 
research nurses did not guess the treatment allocation 
FRUUHFWO\ZKHQDVNHG³'R\RXWKLQN\RX\RXUSDWLHQWKDYH
KDGDQDFWLYHRUDGXPP\GHYLFH"´7DEOHVDQG
Three main reasons for unblinding of the research nurses were 
given. In the active treatment groups, erythema (3/10; 30%) 
and improvement in vitiligo (6/10, 60%) were cites as reasons 
for unblinding.  In the placebo group, unblinding was driven by 
lack of treatment response (6/6; 100%). 
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Table 4.11 Proportion of participants for whom the blinding of 
the research nurse was maintained 
³:KDWGHYLFHGR\RX
think the patient 
KDG"´ 
 Group allocation in the trial 
Placebo 
treatment 
(Group C; 
N=10) 
Active 
treatment 
(Group A+B; 
N=19) 
Total 
(N=29) 
Active  4 (40%) 10 (52.6%) 14 (48.3%) 
Placebo  6 (60%) 7 (36.8%) 13 (44.8%) 
Missing data 0 (0%) 2 (10.5%) 2 (6.9%) 
 
 
Table 4.12 Proportion of participants for whom the blinding 
was maintained 
³:KDWGHYLFHGR
you think you 
KDG"´ 
Group allocation in the trial 
Placebo 
treatment 
(Group C; 
N=10) 
Active treatment 
(Group A+B; 
N=19) 
Total 
(N=29) 
Active 4 (40%) 13 (68.4%) 17 (58.6%) 
Placebo 6 (60%) 4 (21.1%) 10 (34.5%) 
Missing data 0 (0%) 2 (10.5%) 2 (6.9%) 
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4.4.4 Missing data  
As described above, it was not always possible to fully 
pre-screen participants over the telephone (16/97; 16.4%).  
All participants, except one who was lost to follow-up, 
completed the end of study questionnaire in full (28/29; 
96.5%). The DLQI and PBI questionnaires at baseline and 
week 16 were completed by 96.5% (28/29) of participants 
also; at baseline one participant did not complete the 
questionnaires. One missing diary and week 16 questionnaire 
(3%; 1/29) belonged to the lost to follow-up patient.  Our 
research team made every effort possible to contact and find 
the patient, including reaching out to his regular GP. 
Unfortunately neither the diary nor the device were recovered. 
 
4.4.5 Side effects  
Side effects such as erythema grades 1 and 2, pruritis, 
hyperpigmentation around the lesions and dry skin were self-
reported by the participants in their diaries. In the case of 
erythema grades 3 and 4, hypersensitivity reaction and cold 
sores, participants were advised to call the research nurse or 
the co-ordination centre and an adverse event form was 
completed (Table 4.13). 
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Table 4.13 Side effects for active (A+B) groups and placebo 
(C) group per number of patients and incidents 
 
Side effects 
Active arms Placebo arm Total 
Patients Incidents Patients Incidents Patients Incidents 
Erythema grade 1 6 18 2 14 8 32 
Erythema grade 2 4 5 0 0 4 5 
Erythema grade 3 1 1 0 0 1 1 
Erythema grade 4 0 0 0 0 0 0 
Sold sores 1 1 0 0 1 1 
Dry skin 3 5 0 0 3 5 
Hyperpigmentation 3 10 0 0 3 10 
Pruritis 1 1 1 1 2 2 
 
4.4.6 Repigmentation   
Overall, mean size of all (84) representative lesions at 
baseline was 17.12 cm2 (SD=+/- 20cm2; min=0.35cm2; 
max=107.5cm2; median=90.6cm2). After 16 weeks of 
treatment, only a slight decrease in mean lesions size was 
noticed; mean size of all representative lesions was 16.80 cm2 
(SD=+/- 19.37cm2; min=0.05cm2; max=83.9cm2; 
median=10.95cm2).  In active groups (A+B), the mean size of 
all lesions was 15.42cm2 at baseline (SD=+/- 20.2cm2; 
min=0.35cm2; max=107.5cm2; median=67.7cm2) and 14.43 
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cm2 at week 16 visit (SD=+/- 18cm2; min=0.05cm2; 
max=83.87cm2; median=67.1cm2). For the placebo group, a 
slight deterioration in mean lesion size was seen, 20.54 cm2 at 
baseline (SD=+/- 19.4cm2; min=1.34cm2; max=76.6cm2; 
median=15cm2) and 21cm2 at week 16 visit (SD=+/- 
20.85cm2; min=1.5cm2; max=76.9cm2; median=15.4cm2).  
When analysing the overall treatment response per 
participant, mean percentage of repigmentation of all 
representative lesions for each participant was estimated. This 
was done by simply finding the total difference in size, of all 
lesions at baseline and week 16 in cm2. The results were 
afterwards converted into percentages and allocated to one of 
the five groups (negative-0%, 1-24%, 25-49%, 50-74%, 75-
100%). In active groups, 12% (2/17) of participants had high 
grade repigmentation (75-100%) compared to none in placebo 
group (Table 4.14). 
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Table 4.14 Mean percentage of repigmentation for all 
representative lesions per participant  
Number of 
participants in 
Mean % repigmentation after 16 weeks of 
treatment per participant 
³-³-0   1-24  25-49 50-74 75-100 Total 
Active groups 
(A+B) 
6 (35%) 8 (47%) 1 (6%) 0 2(12%) 17 
Placebo group 
(C) 
4 (40%) 6 (60%) 0 0 0 10 
Total  10 (37%) 14(52%) 1 (4%) 0 2 (7%) 27 
 
In the active groups, the anatomical sites which 
responded best to treatment were the face and neck. Thirty 
three percentage of lesions achieved repigmentation above 75% 
in these areas. In addition, 17% of lesions on the trunk and 8% 
of lesions on upper limbs (except hands) also showed very 
good treatment response i.e. repigmentation above 75% 
(Pictures 4.3 and 4.4). Overall, 75% (29/39) of all lesions in 
the active group showed some response to the treatment 
(Table 4.15). 
On the other hand, in the placebo group, none of the 
anatomical areas achieved repigmentation above 40%. Thirty 
nine per cent of lesions showed some degree of 
repigmentation (9/23) (Table 4.16). 
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Table 4.15 Percentage of repigmentation (negative-0%, 1-
24%, 25-49%, 50-74%, 75-100%) in active groups (A+B) for 
each anatomical site (face and neck, trunk, lower limbs except 
feet, upper limbs except hands, hands and feet) 
 Anatomical site 
Face/neck Trunk Upper 
limbs 
Lower 
limbs 
Hands/feet 
Number of 
participants*  
6 6 13 11 3 
Repigmentation:       
Negative-0% 2 (33%) 3 (50%) 3 (22%) 2 (18%) 0 
1-24% 1 (17%) 2 (33%) 8 (62%) 7 (64%) 2 (67%) 
25-49% 1 (17%) 0 1 (8%) 2 (18%) 1 (33%) 
50-74% 0 0 0 0 0 
75-100% 2 (33%) 1(17%) 1 (8%) 0 0 
Baseline:  
Mean lesion size 
(cm2+/-SD) 
75.4+/-
7.4 
13+/-
15.9 
11.2+/-
10.9 
21+/-
29.1 
18.9+/-
25.7 
16week:   
Mean lesion size 
(cm2+/-SD) 
47.4+/-
4.4 
13.7+/-
17.4 
10.3+/-
9.6 
20.6+/-
25.8 
22.6+/-
26.6 
* One lesion per anatomical site per participant was analysed. If two or 
more lesions were available on the same anatomical site, lesion on the 
right side was chosen. If no lesions were available on the right side, then 
the lesion, which repigmented the most, was included in the analysis. 
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Picture 4.3 Facial vitiliginous lesion (A) at baseline and (B) after 16 weeks 
of home NB-UVB phototherapy 
Picture 4.4 Vitiliginous lesion on the trunk (A) at baseline and (B) after 16 
week of treatment with home NB-UVB phototherapy 
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Table 4.16 Percentage of repigmentation (negative-0%, 1-
24%, 25-49%, 50-74%, 75-100%) in placebo group (C) for 
each anatomical site (face and neck, trunk, lower limbs except 
feet, upper limbs except hands, hands and feet) 
 Anatomical site 
Face/neck Trunk Upper 
limbs 
Lower 
limbs 
Hands/feet 
Number of 
participants*  
5 1 8 5 4 
Repigmentation:       
Negative-0% 3 (60%) 0 3 (37%) 5(100%) 2 (50%) 
1-24% 1 (20%) 1(100%) 5 (63%) 0 2 (50%) 
25-49% 1 (20%) 0 0  0  0 
50-74% 0 0 0 0 0 
75-100% 0  0 0 0 0 
Baseline:  
Mean lesion size 
(cm2+/-SD) 
10.7+/-
5.6 
34.8 22.6+/-
18.4 
22.6+/-
24 
20.9+/-
8.8 
16week:   
Mean lesion size 
(cm2+/-SD) 
11.3+/-7 28.2 23.2+/-
21.6 
26.1+/-
27.2 
20.7+/-
6.4 
*One lesion per anatomical site per participant was analysed. If two or 
more lesions were available on the same anatomical site, lesion on the 
right side was chosen. If no lesions were available on the right side, then 
the lesion, which repigmented the most, was included in the analysis. 
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4.4.7 Cessation of spreading of vitiligo, global 
improvement and colour match 
4.4.7.1 Cessation of spreading  
Seventy eight representative lesions were assessed 
(93%; 78/84) at week 16 hospital visit due to withdrawal and 
loss in follow-up. In the active groups (A+B), 44% of lesions 
(22/50) remained stable throughout the trial. Twenty two per 
cent (11/50) of stable lesions started repigmenting.  Fifty 
seven per cent (4/7) of actively spreading lesions stopped 
progressing (Table 4.17). 
On the other hand, in the placebo group, eight lesions in 
the placebo group had also stopped spreading (28%; 8/28) 
during the trial (Table 4.18). 
 
Table 4.17 Lesions stability in groups with active 
interventions (A+B)  
Lesion stability 
at baseline visit 
Lesion stability at week 16 hospital visit 
Stable Spreading Repigmenting Total 
Stable 22 (44%) 7 (17.5%) 11 (27.5%) 40 (80%) 
Spreading 4 (57%) 3 (43%) 0 7 (14%) 
Repigmenting 0 0 3 (100%) 3 (6%) 
Total  26 (52%) 10 (20%) 14 (28%) 50 
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Table 4.18 Lesions stability in group with placebo intervention 
(C) 
Lesion stability 
at baseline visit 
Lesion stability at week 16 hospital visit 
Stable Spreading Repigmenting Total 
Stable 13 (72%) 1 (6%) 4 (22%) 18 (64%) 
Spreading 8 (80%) 0 2 (20%) 10 (36%) 
Repigmenting 0 0 0 0 
Total  21 (75%) 1 (4%) 6 (21%) 28 
 
 
4.4.7.2 Global improvement in vitiligo 
When asked to rate the overall changes in vitiligo 
following treatment,  around half of patients, research nurses 
and independent outcome assessors, rated changes in 
UHSUHVHQWDWLYHOHVLRQVDV³DELWEHWWHU´ RU³PXFKEHWWHU´7DEOH
4.19 and 4.20). 
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Table 4.19 Global improvement in vitiligo rated by patients, 
research nurses and independent outcomes assessors for 
active groups (A+B)  
Global improvement in vitiligo Patient 
 
Research 
nurse 
Independent 
outcome assessor 
Much worse 1(5%) 0 0 
A bit worse 0 3 (18%) 0 
No change 7 (39%) 6 (35%) 5 (29.5%) 
A bit better 7 (39%) 4 (23.5%) 8 (47%) 
Much better 3 (17%) 4 (23.5%) 4 (23.5%) 
Total number of assessments 18 17 17 
 
Table 4.20 Global improvement in vitiligo rated by patients, 
research nurses and independent outcomes assessors for 
placebo group (C) 
Global improvement in vitiligo Patient 
 
Research 
nurse 
Independent 
outcome assessor 
Much worse 0 0 0 
A bit worse 0 1 (10%) 1 (10%) 
No change 6 (60%) 5 (50%) 7 (70%) 
A bit better 4 (40%) 4 (40%) 2 (20%) 
Much better 0 0 0 
Total number of assessments 10 10 10 
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4.4.7.3 Colour match of vitiliginous patches 
In active groups, when asked to colour match the 
representative vitiliginous lesions, 30% of patients, 32% of 
research nurse and 24% of independent assessors, rated the 
colour on the newly repigmented lesions as good or excellent. 
On the other hand, no one rated the colour match of newly 
repigmented lesions as good or excellent in the placebo group 
(Table 4.21 and 4.22). 
 
Table 4.21 Colour match in representative vitiliginous lesions 
as rated by patients, research nurses and independent 
outcomes assessors for active intervention groups (A+B) 
Colour match 
at week 16 
visit 
Patient Research 
nurse 
Independent 
outcome assessor 
Bad 27 (51%) 25 (50%) 23 (46%) 
Fair 10 (19%) 9 (18%) 15 (30%) 
Good 15 (28%) 14 (28%) 12 (24%) 
Excellent 1 (2%) 2 (4%) 0 
Total 53 50 50 
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Table 4.22 Colour match in representative vitiliginous lesions 
as rated by patients, research nurses and independent 
outcomes assessors for placebo intervention group (C) 
Colour match 
at week 16 
hospital visit 
Patient Research 
nurse 
Independent 
outcome assessor 
Bad 20 (71%) 21 (75%) 20 (71%) 
Fair 8 (29%) 7 (25%) 8 (29%) 
Good 0 0 0 
Excellent 0 0 0 
Total 28 28 28 
 
 
4.4.8 Quality of life and benefit evaluation in vitiligo 
4.4.8.1 Quality of life 
Twenty eight participants (96.5%) completed either 
Dermatology Life Quality Index questionnaire (DLQI) or 
&KLOGUHQ¶V'HUPDWRORJ\/LIH4XDOLW\,QGH[&'/4,2YHUDOO
there was a little change in the DLQI scores from baseline to 
week 16, suggesting that the treatment had little impact on 
quality of life (Table 4.23). 
&KLOGUHQ¶V'HUPDWRORJ\/LIH4uality Index was not 
analysed due to insufficient numbers of children in the trial. 
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Table 4.23 Dermatology Life Quality Index at baseline and 
week 16 hospital visits 
DLQI scores Placebo group 
(C) (N=9) 
Active groups 
(A+B) (N=12) 
Total 
(N=21) 
Baseline mean +/-SD 3.8+/-3.2 2.8+/-2.3 3.3+/-2.7 
16 week mean +/-SD 3.7+/-3.8 3.2+/-2.3 3.4+/-3 
Baseline min ± max 0 - 10 0 - 6 0 - 10 
16 week min ± max 0 - 12 0 - 7 0 - 12 
Baseline missing 
questionnaires 
0  1 (8.3%) 1 (4.8%) 
16 week missing 
questionnaires 
0 1 (9%) 1(5%) 
 
4.4.8.2 Benefit evaluation in vitiligo 
Twenty seven participants (93%) completed both the 
SDWLHQW¶VQHHGTXHVWLRQQDLUH3NQ) at the baseline visit and 
SDWLHQW¶s benefit questionnaire (PBQ) at the week 16 hospital 
visit. The need prior to therapy (PNQ) and the benefits 
achieved by therapy (PBQ) were converted to a weighted 
index value, the patient benefit index (PBI). The values of PBI 
range from zero=no benefit to four=maximal benefit. 
There was no difference between the active and placebo 
groups in the PBI index.  The mean PBI for active groups (17 
participants was 0.92 (SD+/- 1.16; min=0; max=3.68) and 
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mean PBI for placebo group (10 participants) was 0.91 (SD+/-
0.99; min=0; max=3.26). Both groups reported a PBI of 
approximately 1, which equals tR³VOLJKWEHQHILW´ 
 
4.4.9 Other outcomes  
4.4.9.1 Minimal Erythema Dose  
It was important to detect any differences in the skin 
type determined by the MED test and by a dermatologist at 
baseline. 
In only half of patients (16/29; 55%), was the same 
starting dose determined by both the MED test and a 
dermatologist.  In 17% (6/29) of participants the MED test 
results showed that their skin was more sensitive to sunlight 
than determined by a dermatologist. In 24% (7/29) of 
participants the MED results were higher than the ones 
determined by dermatologists allowing them to be prescribed 
a higher dose of NB-UVB.  
4.4.9.2 Future trials suggestions  
:KHQDVNHG³ZKDWGLG\RXOLNHDERXWWKHWULDO´
VWDWHPHQWVVXFKDV³WUHDWPHQWDWKRPHHDV\WRSHUIRUPDQG
flexible, comprehensive patient literature and forms to 
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FRPSOHWHKRSHLQYLWLOLJRWUHDWPHQWUDLVLQJDZDUHQHVV´ZHUH
made.  
When asked if the future main trial should be on hand-
held device compared to placebo or hand-held device 
compared to steroid or a trial on combination of light and 
steroid cream, the majority of participants said yes to all 
(Table 4.24). 
 
Table 4.24 Participants opinion on future trials on vitiligo 
Would you be 
willing to take 
part in future 
clinical trials on 
vitiligo comparing 
Yes  No Unsure Reasons for 
negative or 
unsure answers 
NB-UVB vs. 
placebo  
23 (82%) 
4 
(14%) 
1 
(3.5%) 
Previous use of 
steroids 
No treatment 
response in 
current trial  
Current trial was 
too time-
consuming 
NB-UVB vs. 
topical 
corticosteroids 
21 (75%) 2 (7%) 5 (18%) 
Combination of  
NB-UVB and 
topical 
corticosteroids 
20 
(71.5%) 
5 
(18%) 
3 (11%) 
Total number of 
participants 
28 28 28 
 
Page 271 of 338 
4.4.10 Hand-held devices output 
4.4.10.1 Device output 
The mean post-trial outputs, both the Waldmann and 
Dermfix units, were less than the pre-trial values (Table 4.25) 
 
Table 4.25 Pre and post-trial output values for Waldmann and 
Dermfix hand-held devices 
 Dermfix Waldmann 
Pre-
trial 
Post-
trial 
Pre-
trial 
Post-
trial 
Mean output mW/cm2 3.81 3.24 4.5 3.92 
SD mW/cm2 0.37 0.42 0.2 0.67 
Coefficient of variation 9.7% 12.9% 4.4% 17% 
Mean difference  -14.5% -13% 
Maximum difference pre and 
post-trial 
-28.5% -38.5% 
Minimum difference pre and 
post-trial 
-7.4% +10.5% 
 
Additionally, the mean Waldmann output values were 
slightly greater compared to Dermfix devices. Interestingly 
one of the Waldmann devices had a greater post-trial output 
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than pre-trial output. The Dermfix devices showed more 
consistent decrease in output pre and post-trial (Figure 4.5). 
 
Figure 4.5 ± Comparison of both manufacturers (Waldmann 
and Dermfix) mean pre and post-trial device output 
measurements to the device operation time 
 
 
4.4.10.2 Output with respect to time 
Both the Waldmann and Dermfix hand-held units follow 
a similar pattern, with a sharp increase in output from lamp 
ignition to the peak value and then a gradual decay in output 
over time (Figure 4.5). The pre-trial output values of 
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Waldmann devices were more closely matched than their post-
trial measurements, while for the Dermfix devices the 
variation in output looks more consistent both pre and post-
trial (Figure 4.6 and 4.7). 
 
Figure 4.6 ± Mean output (mJ/cm2) of Waldmann hand-held 
devices pre and post-trial in correlation with time (seconds)  
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Figure 4.7 ± Mean output (mJ/cm2) of Dermfix hand-held 
devices pre and post-trial in correlation with time (seconds) 
 
 
4.4.10.3 Spectral profile 
All the devices showed that, pre and post-trial, the main 
UVB peak occurs in the range 310nm-315nm. The Dermfix 
devices  spectral profiles, both pre and post-trial, showed that 
there was a greater relative UVB irradiance exposure (280nm 
to 315nm) and UVA irradiance exposure (315nm to 400nm) 
compared with the Waldmann device profiles (Figure 4.8). 
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Figure 4.8 Comparison of both manufacturers (Waldmann 
and Dermfix) mean pre and post-trial tube spectral profile 
output 
 
 
4.5 Discussion 
Although, vitiligo is the most common depigmentation 
disorder, it is greatly understudied. The majority of clinical 
treatment recommendations for vitiligo are based on small, 
inconclusive trials, specialist consensus and on data from other 
skin diseases (Whitton et al., 2010; Gawkrodger et al., 2008). 
Perhaps, unsurprisingly, patients often feel abandoned and 
believe that they do not receive adequate support from their 
doctors (Porter et al., 1987). Many patients obtain information 
about vitiligo from non-medical sources (Talsania et al., 2010). 
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For example, the Vitiligo Society UK and the Vitiligo Support 
International receive numerous enquiries about hand-held NB-
UVB, which are freely available to buy form the internet 
(personal communication). Although, home phototherapy for 
psoriasis is widely available (whole body units), no randomised 
controlled trial to-date has evaluated the safety and 
effectiveness of hand-held home phototherapy for vitiligo. 
The Hi-light pilot trial was the first trial evaluating the 
safety of using hand-held phototherapy at home and testing 
the feasibility of conducting the first national multi-centre 
randomised controlled trial (RCT) on home hand-held 
phototherapy for vitiligo. Although this was not an efficacy 
trial, this pilot trial was a crucial preliminary step to support a 
grant application for the main RCT and to develop a training 
package on home targeted phototherapy for vitiligo. 
 
4.5.1 Summary and comments on the main findings 
Recruitment into the trial went surprisingly well. The 
number of originally anticipated participants was exceeded and 
recruitment period lasted only three months instead of six. 
Secondary care recruitment (response rate=79%), especially 
in Nottingham (response rate=93.5%), was excellent. The 
higher response rate for Nottingham is probably explained by 
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the specialist interest of the principal investigator at this 
centre (JR), who mentioned the possibility of participation in 
the proposed trial during routine clinic visits (prior to sending 
out the invitation letters).  
Recruitment in primary care was similarly successful, 
where we were forced to limit the number of surgeries 
conducting the mail-out.  
Telephone pre-screening of potential participants prior to 
the hospital visit proved to be very successful. All potential 
participants, who attended clinic, were subsequently enrolled 
into the trial. Pre-screening participants over the phone, saved 
time and resources, considering that both a dermatologist and 
a research nurse had to be present during the initial hospital 
visit and a room had to be booked (2 hour slot) in a busy 
dermatology clinic for each potential participant. Thus, it was 
possible to arrange an appointment for a maximum of two to 
three patients per week in Nottingham and for only one 
patient in Leicester. Telephone pre-screening was one of the 
main reasons behind these excellent recruitment rates.  
Only 10% of participants withdrew from the trial 
compared to the previously reported 20%, in a trial on 
hospital phototherapy (Lim-Ong et al., 2005). The findings of 
this trial, suggest that patients with vitiligo are very keen to 
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take part in trials on home light phototherapy using hand-held 
devices. Main reasons for the above were the fact that the 
treatment was self-administered at home, allowing flexibility 
around days and times for administration.  
The training session and materials on how to self-
administer home phototherapy and deal with short term side-
effects were comprehensive, adequate and easy to follow, as 
evidenced by only one incident of erythema grade 3 and high 
level of adherence to the treatment plan (75%).  Erythema 
grade 1 and 2 are generally considered adequate and sought 
after response to light therapy. Surprisingly, two patients in 
the placebo group also reported Erythema grade 1. The most 
likely explanation might be confusion of Erythema grade 1 
with erythema which was caused by normal warming up of the 
device during treatment. 
Two thirds of participants (68% in active groups and 
60% in placebo group) and half of the research nurses (55%) 
guessed group allocation correctly due to the response to 
treatment and erythema; therefore it is likely that the blinding 
in the main trial will be compromised and should be carefully 
planned for. 
Only one third of patients in the active groups (31.5%) 
were somewhat satisfied with the treatment and no-one was 
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very satisfied.  Just under half of patients in active groups 
UDWHGRYHUDOOFKDQJHVLQWKHLUYLWLOLJRDV³DELW EHWWHU´RU
PXFKEHWWHU´7KLVFRPHVWRQRVXUSULVHDVWKHWUHDWPHQW
period was clinically inadequate. Similarly, only four lesions 
(10%) in active groups showed high degree of repigmentation 
(75-100%). On the other hand, 75% of lesions in the active 
groups showed some degree of repigmentation. In clinical 
setting, this is usually an indication to continue phototherapy 
treatment (Gawkrodger et al., 2008). 
)LQDOO\DFWLYHDQGSODFHERJURXSVUHSRUWHGRQO\³VOLJKW
EHQHILW´from the treatment (Patient Benefit Index) and, in 
general, did not show any changes in their quality of life. This 
comes as no surprise given the limited duration of treatment 
for this pilot trial; these outcomes were collected primarily to 
test their use in the clinical setting, rather than as an 
assessment of efficacy. 
 
4.5.2 Limitations of this trial 
The main limitation of this trial was the short treatment 
period and I would recommend a much longer treatment 
period for the main trial. Nevertheless, four months was 
adequate to capture initial treatment response, if any, and 
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therefore to provide an indication as to whether or not 
treatment should be continued. 
Although the secondary care recruitment was excellent, 
this is likely to be lower in centres where there is no adequate 
CLRN support or an investigator with a specialist interest in 
vitiligo. Primary care seems likely to be a good source of 
treatment-naive potential participants. 
The unsuitability of the ConvaTec transparencies for skin 
mapping of vitiliginous lesions was a potential source of 
measurement error in the repigmentation measurements.  As 
this pilot trial did not seek to answer efficacy questions on 
home hand-held phototherapy, the above did not affect the 
validity of this trial. For the main trial, however, alternative 
methods will be used as outlined below.  
 
4.5.3 Challenges and recommendations for future trials 
In order to inform future trials on home hand-held 
phototherapy, it is helpful to present some of the key 
challenges that were faced and to provide recommendations 
on how to overcome these. 
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Challenge 1: Assessment of repigmentation rate and 
skin mapping technique. The main reasons behind this 
challenge were:  
x The pattern of repigmentation, perifollicular or 
diffuse, and the colour match of newly repigmented 
lesions, which tends to be either darker or lighter, than 
the normal skin. Sometimes, it was difficult to clearly 
identify the edges of the vitiliginous area. 
x The transparencies used in this trial (ConvaTec) 
were not designed with vitiligo lesions in mind. Although 
their texture and size were convenient, they were too 
shiny, which made skin mapping difficult and time 
consuming; especially in light-coloured individuals. 
x Transfer of the transparencies into digital images 
was very time consuming. 
Recommendation 1: The main advantage of using skin 
mapping techniques, seems to be the fact that it captures 
the three dimensional character of vitiliginous lesions 
around eyes, mouth, armpits and other physical cavities, 
and does not require standardisation, specific body 
positioning or expensive equipment, which are all needed 
with digital imaging. It is also easy to replicate and 
relatively cheap. Based on the above, a different 
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transparency, which could also be scanned into a digital 
image without manual transferring, would be preferable. 
Good lighting in the clinic room and contouring of the 
vitiliginous lesion edges with a surgical skin mapping pen 
are also recommended. 
Challenge 2: Great variability in the output of hand-held 
devices. In particular, although Waldmann units had 
greater mean output both pre and post-trial, they were also 
PRUH³VHQVLWLYH´WRXVDJHDVWKHSHUFHQWDJHGLIIHUHQFH
between their pre and post-trial output varied from 10.5% 
increment to 38.5% decline. Two possible reasons behind 
greater pre-trial output of Waldmann devices compared to 
Dermfix are 1) the fact that the comb attachment on 
Dermfix units completely covers the NB-UVB tube, while for 
Waldmann units, there was no cover in the central part of 
the tube and 2) the distance between the surface of the 
tube and the tip of the comb was different. On the other 
hand, Dermfix units had more consistent output variation 
pre and post-trial. Correspondence with the devices¶ 
manufacturers (Waldmann and Androv) confirmed that the 
output of the units tend to decrease after the first 100 
hours of use. They also advised that output may decrease if 
the device is continuously switched on/off when treating 
multiple lesions.  
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Recommendation 2: Considering previously mentioned 
features of Dermfix such as lighter weight, longer cable, 
cheaper price, slightly larger treatment window and more 
convenient shape, in comparison to Waldmann (Table 4.3) 
and the above output characteristics, Dermfix hand-held 
units seems to be a better candidate for future trials on 
targeted phototherapy. All the devices should be screened 
EHIRUHWKHWULDODQGSRWHQWLDO³RXWOLHUV´ZLWKDORZHUSUH-trial 
output than the rest of the devices should be replaced. 
Output should also be monitored at the end of the trial.  
Close collaboration with local Medical Physics department 
is, therefore essential. 
Challenge 3: Requirement for the Minimal Erythema 
Dose (MED) test. Additional strain was added to the pilot 
trial configuration with the decision to perform an MED test 
at the baseline visit. Each participant had to come back to 
clinic the following day and therefore additional clinic space 
and research staff time was needed. The results of the pilot 
trial showed that 41% of participants required a different 
starting dose following their MED results compared to the 
staring dose suggested by a dermatologist; therefore a 
second visit was necessary and justifiable. 
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Recommendation 3: MED test is recommended for future 
trials on home hand-held phototherapy and is necessary to 
HQVXUHSDWLHQWV¶VDIHW\DQGDSSURSULDte NB-UVB dose 
administration. 
 
4.5.4 Conclusions 
Home hand-held phototherapy is of a great interest 
amongst patients and clinicians. It is potentially dangerous 
and worrying that these devices are currently bought by 
patients and used in an unsupervised way.  In light of newly 
emerged preliminary evidence that treatment of early or 
spreading lesions with combination of phototherapy and 
topical corticosteroids seems to be effective, a trial utilising 
hand-held phototherapy seems like an appropriate way 
forward.  
The Hi-light pilot trial showed that the training provided 
to patients on hand-held devices was comprehensive and well 
tolerated. Home hand-held phototherapy seems to be a safe 
intervention for both adults and children. 
In conclusion, the results of this pilot trial strongly 
suggest that a national multi-centre double blind randomised 
controlled trial for vitiligo involving home hand-held 
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phototherapy is both feasible and acceptable to patients. It 
would address an important area of unmet need, and 
potentially provide a useful treatment strategy for patients 
with limited and early disease.   
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CHAPTER 5: Impact of my research 
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Abstract  
In this final chapter, I outline the impact that my 
research has had in the field of vitiligo research, and outline 
what will that led on to next. Priorities identified by the vitiligo 
Priority Setting Partnership lead to a HTA commissioning call 
for a multi-centred RCT for the treatment of vitiligo. The 
results of the outcomes systematic review and the survey 
amongst patients and clinicians, renewed interest in patient-
reported outcomes in vitiligo, and is being used to inform an 
international initiative to establish core outcome measures for 
use in future trials. The results of the pilot RCT (Hi-Light trial) 
informed the trial design of the grant submission for a full 
scale multi-centred RCT. Personally, I have also acquired 
numerous experiences and academic skills and competencies 
such as scientific papers writing, collaboration, peer-reviewing 
and networking and developed as a researcher, an academic, 
a clinician and a person. 
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5.1 Introduction 
In previous chapters, I outlined some of the issues 
around research into vitiligo (Chapter 1) and what have I done 
to address these. In particular, I described the process of 
selection of interventions to be tested (Chapter 2), outcomes 
measures to be used in a trial on vitiligo treatment (Chapter 3) 
and also tested the feasibility of conducting a multi-centre 
randomised placebo-controlled trial. In this chapter, I reflect 
on the impact that each of my projects has had, what it will 
lead on to next, and the lessons I have learned during my PhD 
research.  
 
5.2 Vitiligo Priority Setting Partnership 
As mentioned previously (Chapter 2), five vignettes from 
the Top 10 treatment uncertainties were submitted to the 
National Institute for Health Research Health Technology 
$VVHVVPHQW1,+5+7$SURJUDPPH¶VSULRULWLVDWLRQSDQHO7KH
choice of uncertainties to be submitted as vignettes was based 
on currently available evidence for each intervention in 
question. In May 2012, the HTA published a commissioning 
call on vitiligo treatments that addressed two of the original 
WUHDWPHQWXQFHUWDLQWLHV³+RZHIIHFWLYHLV89%OLJKWZKHQ
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FRPELQHGZLWKWRSLFDOSUHSDUDWLRQV´DQG³:KLFKWUHDWPHQWLV
more effective: topical corticosteroid of light therapy"´7DEOH
5.1). 
Table 5.1 Summary of the HTA commissioning call on vitiligo  
What is the clinical and cost effectiveness of home-based narrow 
band ultra-violet light therapy (NB-UVB) using a hand-held device 
with or without topical steroid treatment?  
1. Intervention: Home-based NB-UVB using a hand-held device.  
2. Patient group: Patients with early and limited vitiligo who are suitable 
for NB-UVB therapy (could include adults and children).  
3. Setting: Initiated in secondary care with ongoing treatment delivered at 
home and supported by primary care.  
4. Control or comparator: Topical corticosteroid or placebo. Applicants to 
define and justify choice of topical corticosteroid.  
5. Study design: RCT comparing topical steroids, home-based handheld 
NB-UVB or both interventions. Applicants to define and justify study design 
in order to answer the main questions which are (i) is one monotherapy 
better than the other; and (ii) is combination treatment better than 
monotherapy. Applicants may wish to consider including placebo 
treatments for both NB-UVB and steroids.  
6. Important outcomes: Percentage of repigmentation of vitiliginous 
skin, quality of life (psychological impact, self-esteem), patient satisfaction. 
Other outcomes: Cessation of spread of vitiligo, relapse, adverse effects 
(e.g. skin cancer), cost effectiveness.  
7. Minimum duration of follow-up: 1 year after treatment cessation 
(with duration of treatment being 3-4 months)  
8. Has the device in question been granted a CE mark for the use 
proposed in this study? Yes  
  
The above commissioning call meant that vitiligo had 
been identified as an important NHS health topic and that a 
funding opportunity for the first large, multi-centre, 
randomised controlled trial (RCT) on vitiligo was available. In 
June 2012, in collaboration with colleagues from the Centre of 
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Evidence Based Dermatology and the Nottingham Clinical 
Trials Unit, an outline research proposal was submitted. I was 
a co-applicant on this bid. In April 2013, our research team 
was informed that our bid was successful. 
 
5.3 Systematic review and survey on outcome 
measures for vitiligo 
In chapter 3, I stressed the importance of core outcome 
sets for vitiligo trials. In an understudied skin disease such as 
vitiligo, it is extremely important that the findings of small 
trials are combined using meta-analysis, in order to produce 
meaningful results and clinical recommendations. These are 
not possible until a core outcomes set has been defined.  
Recently, the COMET (Core Outcome Measures in 
Effectiveness Trials) initiative was established 
(http://www.comet-initiative.org/) and it has been 
increasingly recognised that outcomes measures in trials 
should also be relevant to patients and clinicians(COMET, 
2010)(Chapter 3). Following my presentation on the results of 
the outcomes systematic review and the survey of most 
desirable outcomes amongst patients and clinicians 
(International Pigment Cell Conference 2011, Bordeaux, 
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France), I proposed the inclusion of core outcomes set for 
vitiligo into the agenda of the International Federation of 
Pigment Cell Societies (IFPCS). My proposal was accepted and 
core outcomes set for vitiligo was the topic of the next Vitiligo 
Global Issues Consensus Conference. I was appointed as a 
leader of this international project and am in the process of 
initiating a three-round e-Delphi consensus exercise.  The first 
round of this international consensus is now underway. I am 
currently preparing for the next Vitiligo Global Issues 
Consensus Conference (28th of February 2013) during the 
American Academy of Dermatology annual meeting (Miami, 
USA), where the results of the first round will be presented 
and next steps will be discussed. 
Finally, the findings of the systematic review and the 
results of the survey of the most desirable outcomes amongst 
patients and clinicians were crucial in defining the primary 
outcome in our subsequent full research proposal for the 
development of a multi-centre randomised controlled trial on 
vitiligo (see below). 
 
5.4 Pilot Hi-light trial  
Following the HTA Commissioning Board meeting on 16th 
and 17th of October 2012, our outline proposal on hand-held 
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home NB-UVB phototherapy in combination with topical 
corticosteroids was shortlisted and we were invited to submit a 
full research proposal.  
The pilot Hi-Light trial was completed in time for the 
submission of the full proposal and helped to inform the design 
and conduct of the full scale RCT (Table 5.2). The pilot trial 
successfully recruited 29 participants from two recruiting 
centres (Nottingham and Leicester) with the support of the 
Comprehensive Local Research Network (CLRN) nurses. The 
treatment period lasted four months and participants were 
assessed at two-monthly intervals, with additional telephone 
support as required.  
The primary outcome of the pilot trial was the proportion 
of the screened patients who were eligible and willing to 
participate (Chapter 4). 
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Table 5.2 Lessons learned from the pilot Hi-Light trial and 
implications they had on the main RCT proposal 
Aspect of the 
trial 
Lessons from pilot trial Implications for main 
RCT 
Recruitment 
into the trial 
x 29 participants were 
randomised in three 
months at two centres. 
Recruitment of 4-5 
participants per centre 
each month is realistic. 
 
x Identifying patients 
through primary care is 
likely to be important. 
Response from GP mail 
out was as follows: 67 
letters were sent from 
two GP practices; these 
generated 28 
expressions of interest 
(42% response rate). 
 
x Exclusion based on 
concurrent medication 
with potential 
photosensitive drugs 
was high (accounting 
for 70% of all 
exclusions). 
 
 
 
x Main limitations were in 
clinic space and 
availability of Principle 
Investigators (PIs) for 
confirmation of 
diagnosis and issuing of 
prescription. 
x Telephone pre-
screening of trial 
participants worked 
well. All potential 
participants (100%) 
who attended clinic 
were subsequently 
enrolled into the trial. 
x Recruitment of 40 - 50 
participants per centre 
in 18 months seems 
appropriate (at a rate 
of 3-5 per month in 8-
12 recruitment 
centres). 
x Recruitment through 
primary care is likely to 
be the main source of 
potential participants 
(especially for early 
and limited disease). 
 
 
 
 
x Eligibility criteria 
amended to be clearer 
as to which 
photosensitive drugs 
warrant exclusion. 
(Many drugs may 
potentially cause 
photosensitization but 
for most of these, it is 
a rare side effect). 
 
x Trial participants will 
be sent trial 
information and pre-
screened prior to 
attending their clinic 
appointment in order 
to reduce the burden 
on clinic space and 
availability of PIs.  
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Participant 
characteristics 
 
x 69% of participants 
were white British 
x Given the higher 
impact of vitiligo in 
patients with darker 
skin, special efforts will 
be made to engage 
with Black and Ethnic 
minority patients. 
Retention in the 
trial 
x 3 / 29 (10%) of 
participants withdrew 
from treatment during 
the 4-month 
intervention period (2 
active UVB; 1 dummy 
UVB).  
x Only one participant 
(3%) was lost to follow-
up  
x Participants who stop 
treatment early will be 
encouraged to continue 
in the trial in order to 
provide follow-up data. 
x To reduce missing data 
at 9 months, 
participants will be 
asked to return postal 
questionnaires if they 
are unable to attend 
this clinic visit. 
Assessment of 
outcomes 
x Mapping vitiligo patches 
(three patches per 
participant) using 
transparencies is 
possible, but can be 
difficult. Transferring 
the transparencies into 
digital imaging software 
can be time consuming. 
x Photographs taken by 
research nurses were of 
variable quality.  
x Tracing of only one 
target lesion will be 
performed and 
adequate data 
management support 
will be ensured. 
x Medical photography 
facilities at recruiting 
centres will be used to 
standardise the images 
and ensure their high 
quality. 
x The number of digital 
images required will be 
reduced. These will be 
taken only on baseline 
visit and will be used 
as a reference 
standard for 
participants to judge 
treatment response at 
the end of the trial 
Use of hand-
held UVB 
devices 
x Greater than 
anticipated variability in 
the output of individual 
units was noted. 
x Re-cycling devices for 
re-use by other 
participants is time 
consuming and requires 
additional resources for 
re-testing of output and 
x One device per 
participant will be 
issued. 
x Dermfix will be used in 
the main trial.  
x All units prior to 
distribution will be 
tested to ensure a 
baseline quality 
standard in output of 
Page 295 of 338 
subsequent distribution 
back to participants 
x Devices that log 
treatment usage 
electronically as part of 
the unit are attractive 
for research purposes, 
but are more expensive 
and are not currently 
licensed for use in 
Europe. 
x Both devices used in 
the pilot had 
appropriate CE marking 
and a very similar 
output. Dermfix showed 
to have a more 
convenient treatment 
window shape and 
costs half price less 
than Waldmann. 
the device.  
x Co-applicant added 
with experience in this 
area (Medical 
Physicist). 
 
Training and 
MED testing 
x Training in the use of 
the devices at home 
was difficult to 
standardise across 
sites, despite the use of 
a training manual. 
x Compared to the 
starting dose suggested 
by the clinicians on the 
basis of skin type, 41% 
of participants required 
a different starting dose 
following their Minimum 
Erythemal Dose (MED) 
test (doses were 
adjusted down in 6 / 29 
(17%) of cases, and up 
in 7 / 29 (24%) of 
cases).  
x Training DVD produced 
in order to standardise 
the intervention and 
ensure consistency in 
the training provided. 
x MED testing is good 
practice prior to use of 
NB-UVB treatment and 
is necessary to ensure 
the safety of the 
patient in the trial. A 
second visit the day 
after baseline in order 
to read the test results 
is justified and 
necessary. 
Blinding x 65% of participants 
guessed their allocation 
correctly at the end of 
the 4-month treatment 
period (68% active; 
60% dummy) 
x 55% of research nurses 
guessed the allocation 
correctly (53% active; 
60% dummy) 
x Main reasons given: 
response to treatment; 
x Although it is possible 
to mask the treatment 
allocation, this is likely 
to be compromised and 
should therefore be 
planned for. 
x Inclusion of active 
treatments in all 
groups should help 
avoid unblinding 
resulting from 
differential treatment 
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erythema response. 
Use of diaries to 
collect 
treatment 
adherence and 
adverse events. 
x 28/29 (97%) of diaries 
were returned to the 
trial team. 
x 75% of people adhered 
fully to the treatment 
plan (with appropriate 
stepping up and down 
of exposure times). 
x Patient diaries will 
continue to be used as 
aid memoires for the 
collection of side 
effects and treatment 
adherence. 
 
In addition, the importance of acceptability of treatment 
response by patients has been stressed as one of the most 
important outcomes to collect in vitiligo trials (Whitton et al., 
2010; Eleftheriadou et al., 2012 and Gonzalez et al., 2011). 
Currently there are very few data on validity of outcome 
measures used in vitiligo trials (Eleftheriadou et al., 2012).  
Intuitively, recording treatment success or failure, based 
on changes in the amount of repigmentation observed, would 
seem to be the most appropriate outcome and a simple matter 
to measure. However, when repigmentation of vitiliginous 
patches does occur, this tends to be perifollicular. 
Hyperpigmentation often appears around the lesions also. 
These can reduce the cosmetic acceptability of the treatment 
response and means that a simple assessment of percentage 
of repigmentation, may fail to capture important information 
i.e. patient-reported acceptability of treatment response.  
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For this reason, as a primary outcome for the main RCT, 
measurement of acceptability of treatment response from the 
SDWLHQWV¶SHUVSHFWLYHZDVSURSRVHG7KLVZLOOEHDVVHVVHG
XVLQJWKHIROORZLQJTXHVWLRQ³+RZZRUWKZKLOHLVWKHOHYHORI
WUHDWPHQWUHVSRQVHWR\RX"´5HVSRQVHs will be recorded using 
a 5-/LNHUWVFDOHUDQJLQJIURP³YHU\ZRUWKZKLOH´WKRXJKWR³QRW
DWDOOZRUWKZKLOH´6LQFHSHUFHQWDJHRIUHSLJPHQWDWLRQKDV
been used in the majority of the RCTs to date (Eleftheriadou et 
al., 2012), we will also measure this as one of the secondary 
outcomes in the trial. This will allow meta-analysis of the trial 
results in combination with previous research.  
To conclude, assessing treatment results by measuring 
WKHDFFHSWDELOLW\RIWUHDWPHQWUHVSRQVHIURPSDWLHQWV¶
perspective has not been done previously in vitiligo trials and 
we hope that the results of the main RCT will help to inform 
WKHGHILQLWLRQRI³FRVPHWLFDOO\DFFHSWDEOHUHSLJPHQWDWLRQ´
which is part of the proposed core outcomes set for future 
vitiligo trials. 
Finally, should our application of the full scale RCT on 
home hand-held phototherapy in combination with topical 
corticosteroids for the treatment of vitiligo (Hi-Light trial) be 
successful, this would be an important addition to the 
treatment options available in the NHS to patients with 
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localised disease. It could also improve treatment adherence 
and the quality of life of vitiligo patients by offering them a 
treatment option that they can use at home.  
This trial addresses some of the most basic questions 
around the long-term management of vitiligo. In the absence 
of new and emerging treatments, these results will be relevant 
and important in determining clinical practice for many years.  
 
5.5 Wider application of hand-held NB-UVB devices  
Phototherapy is currently used in the NHS for the 
treatment of many skin diseases, such as psoriasis, eczema, 
vitiligo cutaneous T-cell lymphoma and lichen planus. Home 
phototherapy using whole body units is increasingly being 
used for the treatment of psoriasis. 
My pilot trial showed that the educational package on 
how to use hand-held phototherapy and how to deal with 
short-term side effects at home was comprehensive and easy 
to implement. Treatment with hand-held devices was well 
tolerated, easy to use and safe. In conclusion, the education 
DVD, produced to assist standardisation of the intervention 
and to ensure consistency during the main trial, could also be 
used by other researchers and the NHS in the treatment of 
Page 299 of 338 
other limited skin conditions such as scalp psoriasis and hand 
eczema. 
The training video will be freely available on the website 
of the Centre of Evidence Based Dermatology 
(www.nottingham.ac.uk/scs/divisions/evidencebaseddermatolo
gy/index.aspx)  
 
5.6 Lessons I learned during PhD research  
Throughout my research, I have acquired new skills, 
competencies and experiences, which allowed me to develop 
both as a research-clinician and an individual: 
x Writing medical papers: I have published 7 papers 
during my studies. A further three articles are being 
prepared for submission to major medical journals. I 
have subsequently improved my writing skills, learned 
how to write clear abstracts and to follow standard 
formats such as IMRAD (introduction, methods, results 
and discussion), CONSORT statement (Consolidated 
Standards of Reporting Trials) and PRISMA statement 
(Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses).  
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x Protocol, regulatory approvals and clinical file 
records: I had the opportunity during my pilot trial to 
learn how to write a study protocol, prepare for ethics 
submission and obtain Primary Care Research Network 
(PCRN) and Comprehensive Local Research Network 
(CLRN) support. It was time consuming to develop the 
clinical records files and other necessary paperwork such 
DVUHVHDUFKHU¶VPDQXDOIRUWKHSLORWWULDO  Also, I learned 
how to address peer-review comments and deal with 
unexpected obstacles when identifying which hand-held 
device to use in the trial. 
x Membership of the Vitiligo European Task Force: 
since 2010, I have been an active member of the Vitiligo 
European Task Force. My research enabled me to 
complement the work of this international group of 
experts in vitiligo by providing a steer for future 
research activity towards questions important to patients 
and clinicians, and in leading an international consensus 
on core outcomes set for vitiligo. In addition, I was 
asked to join the team of expert authors of the latest 
European guidelines for the management of vitiligo 
(Taieb et al., 2013). My contribution to this major 
international publication was to review and update the 
references, check the document for consistency and 
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ensure that all the subchapters were up-to-date with the 
latest evidence based research. 
x Collaboration and networking: in May 2011, I won 
the Building Experience and Skill Travel Scholarships 
(BESTS) from the University of Nottingham. BESTS gave 
me a chance to visit the San Gallicano Institute (Rome, 
Italy), a well-known dermatological research centre for 
diagnosis and treatment of skin diseases including 
vitiligo with numerous national and international 
collaborations. This fully funded two-week visit 
broadened my experience and understanding of vitiligo 
and its treatment options, helped me to establish a 
network of new contacts, strengthened my 
understanding of what being a researcher means and 
the skills and attitudes one needs to make a success of a 
career in clinical research. 
x The International School of vitiligo and pigmentary 
disorders: Recently, the first International School of 
vitiligo and pigmentary disorders was launched in 
Barcelona, Spain by the Vitiligo Research (VR) 
Foundation (http://vrfoundation.org/); a philanthropic 
organisation committed to research into vitiligo. I 
attended this course, which targeted mainly young 
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professionals. The event gave the opportunity for 
learning, sharing ideas and networking. Following the 
event, the VR Foundation has funded an international 
study on Quality of Life in vitiligo patients. I assisted in 
the development of the study protocol for this important 
initiative. Finally, I was invited to join the Scientific 
Advisory Board of the Vitiligo Research Foundation (VR 
Foundation). Together with the Scientific Committee, the 
Scientific Advisory Board helps to develop the VR 
Foundation research agenda, identify established and 
emerging researchers and evaluate grants application.  
x Other academic skills: throughout my research I 
have gained experience on how to peer-review for 
various dermatology journals such as the Journal of 
American Academy of Dermatology, the Re-invention-
journal for undergraduate research, the Clinical and 
Experimental Dermatology. I also act as a regular 
UHYLHZHUIRUWKH³+RW/LQH´VHFWLRQRIWKH'HUPDWRORJLF
Therapy Journal. This experience has helped me to 
understand what a reviewer is looking for and 
subsequently to improve my own writing skills. In 
addition, during my second year, I was invited by the 
8QLYHUVLW\RI1RWWLQJKDP¶V6FKRRORI&OLQLFDO6FLHQFHV
to conduct a viva examination of a 3rd year medical 
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student who completed her BMedSCi project on varicose 
veins. This experience assisted me in my understanding 
and preparation of my own viva examination. 
x Vitiligo Newsletter: I developed a network of 
participants who took part in my projects and wished to 
be informed about the results as well as future studies 
on vitiligo. To keep them up-to-date, I developed a 
quarterly newsletter, the Vitiligo Newsletter, and 
published lay summaries of my own research as well as 
other important findings in vitiligo worldwide. So far, my 
database contains around 450 people, patients with 
vitiligo (mainly) and clinicians with an interest in the 
disease. I strongly believe that communicating research 
back to the patients is one of the most important 
aspects of bringing research results back to the heart of 
clinical care. 
 
5.7 My future plans 
My career aim is to become a Professor and Consultant 
Dermatologist. I aim to continue being involved in research 
until I complete my Specialty Training and further develop my 
skills and expertise. I am involved in the following research 
projects: 
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x International consensus on core outcomes set for 
future vitiligo trials. As mentioned above, I am leading 
this international e-Delphi consensus exercise. 
x Cochrane Systematic revieZV³,QWHUYHQWLRQV
IRUYLWLOLJR´,ZRUNRQWKHODWHVWXSGDWHRIWKH&RFKUDQH
systematic review as one of the co-authors.  It is 
anticipated that the update will be completed by the end 
of 2013. 
x Vitiligo European Task Force and Vitiligo Research 
(VR) Foundation. I plan to carry on my involvement as a 
member of VEFT and member of the VR Foundation 
Scientific Research Committee. 
x If our detailed proposal for the mail RCT is 
successful, I will work on the trial as a member of the 
Trial Management Group. 
In conclusion, alongside research skills on various 
methodologies from systematic reviews to randomised 
controlled trials, I have also developed other skills of major 
importance to every academic such as writing scientific 
papers, peer-reviewing, teaching and networking. I have come 
to realise how crucial it is to communicate your research to a 
community of users, and to keep them updated. Finally, the 
most important lesson I have learned is to be patient and stay 
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calm, no matter the obstacles and delays in research as it can 
only get better. 
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VITILIGO SURVEY for the vitiligo Priority Setting Partnership  
 
We think it is vital that more research is done into treatments for vitiligo, and 
this research focuses on the questions that are important to people who have 
vitiligo, parents of children with vitiligo and the health professionals (doctors 
and nurses) that treat vitiligo. We are therefore collecting questions that all 
these groups of people have about treatments for vitiligo. We will use these 
to identify where there is true uncertainty, that is to say where there is no 
existing research that already provides a reliable answer, so that future 
research can focus on the most important questions.  
If you have vitiligo; are the parent of a child with vitiligo; or a health 
professional with an interest in the condition, you can help us by completing 
this survey and telling us what questions you have.  
The sorts of things we would like to know about are any questions you have 
about treatments for vitiligo, for example: prescribed medicines (e.g. tablets 
or creams), light therapy (e.g. UVA), surgical procedures (e.g. skin grafting), 
psychological therapy (e.g. coping methods) or cosmetic applications (e.g. 
camouflage).  
To help you, here are some examples of research questions for other health 
conditions:  
x Are breathing exercises helpful in controlling asthma? 
x What is the evidence for gargling aspirin to relieve a sore throat? 
x Are topical steroids for atopic eczema safe in the long-term? 
 
 
Q1 What questions about the treatments for vitiligo would you like to see 
answered by research? 
 
1.  ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?.................................................... ? ? ? ? ? ? 
          
    2.  ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?.................................................... ? ? ? ? ? ? 
          
          ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? 
 
    3.  ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?.................................................... ? ? ? ? ? 
          
          ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? 
 
    4.  ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?.................................................... ? ? ? ? ? ? ? ? 
          
          ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? 
 
        Please feel free to continue on the back if you have more than 4 questions. 
 
Q2 What desirable effects do you hope the treatments would produce? 
 
          ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? 
 
          ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?............................................. 
        
          ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? 
  
 More information about you 
 
It would be really helpful for our research to know a little more about you, so 
we would be grateful if you could answer the questions in this box. However, 
if you would prefer not to, then just leave this section blank. 
 
1. Which of these best describes you (please tick all that apply):  
Health professional (e.g. doctor, nurse) 
Person with vitiligo 
The parent of a child with vitiligo 
KƚŚĞƌ ?ƉůĞĂƐĞƐƉĞĐŝĨǇ ? ? ? ? ? ? ? ? ? ? ?..................... ? ? ? 
 
2. What is your  ?ŽƌǇŽƵƌĐŚŝůĚ ?Ɛ ?age (please tick)? 
  
0  ? 5          6-10     11-17   18  ? 29          30-60          over 60   
 
3. What is your  ?ŽƌǇŽƵƌĐŚŝůĚ ?Ɛ ?gender (please tick)?  
 
Male  
            
Female 
 
Would you like more information about the next stage of this research study 
where we decide which research question is the most important and should 
be developed into a clinical trial proposal (please tick)?             
 
 
Would you like to be informed of the results of this study (please tick)? 
 
 
 
If you have answered yes to either of the above questions please provide your 
contact details: 
Name: 
 ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?........................................... ? ? 
Email/address: 
 ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?........................................ ? ? ? ? ? ? ? ? ? ? ? ? ? ? 
Postal/address: 
 ? ? ? ? ? ? ? ? ? ? ? ? ? ?........................................ ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?
What is your preferred method of contact (please tick)? 
 
 
dŚĂŶŬǇŽƵĨŽƌĐŽŵƉůĞƚŝŶŐƚŚŝƐƐƵƌǀĞǇ 
Please return this survey to: Vitiligo Study, Centre of Evidence Based 
Dermatology, University of Nottingham, <ŝŶŐ ?ƐDĞĂĚŽǁĂŵƉƵƐ, Lenton Lane, 
Nottingham, NG7 2NR.
Yes 
No 
Yes 
No 
email 
post 
Systematic review of outcome measures data extraction form                                                 
Version 7.0  
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Data extraction form 
for the Systematic review of outcome measures for the 
treatment of vitiligo 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Systematic review of outcome measures data extraction form                                                 
Version 7.0  
First Author 
 
 
Year 
 
 
Country 
 
 
Intervention A 
 
 
Intervention B 
 
 
Intervention C 
 
 
Duration of treatment  
Duration of follow up  
Target lesions analysed  
or all lesions 
 
Primary outcome(s) 
specified? 
 
Y/N 
What was it ( put as 
outcome A) 
 
Number of participants 
randomised 
 
Number of participants 
analysed 
 
Outcome A/ name of scale 
or categories  if exists 
 
 
Scales or categories used 
for outcome A 
 
 
Outcome assessed by  
patient 
clinical assessment or  
digital image? 
 
 
Comments on outcome A 
 
 
Outcome A measured 
during treatment or follow 
up period 
 
Outcome A assessed on ( 
indicate on what week(s) 
the outcome was assessed 
( e.g. on the 6
th
, 9
th
 and 
12
th
 weeks repigmentation 
was measured)  
                             weeks 
Outcome B/ name of scale  
Systematic review of outcome measures data extraction form                                                 
Version 7.0  
or categories  if exists 
  
Scales or categories used 
for outcome B 
 
Outcome assessed by  
patient 
clinical assessment or  
digital image? 
 
 
Comments on outcome B 
 
 
Outcome B measured 
during treatment or follow 
up period 
 
Outcome B assessed on ( 
indicate on what week(s) 
the outcome was assessed 
( e.g. on the 6
th
, 9
th
 and 
12
th
 weeks repigmentation 
was measured) 
                        weeks 
Outcome C/ name of scale 
or categories  if exists 
 
 
Scales or categories used 
for outcome C 
 
Outcome assessed by  
patient 
clinical assessment or  
digital image? 
 
 
Comments on outcome C 
 
 
Outcome C measured 
during treatment or follow 
up period 
 
Outcome C assessed on ( 
indicate on what week(s) 
the outcome was assessed 
( e.g. on the 6
th
, 9
th
 and 
12
th
 weeks repigmentation 
was measured) 
                  weeks 
Outcome D/ name of scale 
or categories  if exists 
 
 
 
Scales or categories used 
for outcome D 
 
 
Outcome assessed by  
patient 
clinical assessment or  
 
Systematic review of outcome measures data extraction form                                                 
Version 7.0  
digital image? 
 
Comments on outcome D 
 
 
Outcome D measured 
during treatment or follow 
up period 
 
Outcome D assessed on ( 
indicate on what week(s) 
the outcome was assessed 
( e.g. on the 6
th
, 9
th
 and 
12
th
 weeks repigmentation 
was measured) 
                    weeks 
Outcome E/ name of scale 
or categories  if exists 
 
 
Scales or categories used 
for outcome E 
 
 
Outcome assessed by  
patient 
clinical assessment or  
digital image? 
 
 
Comments on outcome E 
  
 
 
Outcome E measured 
during treatment or follow 
up period 
 
Outcome E assessed on ( 
indicate on what week(s) 
the outcome was assessed 
( e.g. on the 6
th
, 9
th
 and 
12
th
 weeks repigmentation 
was measured) 
                   weeks 
 
 
Instructions to the data extractors: 
1. Please add the outcomes in the form in the order they appear in the text. 
 
2. If outcome measured were the treatment ?Ɛ  ?ŚĂƌŵƐ ?, please do not specify 
ǁŚŝĐŚƐŝĚĞĞĨĨĞĐƚƐǁĞƌĞŵĞĂƐƵƌĞĚďƵƚƉƵƚŽŶůǇ ?ƐŝĚĞĞĨĨĞĐƚƐ ? in the outcome 
box and continue to fill the rest of the questions as usual i.e. assessed by 
whom. 
 
3. &Žƌ ?ŚĂƌŵƐ ? ?please put N/A on the  ?ĂƐƐĞƐƐĞĚďǇ ? box 
  
APPENDIX 3 
 
 
 
 
 
GUIDANCE MANUAL FOR RESEARCHERS  
The HI-Light Trial for vitiligo 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Abbreviations 
 
Co-I  Co-investigator 
GCP  Good Clinical Practice 
NIHR CRN National Institute for Health Research ± Clinical 
Research Network  
PI  Principal Investigator 
R&D  Research & Development Department 
REC  Research Ethics Committee 
RCT  Randomized Controlled Trial 
TMG  Trial Management Group 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Section 1: Overview 
 
This study is a small pilot randomised controlled trial (RCT) 
comparing hand-held NB-UVB light devices with placebo devices. 
These devices will be used by the participants to treat their vitiligo 
at home for a period of four months. The main purpose of the trial is 
to provide feasibility data that can be used to inform the design of a 
future multi-centre RCT of these devices. Two similar types of hand-
held UVB device are being tested during this pilot study. This trial 
will help us to establish which device is likely to be best for the main 
trial. 
Participants will be approached in a variety of ways (through 
secondary care, primary care and through direct advertising). 
Potential participants who contact the co-ordinating centre 
expressing an interest in the trial will be given more information 
about the trial, checked for preliminary eligibility, and sent an 
appointment for a screening visit at the closest recruiting hospital 
(Nottingham or Leicester). 
This screening visit will be conducted by a research nurse, but a 
dermatologist will also be present in order to confirm the diagnosis 
RIYLWLOLJRDQGWRFRQILUPWKHSDUWLFLSDQW¶VVXLWDELOLW\IRU89%
treatment at home. If eligible and willing to take part in the trial, 
participants will provide written informed consent and baseline data 
will be collected. In order to define the starting dose to be used 
when treating the vitiligo, a minimum erythema dose (MED) test will 
be conducted. 
An educational session will be provided by the research nurse 
outlining how to use the devices, how to assess side-effects of the 
treatment and how to complete the treatment diary. Participants 
and nurses will sign an additional consent form on completion of the 
educational session to confirm that the session has taken place and 
that both nurse and participant understand how to use the devices 
appropriately. 
It is anticipated that the screening visit and educational session will 
take place on the same day and may take up to 1.5 hours. 
On the following day, a brief visit to the hospital will be required in 
order to examine the skin and read the MED results (if more 
convenient, the educational session may be delivered at this time). 
Once this has been done, participants will be given the devices to 
use at home ± treatment is applied 3 times per week on alternate 
days. They will be followed up by telephone at week 1, week 2 and 
  
week 12 - in order to provide support and to monitor side-effects. 
Participants will be asked to keep a treatment diary that records 
when the treatment has been used and records side-effects 
experienced. Emergency contact details will be provided in case of 
urgent medical need. 
Participants will continue with treatment at home for the 16-week 
trial period. Two further hospital visits will take place in order to 
record outcome data (week 8 and week 16). 
 
Section 4: MED test and reading 
Please refer to the booklet provided with your MED tester for 
more detailed information 
Please remember: 
1. Please mark carefully the patient before the procedure skin so 
you know where is the open aperture (the highest dose) and 
the aperture 10 (lowest dose) the next day of the reading. 
2. Leave the tester on for 10 min before performing the MED 
test.  
3. Switch the unit off after 10 min BUT do not allow it to cool 
down. Perform the test immediately. 
4. Allow the device to cool down completely (minimum 30 min) 
before starting the procedure again. 
Use the following table to perform the MED test and decide upon the 
treatment schedule: 
Dosage in J/cm2 0.50 
Aperture MED 
norma
l skin* 
 
 
Treatment regimen 
according to MED normal 
skin 
 
Aperture MED vitiligo 
skin** 
Treatment regimen 
according to MED vitiligo 
skin 
 
Open 0.5 &ŝƚǌƉĂƚƌŝĐŬ ?ƐƐŬŝŶƚǇƉĞ ?-6 Open 0.5 &ŝƚǌƉĂƚƌŝĐŬ ?ƐƐŬŝŶƚǇƉĞ ?-6 
2 0.45 &ŝƚǌƉĂƚƌŝĐŬ ?ƐƐŬŝŶƚǇƉĞ ?-6 2 0.45 &ŝƚǌƉĂƚƌŝĐŬ ?ƐƐŬŝŶƚǇƉĞ ?-6 
3 0.38 &ŝƚǌƉĂƚƌŝĐŬ ?ƐƐŬŝŶƚǇƉĞ ? 3 0.38 &ŝƚǌƉĂƚƌŝĐŬ ?ƐƐŬŝŶƚǇƉĞ ?-6 
4 0.31 &ŝƚǌƉĂƚƌŝĐŬ ?ƐƐŬŝŶƚǇƉĞ ? 4 0.31 &ŝƚǌƉĂƚƌŝĐŬ ?ƐƐŬŝŶƚǇƉĞ ?-6 
5 0.24 &ŝƚǌƉĂƚƌŝĐŬ ?ƐƐŬŝŶƚǇƉĞ ? 5 0.24 &ŝƚǌƉĂƚƌŝĐŬ ?ƐƐŬŝŶƚǇƉĞ ?-6 
6 0.18 &ŝƚǌƉĂƚƌŝĐŬ ?ƐƐŬŝŶƚǇƉĞ ? 6 0.18 &ŝƚǌƉĂƚƌŝĐŬ ?ƐƐŬŝŶƚǇƉĞ ?
 
7 0.15 &ŝƚǌƉĂƚƌŝĐŬ ?ƐƐŬŝŶƚǇƉĞ ? 7 0.15 FitzpĂƚƌŝĐŬ ?ƐƐŬŝŶƚǇƉĞ ?
8 0.13 &ŝƚǌƉĂƚƌŝĐŬ ?ƐƐŬŝŶƚǇƉĞ ? 8 0.13 &ŝƚǌƉĂƚƌŝĐŬ ?ƐƐŬŝŶƚǇƉĞ ?
9 0.10 &ŝƚǌƉĂƚƌŝĐŬ ?ƐƐŬŝŶƚǇƉĞ ? 9 0.10 &ŝƚǌƉĂƚƌŝĐŬ ?ƐƐŬŝŶƚǇƉĞ ?
10 0.08 &ŝƚǌƉĂƚƌŝĐŬ ?ƐƐŬŝŶƚǇƉĞ ? 10 0.08 &ŝƚǌƉĂƚƌŝĐŬ ?ƐƐŬŝŶƚǇƉĞ ?
  
MED normal skin*- pleaVHUHIHUWRWKH³7UHDWPHQWUHJLPHQ
DFFRUGLQJWR0('QRUPDOVNLQ´FROXPQLI\RXKDYHSHrformed the 
erythema testing a patch of normal (pigmented) skin of a vitiligo 
patient 
MED vitiligo skin**-SOHDVHUHIHUWRWKH³7UHDWPHQWUHJLPHQ
according to MED vitiligLQRXVVNLQ´FROXPQLI\RXKDYHSHUIRUPHG
the erythema testing a patch of vitiliginous (depigmented) skin of a 
vitiligo patient 
 
Section 5: How to deal with side effects and what to 
advice to the patients? 
Side effect Co-originating centre  Advice/action of phototherapy nurse 
Erythema grade 1 
-skin is slightly pink 
/ red in colour. It 
will develop on the 
day of treatment, 
and settle within a 
day. Erythema 
does not feel hot 
and is NOT painful. 
 
 
 
 
No action  required 
Reassure 
Advice to complete the diary 
accordingly 
Advice to apply moisturizer on 
treated patches after session it 
itchy or dry skin 
Continue treatment as normal 
No action  required 
Reassure 
Advice to complete the diary accordingly 
Advice to apply moisturizer on treated 
patches after session if itchy or dry skin 
Continue treatment as normal 
Erythema grade 2 
- skin is obviously 
red in colour. It will 
develop on the day 
of treatment and 
will still be there 
approximately two 
days after the 
treatment. 
Erythema does not 
feel hot, might feel 
slightly 
uncomfortable but 
is NOT painful. 
 
Reassure that this is normal skin 
reaction and ensure that the 
correct diagnosis was made (i.e. 
erythema grade 2). 
Skip one session i.e.  until the 
erythema has completely resolved 
and continue the next session with 
reduced time ( restart as per 
session BEFORE the burn occurred) 
Advice to complete the diary 
accordingly 
Advice to apply moisturizer on 
treated patches after session it 
itchy or dry skin 
If not sure or patient is still anxious 
arrange for Research nurse call. 
Reassure that this is normal skin reaction 
and ensure that the correct diagnosis was 
made (i.e. erythema grade 2). 
Skip one session i.e.  until the erythema 
has completely resolved and continue the 
next session with reduced time ( restart as 
per session BEFORE the burn occurred) 
Advice to complete the diary accordingly 
Advice to apply moisturizer on treated 
patches after session it itchy or dry skin 
If not sure or patient is still anxious arrange 
an unscheduled visit. 
Erythema grade 3 
- skin is very red 
and feels like 
sunburn. Erythema 
feels hot, 
uncomfortable and 
PAINFUL. This will 
last for two to 
Stop treatment immediately and 
seek medical advice  
Speak to the research nurse or 
oncall dermatologist if no-one 
available or out of hours. 
The patient will have to at least 
speak to  a research nurse or a 
Ensure that the correct diagnosis was 
made (i.e. erythema grade 3).  
If not sure or patient is still anxious arrange 
an unscheduled visit when clinics reopens. 
If the patient is not coping with the pain, 
advise they attend for review asap when 
clinics reopens.  
  
three days. The 
symptoms will 
reduce in severity 
as the days pass. 
 
dermatologist asap. 
Advice to apply regular 
moisturizers on the red skin to 
relieve the symptoms in the 
meantime. 
Advice to complete the diary 
accordingly. 
 
The frequent application of emollient is 
advised. 
Topical steroid may be prescribed if the 
use of emollient  does not relieve the 
symptoms.  
It is a good idea to store steroid and 
moisturizer it in the fridge so it is cool 
when applied to the skin. 
The treatment will be stopped until 
erythema is resolved completely. 
Arrange a follow up telephone call or visit 
to the patient in 2 or 3 days to ensure the 
erythema has resolved prior restarting the 
treatment. 
Restart on reduced by 50% time of the last 
treatment administered. Always consult 
the individual treatment schedule to 
ensure that the restarting time follows the 
schedule. 
Advice to complete the diary accordingly. 
Erythema grade 4 
or blisters 
-skin is very red 
and hot and has 
blisters. This 
reaction is VERY 
PAINFUL. This burn 
can last for four to 
five days. The 
symptoms will 
reduce as the days 
pass. 
Stop treatment immediately and 
seek medical advice  
Speak to the research nurse or 
oncall dermatologist if no-one 
available or out of hours. 
The patient will have to at least 
speak to a research nurse or a 
dermatologist asap. 
Advice to apply regular 
moisturizers on the red skin to 
relieve the symptoms in the 
meantime. 
Advice to complete the diary 
accordingly. 
 
Ensure that the correct diagnosis was 
made (i.e. erythema grade 4).  
Arrange an unscheduled visit asap when 
clinics reopens 
A dermatologist review is advisable. 
The frequent application of emollient 
alongside topical steroids is advised. 
It is a good idea to store steroid and 
moisturizer it in the fridge so it is cool 
when applied to the skin. 
The treatment will be stopped until 
erythema is resolved completely. 
Arrange a follow up telephone call or visit 
to the patient in 3 or 4 days to ensure the 
erythema has resolved prior restarting the 
treatment.  
Arrange an unscheduled visit with a 
dermatologist prior restarting the 
treatment to ensure all the symptoms are 
gone and to decide upon the restarting 
dose ( e.g. reduce dose by 50% or more or 
even switch the patient to a  lower skin 
type schedule) 
 
 
 
Itchy No action  required 
Reassure 
Same as Co-ordinating centre 
  
Advice to complete the diary 
accordingly 
Advice to apply moisturizer on 
treated patches after session  
Continue treatment as normal 
Hyperpigmentatio
n (brown) around 
the patch 
No action  required 
Reassure this is normal reaction 
Advice to complete the diary 
accordingly 
Continue treatment as normal 
Same as Co-ordinating centre 
Cold sores Reassure that this can happen 
Advice to stop the treatment of 
the affected area (lips) only and 
continue to treat the rest of the 
patches as normal. 
Ask the research nurse to give a 
patient a call if not sure or patient 
is anxious.  
This is not an emergency and 
therefore no unscheduled visit or 
referral to a dermatologist 
required. 
Advice to complete the diary 
accordingly 
Advice to apply topical acyclovir on 
the cold sores. 
Reassure 
Ensure the correct diagnosis has been 
made. 
Application of topical Acyclovir would be 
advised. Depending on the area, it might 
be worthwhile advising the patient to apply 
sun block to the affected site, e.g. the lips 
(to help prevent recurrence). 
Ask the patient to restart the treatment of 
the affected area once the cold sores are 
completely resolved. 
Restart on reduced by 50% time of the last 
treatment administered. Always consult 
the individual treatment schedule to 
ensure that the restarting time follows the 
schedule. 
Advice to complete the diary accordingly. 
 
 
 
 
Rash Stop treatment immediately and 
contact the research nurse or the 
on call dermatologist if no-one is 
available or out of hours. 
Arrange for an unscheduled visit 
with a research nurse or a 
dermatologist 
Confirm the diagnosis of polymorphic light 
eruption and consult with a dermatologist. 
The patient will have to be withdrawn 
from the trial 
 
 
 
 
 
 
 
 
  
Sections 6: What to advice to the patient about missing 
sessions for reasons other than side effects? 
 
1 treatment - continue treatment as normal 
2-3 treatments - administer the same dose as per last treatment 
session  
4 or 5 treatments - administer 60% of the last treatment dose 
2 or 3 weeks - administer 50% of the last treatment dose 
More than 3 weeks - the patient has to be reviewed by a research 
nurse to discuss the issues of non-compliance and by a clinician who 
will decide on a reduced dose, if the patient still wishes to continue 
the treatment.  
 
Section 7: What to do if the patient took/ was 
prescribed a new medication during the trial? 
Step 1: Complete the New Medication CRF and establish if the new 
drug is photosensitive or not 
If not photosensitive, no actions need to be taken 
Step 2: If photosensitive, establish for how long the patient is likely 
to be taking this medication. 
x If it is a one off  
e.g. has taken ibuprofen because of headache, advice to the patient 
NOT to have treatment on that day. Continue the treatment the 
next day and repeat the same treatment dose as previously e.g. 
Monday: treatment time=17 sec 
Taken ibuprofen on Wednesday 
Advice Not to have treatment on Wednesday, but carry on Thursday 
and repeat the same dose i.e. 17 sec (rather than 21 sec).  
x If up to 2  weeks 
Stop the treatment for the time period that the patient will be taking 
the photosensitive drug and restart the treatment after the course 
has been completed. 
The re-starting dose will be reduced by 50% from the last dose i.e. 
as per ³PLVVLQJVHVVLRQV´JXLGDQFHRUPLVVLQJWUHDWPHQWV 
x If up to 3 weeks 
Stop the treatment for the time period that the patient will be taking 
the photosensitive drug and restart the treatment after the course 
has been completed. 
The re-starting dose will be reduced by 60% from the last dose i.e. 
DVSHU³PLVVLQJVHVVLRQV´JXLGDQFH-3 weeks missing treatments) 
x If more than 3 weeks  
Please withdraw the patient from the trial and complete the 
withdrawal form. 
Step 3 Take accurate details of the exact dose and the advice that 
WKHSDWLHQWUHFHLYHGDFFRUGLQJWRWKHDERYHLQWKHSDWLHQW¶VQRWHV 
  
Section 8: CRFs and consent forms 
                                                               Researcher 
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Pre-trial contact/ telephone pre-screening 9     
Screening/educational visit  9 
(Part C) 
9 
Part A,B and 
MED) 
Baseline visit (MED test reading)     9  
Follow up telephone calls ( 1 week, 2 weeks, 6 weeks and 12 
weeks) 
9      
Follow up face to face visit at 8 weeks      9 
Final trial visit (16 weeks)   9 
(Part 
C)  
9  
(Part A, B) 
Part C if blinded  
Unscheduled visits/calls 9  9  9  
Withdrawal    9  
 
Each patient/carer will have to sign 2 consent forms: 
1) At the beginning of the screening visit: to consent for the 
information to be gathered 
2) After the educational session: to ensure that he/she has 
understood the educational material 
Final visit (16 weeks) Part C- to be completed by a dermatologist 
or a research nurse who has not seen the patient during the trial ( 
e.g. for side effects or trial hospital visits) 
 
Section 9: Digital images 
When should I take an image? 
A maximum of 3 lesions will be chosen for each participant and 
images are taken: 
x Baseline 
x 2 Months 
x 4 Months 
 
How should I take an image? 
You will have been provided with a camera from the co-ordinating 
centre.  This has been set-up with the required settings - please do 
not alter these. 
 
You do need to ensure the Macro setting is ON each time (it 
automatically turns off each time).  To do this, press the button that 
looks like a flower. 
 
The following points should be noted when taking an image: 
  
Image Size 
x Try to make the lesion and some surrounding skin fills the 
image as much as possible 
x As previously mentioned, try and avoid glare from the 
flash by moving the camera away from the subject and 
using the optical zoom to fill the viewfinder 
 
How many images should I take per visit? 
Four in total ± two with flash, two without.   
Only 2 need to be sent to Viktoria. 
 
How do I upload the images I have taken? 
 Connect the camera to your computer using the USB 
connection cable.  Save them to a local place on your computer 
(e.g. your desktop) as a temporary measure. 
 
      How should images be labeled? 
Once you have uploaded the images to your local computer, you 
should rename them, giving each image the following file name:   
 
Centre number_Participant number_lesion number_Date of Image 
(DDMMMYYYY)_Image letter.  For example;   
 
                                                          001006_1_Base_01FEB1970_A 
 
 
 
 
 
How do I send the image to the co-ordinating centre? 
Save a copy of the image locally (i.e. to the computer you are 
working from) and email the images as an attachment to: 
viktoria.eleftheriadou@nottingham.ac.uk 
 
You will receive an email shortly afterwards telling you the image 
has been received. 
 
When can I delete the images from the camera? 
You must delete images from the camera once you have received 
confirmation from the co-ordinating centre that the images have 
been received.  To do this, open the image on the camera and press 
the green button which looks like a dustbin. 
 
Centre 
number 
    Patient number 
    Date of Image 
    Image number ± please 
label images A, B, 
C, D 
    Lesion number: 
1, 2 or 3 
    Visit name: 
Base, M2, M4 
  
It is wise to keep a file of images locally on your computer or local 
network so you can review before appointments or for someone new 
to review to ensure consistent lesions are measured each visit. 
 
Section 10: Withdrawing a participant 
This section relates only to those participants who are being 
withdrawn entirely from the WULDO,I\RXDUHVWRSSLQJDSDUWLFLSDQW¶V
randomized treatment, this does not mean they are being 
withdrawn. 
It may be necessary to withdraw a participant for a number of 
reasons: 
x Death 
x The participant becomes lost to follow-up 
x The participant no longer wishes to have any part in the trial 
and withdraws their consent 
x The participant no longer meets the eligibility criteria.  For 
example, photosensitive medication was prescribed. 
If a participant is withdrawn from the trial, if possible a final visit 
CRF should be completed.   
 
Section 11: FAQs 
11.1 'R,KDYHWRZULWHWRWKHSDUWLFLSDQW¶V*3" 
You should write to the GP as per your normal care.  The 
coordinating centre sends a letter to the GP to inform them that 
your participant is in the trial.  This letter has been approved by the 
Ethics Committee and your Trust R&D department.  
11.2 How many lesions does the patient allow to treat? 
It is up to the patient how many and which lesions (s)he wants to 
treat. The patient has the liberty to choose and discuss what lesion 
(s)he wants or doesn't want to treat, as long as these discussed 
during the screening visit and documented in the relevant section of 
baseline CRF. It is possible for the patient to treat only one or two of 
her/his lesions if (s)he wishes to. 
Please note that lesions on genitalia are not to be treated. 
11.3 How are the representative lesions decided upon? 
Out of the lesions that the patient wishes to treat, the research 
QXUVHZLOOPDNHWKHGHFLVLRQWRFKRRVHWKUHH³UHSUHVHQWDWLYH´
lesions. Only these will be measured during the trial i.e. 
photographed and assessed. 
Please try and choose 3 lesions on 3 different anatomical sites if 
possible i.e. face, hand, leg, abdomen, back. 
If the number of lesions that the patient wants to treat is less than 3 
then all the treated lesions will be representative. 
 
  
 
APPENDIX 4 
 
 
TRAINING MANUAL FOR PATIENTS  
Instructions on how to use hand-held devices at home  
and deal with side effects 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Introduction 
What is phototherapy? 
Phototherapy is the use of light for the treatment of some skin disorders 
including vitiligo. It reproduces the action of sunlight in a scientific and 
controlled manner. 
NB-UVB light means narrow band ultraviolet B light. These specific wave 
lengths of light are the same as some of those we expose our skin to when 
we are outdoors. 
What is a hand held phototherapy unit? 
This is a hand held device fitted with a NB-UVB lamp. It is used to treat 
skin conditions such as vitiligo. 
You have been selected to use a hand held unit at home following a 
training programme, which will be held in your local hospital. 
Light therapy is almost exclusively available at hospitals, usually involves 
exposing the whole body and requires regular visits to the hospital at least 
three times a week.   
Hand held light therapy units use the same NB-UVB light as the hospital 
ones but are suitable for the treatment of small white patches such as on 
the face, hands, ears and lips. The uninvolved skin is therefore not exposed 
to the light. 
What happens before I start my treatment?  
First of all a member of the research staff will show you the lamp and will 
explain to you all the procedures involved in the treatment. 
Before you begin light treatment, you will receive a small test dose, called 
MED (Minimal Erythema Dose). A number of doses of ultraviolet light B will 
be shone on small squares on your vitiligo skin or on your normal skin if 
your vitiligo patch is not big enough. This takes about 15 minutes and the 
result will be read the next day (24 hours later).  
This reading will help decide the start dose your light treatment should be. 
Even if you have had UVB treatment in the past, MED test will normally be 
UHTXLUHGEHFDXVH\RXUVNLQ¶VVHQVLWLYLW\ WR89%FDQFKDQJH7KH0('QRW
  
only makes sure that you are treated at a safe UVB dose, but also makes 
sure you are started at a high enough dose for you.  
How long will I have UVB treatment?  
Usually, this varies from person to person, but an average course lasts 
from 2 to 6 months.  
For the purpose of this trial you will receive phototherapy for 4 months. 
Before you start UVB treatment the research staff will check the medicines 
that you are taking. If your tablets (including anything you have bought 
form a pharmacist) are changed during the trial, please let the research 
staff know before you start your next treatment. This is because some 
tablets can affect the way treatment works. 
What should I do if I start  taking  new drugs during the trial, 
including over the counter drugs? 
Some drugs could make your skin more sensitive to the light therapy. This 
means that even with small doses of light you might get sunburn.  These 
are called photosensitive drugs.  
Please remember that NOT all individuals who use or take these 
medications will experience a photosensitive reaction. 
x If you are prescribed a new drug during the trial, including 
antibiotics, you should let your doctor know that you are receiving 
light therapy and ask if this drug is ok to take. If your doctor says 
that the new drug is photosensitive, you should stop your light 
treatment and contact your phototherapy nurse for further advice. 
x If you are buying a drug over the counter please see the following 
list of photosensitive drugs. If you are not sure please call your 
phototherapy nurse or if out of hours please call your hospital and 
ask them to connect you to the on-call dermatology Registrar and 
ask them for advice.  
x The following list is not exhaustive and therefore please call 
us BEFORE your next session if you have taken ANY new 
drugs 
 
  
List of photosensitive drugs 
Over the counter drugs: 
1. Painkillers  such as Ibuprofen, Diclofenac 
2. Antihistamines such as Benadryl 
Prescription drugs: 
3. Antibiotics such as Ciprofloxacin, Tetracycline, Doxycycline, 
Trimethoprim 
4. Cardiac drugs such as Amiodarone, Diltiazem 
5. Diuretics such as Furosemide 
6. Diabetic drugs such as chlorpropamide 
7. Acne medications such as isotretinoin 
 
When and how often should I use my hand held 
phototherapy lamp? 
You should treat your vitiligo patches every other day (2nd) e.g. Monday, 
Wednesday, Friday etc.  This means you would do at least 3 and a 
maximum of 4 treatments per week. Please do not treat your vitiligo every 
day, as you have to give your skin a break to recover from the light 
therapy. 
You can do your treatments at any time of the day suitable for you. 
What about my creams?  
For the purpose of this trial you have agreed to stop any current treatment 
for vitiligo, including creams.  
Please continue to use regular moisturisers during your course of 
treatment.  
 
 
 
 
  
Important things to remember 
Before the treatment                                                                          
x Cosmetics and perfumes: On the days of treatment, please avoid 
using perfumed products such as cosmetics, perfumes or 
aftershaves on the treated areas as these can make your skin more 
sensitive to the light.  
x Moisturisers: Please do not use any moisturisers on your vitiligo 
patches any moisturiser for at least 2 hours before treatment as this 
can act like a sunscreen and stop the treatment working.  
x Medication changes: Please inform your research team or your 
nurse of any medication changes during the treatment.  
 
 
 
 
 
 
 
 
 
  
 
During the treatment 
x Sunbeds and sunbathing should be avoided throughout the course 
of treatment. Please apply high SPF sun creams before going out in 
the sun. 
  
When using the hand held units, always wear the protective goggles 
supplied. If another person is administering the treatment he/she 
should also wear protective goggles or glasses.  
 
x Please wear the cotton gloves provided during the treatment in 
order to protect your hands from overexposure.  
x Attach the comb: Only use the unit with the comb on. If the comb 
gets dusty, it can be removed and washed in soapy water. Ensure 
that it is thoroughly dried before reattaching it. 
x If other people are also present in the room during the treatment, 
they all have to wear protective glasses to protect their eyes. 
x The unit is provided for the treatment of your vitiligo and only for 
the patches discussed with your doctor. Do not use it on other areas 
  
of your skin or allow anyone else to use it as they may develop a 
severe burn reaction. 
After the treatment 
x When the equipment is not in use you should ensure that it is 
switched off and unplugged from the main supply. It should be 
stored in a safe place in its case or box, out of reach of children. 
 
Side effects  
A sunburn like reaction may occur at some point during your treatment or 
you may find your skin becomes dry. Occasionally you may develop an 
itchy rash. If you experience any of these reactions, your moisturiser will 
help to soothe your skin. If you are very uncomfortable please contact the 
research team. You may need to see a doctor.  
If you develop a cold sore on the face, please stop the light treatment in 
that area until the cold sore has healed. You can continue treating vitiligo 
patches on other areas of the skin as normal. 
 
Premature ageing of the skin (e.g., dryness, freckling and wrinkling) can 
occur in patients who have had UVB therapy for many years and such 
individuals may be at an increased risk of developing skin cancer. The 
increased risk of skin cancer is related to the total lifetime UVB exposure 
from sunlight as well as treatment. 
Please remember, it is extremely important to check your skin in order to 
identify the side effects that may occur as a result of phototherapy. You 
should examine your skin regularly throughout the treatment course e.g. 
  
before going to bed on the evening of your treatment, the next day and 
before your next treatment. 
What side effects could occur? 
The side effects that could occur on the skin following light therapy are the 
following: 
x Erythema (Redness) 
x Blisters 
x Rash 
x Itching 
x Dry skin 
x Cold sores 
x Tan (brown) around the edges of vitiligo patches 
The most common side effect that could occur is red skin like sunburn. 
There are four different grades of redness, called grades 1-4. Each grade of 
erythema has different symptoms e.g. the colours are different and some 
are painful while others are not. 
 
What should I do if I develop redness of the skin (erythema)? 
Should you develop redness of your skin, you should carry out the 
following steps: 
1. Decide upon the grade of your erythema. Think about how the 
erythema feels, when it first appeared, its colour and how long it 
last for. Please refer to the table below for help. 
2. Apply moisturiser after the treatment on your red skin. 
  
3. Always complete your diary! 
4. Report your side effects to us as advised in the table below. 
5.  If you are not sure about what grade your erythema is and would 
like to double-check you are always welcome to call us on (to be 
inserted). Or if out of hours please call your local hospital and speak 
to the oncall dermatology registrar. 
Please remember ± Redness of your skin, no matter what grade, 
will be visible approximately 4 hours after treatment. 
Grade 1 erythema: skin is slightly pink / red in colour. It will develop 
on the day of treatment, and settle within a day. This means that on 
your next session your skin will look normal again. This burn does not 
feel hot and is NOT painful. 
Action: 
x Apply moisturiser on the affected areas after the treatment 
x Decrease your treatment time on your next session (please see 
the treatment schedule summary on page 17) 
x 7KLVUHDFWLRQLVQRUPDO<RXGRQ¶WKDYHWRFDOOXVWROHWXVNQRZ
but please make a note of it in your diary. 
GRADE 1 ERYTHEMA
 
Grade 2 erythema: skin is obviously red in colour. It will develop on 
the day of treatment and will still be there approximately two days after 
  
the treatment. This burn does not feel hot, might feel slightly 
uncomfortable but is NOT painful. 
Action: 
x Apply moisturiser on the affected areas after the treatment 
x Skip one next treatment session until your skin settles and return 
to normal. 
x  After your skin looks normal again you should restart treatment 
but will have to decrease your treatment time (please see the 
treatment schedule summary on page 17).  
x This is not an emergency as this is also an expected reaction of the 
skin. 
x However if you are not sure or would like to confirm your actions 
please call us BEFORE you restart treatment on (tel: xxxxx name of 
phototherapy nurse) or on 0115 8468629 (co-ordinating centre). 
Inform us of the area of the skin affected, along with the colour 
and symptoms of the burn. State the action you plan to take. Once 
we confirm the correct action to take for your next treatment, carry 
this out on the correct treatment day as per your schedule.  If your 
next session is at the weekend, SKIP it and call us on Monday 
EHWZHHQDQGR¶FORFN 
 E.g. if you developed grade 2 erythema on Monday (treatment 
time=21 sec), you will skip your Wednesday treatment session and 
restart again on Friday (decreased treatment time=18 sec).  
If you have developed redness of your skin and your skin feels 
 HOT and PAINFUL - this is at least a grade 3 erythema. 
Grade 3 and grade 4 erythemas are serious, so please contact the 
research team as soon as possible 
Grade 3: skin is very red and feels like sunburn. Your skin will feel 
hot, uncomfortable and PAINFUL. This will last for two to three days. 
The symptoms will reduce in severity as the days pass. 
Action:  
x Stop treatment 
x Apply moisturiser to the affected areas 
x Contact your phototherapy nurse (tel:xxxxx) or research team 
(tel:xxxxx) ASAP. You will need to stop treatment until your skin 
settles. If this happens at the weekend or out of hours, please 
call your local hospital (insert name and number)  and ask them 
  
to connect you to the oncall dermatology SpR for advice.  
GRADE 2/3 ERYTHEMA
(can be similar in colour, but have different symptoms)
 
Grade 4: skin is very red and hot and has blisters. This reaction is 
VERY PAINFUL and may make you feel unwell. This burn can last for 
four to five days. The symptoms will reduce as the days pass. 
Action:  
x Stop treatment and  
x Contact your phototherapy nurse (tel:xxxx) or research team 
(co-ordinating centre tel:xxxx). If this happens at the weekend 
or out of hours, please call your local hospital(name and phone 
number) and ask them to connect you to the oncall dermatology 
SpR. You will be seen by a doctor in your local hospital. 
x The research nurse will contact you regarding how and when 
restarting your treatment. 
  
GRADE 4 ERYTHEMA
 
 
 
Please remember 
 If you develop grade 3 or 4 erythema of your skin, always contact 
our research team BEFORE your next treatment in order to confirm 
your assessment. By failing to do this, you may cause a more 
severe burn reaction, e.g. if you have assessed your skin wrongly 
or take the wrong action for your next treatment 
 
What should I do if I develop side effects other than redness 
of the skin? 
x If the treated skin is itchy and begins to feel dry, apply your 
moisturiser at least three to four times a day throughout the 
treatment course. Please do not apply moisturiser BEFORE the 
treatment session. 
x If you develop tan (brown) around the edges of vitiligo 
patchesWKLVLVQRUPDOUHDFWLRQRIWKHVNLQ<RXGRQ¶WKDYHto do 
anything and therefore continue your treatment as normal. 
 
  
x If you develop a rash, stop the treatment immediately. Please 
call our research team as soon as possible on ( co-ordinating 
centre tel:xxxx) or if out of hours please call your local 
hospital ( Name of the hospital and telephone to be inserted) and 
ask to speak to the on-call dermatology SpR. 
RASH
 
 
x If you develop cold sores stop the treatment until the cold sore 
has healed. Call us on 0115 84 68629 or on ( tel of research 
nurse) to let us know that you have cold sores as well as 
after they have healed. You research nurse will let you know 
how to correctly restart the treatment on that area. 
x This is not an emergency and therefore please call us during 
day time or wait unitl the next morning. However if you are 
worried and out of hours please call your local hospital 
( Name of the hospital and telephone to be inserted) and ask to 
speak to the on-call dermatology SpR. 
  
COLD SORE
 
x If you have any other questions about side effects, please call 
your research team (co-ordinating centre Tel to be inserted) for 
advice before your next treatment! 
What should I do if I have mechanical problems with the 
lamp? 
If you need advice regarding mechanical problems with the lamp, 
please call your research team on 0115 84 68629 
About the device 
When will I receive my device? 
You will receive your unit on the day of your baseline hospital visit or in 
a few days after your first hospital visit. It will arrive by post as a 
signed for delivery. If you do not receive your device within 5 working 
days of your educational session please contact our research team on 
0115 84 68629 or email vitiligostudy@nottingham.ac.uk. 
What to do when I receive my device? 
After receiving your package, please check that all the following are in 
the box: 
  
 
                                                                                 
 
 
 
 
 
 
 
 
Please call us on (phone number to be inserted) to let us know that you 
have received all the above. 
And now you are ready to start your treatment!  
 
Treatment guidance 
How the device works 
 
Before switching on the device: 
x Hand held lamp 
x Safety goggles  
x Safety glasses  
x A pair or cotton gloves 
x Comb (plastic teeth) 
 
On/off switch  
  
x Ensure you are wearing your protective glasses or goggles 
x Ensure you are wearing the cotton gloves provided  
                         
Please follow the following simple steps to start your treatment: 
1. Make sure you have calculated and recorded your treatment times 
in your diary before you start! 
2. Set up the alarm clock 
3. Connect the lamp to the main supplier 
4. Turn the lamp on 
5. Please remember that during the treatment the device will warm 
up. This is normal. Please continue the treatment  
 
 
Trouble shooting 
 
 Problem Reason Solution 
1 7KHGHYLFHZRQ¶WVZLWFK
on 
 
The device is not 
connected to the 
socket 
Make sure you have 
pressed the lamp entirely 
into the socket. 
 
 
Your treatment schedule 
As prescribed by your doctor, you should do your treatment every other 
day. This means that you will treat your white patches 3 to 4 times a week. 
Please remember NOT to treat your skin every day. 
Your treatment schedule depends on your skin type.  Each session you will 
be increasing your treatment time i.e. if you have skin type 1 and you did 
21 seconds on Monday, you will do 24 seconds on Wednesday providing 
you did not experience any redness of your skin in the meantime. You 
  
should continue increasing your treatment time until you reach the 
MAXIMUM TREATMENT TIME as recorded in your diary.  
Please remember to calculate your treatment times and write them 
down in your diary BEFORE starting you session!  
 Please see the following table for more details. 
Treatment Schedule summary 
Skin 
Type 
Starting 
time 
Time 
increase  
 
 
Exposure 
time 
decrease 
Maximum 
treatment 
time  
Overall 
duration of 
treatment 
I 15 sec + 3 seconds  -3 seconds  
 
3 min 4 months 
II 20 sec + 4 seconds -4 seconds 
 
4 min 4 months 
III 25 sec + 5 seconds -5 seconds 
 
5 min 4 months 
IV 30 sec + 6 seconds  -6 seconds 
 
6 min 4 months 
V 30 sec + 6 seconds -6 seconds 
 
6 min 4 months 
VI 30 sec + 6 seconds -6 seconds 6 min 4 months 
 
 
In summary: 
x Follow the starting time as in your personalised treatment schedule. 
x If you are not experiencing any redness: on each treatment session 
i.e. every other day, increase your treatment according to your 
personal schedule. 
x If you develop redness please refer to the table on page 8 of 
this manual first and always contact the research team if 
appropriate BEFORE your next treatment! 
x If you develop grade 1 erythema: decrease your treatment time as 
above. 
i.e. if your skin type is 1 and after session 3 ( 21 seconds) you 
develop erythema, which is resolved by the next treatment day, you 
will receive 18 seconds on your session 4 instead of 24 seconds. 
x If you develop grade 2 erythema or above: You should skip one 
treatment session and decrease your treatment time on the next 
one. E.g. if after your treatment on Monday (=21 seconds) you 
have developed grade 2 erythema, you will skip your session on 
Wednesday. On Friday, you will receive 18 seconds of light.  
  
x If you develop grade, 3 or 4 erythema: please stop your treatment 
and contact the research team as soon as possible. 
 
What to do if I miss a treatment? 
If for any reason other than side effects, you have missed one or more 
WUHDWPHQWVHVVLRQVHJ\RXZHUHEXV\RUDZD\DQGGLGQ¶WWDNH\RXUODPS
with you please do the followings: 
1. One or 2 missed treatment sessions: administer decreased time 
on your next session i.e. if on Monday you administered 21 seconds 
but you have missed both your Wednesday and Friday treatment, 
you would administer 18 seconds on Saturday.  
2. Three or more missing treatments: please contact your research 
team for advice. 
 
 
 
Treatment time schedule 
Your nurse will give you your personalised treatment schedule suitable for 
your skin type following the results of your MED test. 
Please remember to use this treatment plan as a guide only and if you are 
not experiencing any side effects. 
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Patient¶s diary for home phototherapy 
 
 
 
 
  
Instructions on how to complete this diary 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Please remember to fill your diary BEFORE every treatment session.  
Step  Column Information required Example 
1 Session Session number e.g. 2 
2 Date The date you perform your treatment e.g. 02/03/2011 
3 Area(s) 
treated 
Write down what areas are you treating. 
If you didn't have any side effects on  all patches since your 
last session please  insert  ALL ( patches) 
If one or some areas has  at least one side effect please insert 
in a separate line  
e.g. face, left hand or 
all 
in separate line e.g. face 
and in separate line e.g. 
left hand 
4 Time(sec) Write down the time of treatment session. 
Remember to insert before starting your session 
e.g. 25 sec 
5 Problems? 
(Y/N) 
Did you have any side effects from you previous session?  
If no- insert N and leave the rest of the line empty.  
If yes-continue  
Yes or No 
6 Redness  or 
other side 
effects 
If you had any of the side effects mentioned in your diary or 
your manual please specify accordingly 
Redness: e.g. 1 
Other side effects: e.g. D 
7 Contacted 
research 
team 
If you had side effects, please tell us if you  had called the 
research team by replying yes or no in the column 
Yes or No 
8 if yes, was 
advised 
If you have replied yes to the above question, please tell us 
what were you advised to do e.g. reduce dose= 1 and 
complete the  if yes, was advised column accordingly. 
1 or 2 or 3 
9 Comments If missed a treatment  for ANY reason please insert here  
Or any other comments 
e.g. session 4, date 
11/11/2011 comments: 
missed treatment 
UHDVRQ« 
 
 
ǣ 
If you have any questions or need advice please contact 
us during office working hours: 
x Jo Perdue (administrator, co-ordinating centre):  
x Lisa Charlesworth (administrator, co-ordinating 
centre) 
Telephone: 0115 84 68629  
RESEARCH NURSE:  
(Sue Davies-Jones, 0115 82 31041/07945 420508 or Jo 
Llewellyn 07407 154580) 
EMERGENCY OR OUT OF HOURS: 
If out of hours AND in case of EMERGENCY please 
call your local hospital, Queens Medical Centre on 0115 
9249924 and ask to speak to the on-call dermatology 
registrar. 
 
 
  
 
Skin type treatment plan:                                                              Start time:                  
Maximum treatment time: 
3DUWLFLSDQW¶V0(' 
Name of person administering the treatment (if applicable): 
 
 
PatieQW¶V'LDU\IRU+RPHSKRWRWKHUDS\ 
*if you develop redness of your skin, please describe: 
Grade 1 redness-pink/red skin, settles within a day. NOT 
painful 
Grade 2 redness- red skin, lasts for around 2 days. NOT 
painful. 
Grade 3 redness-very red, like sunburn, lasts for 2-3days. 
HOT and PAINFUL 
Grade 4 redness-very red skin and BLISTERS. VERY 
PAINFUL 
  
Sessi
on 
Date 
(dd/m
m/yyy
y) 
Area(s) 
treated 
Time 
(sec) 
Problems? 
Yes/No 
Redness 
Please 
record 
accordingly 
*:  
Grade 1=1 
Grade 2=2 
Grade 3=2 
Grade 4=4 
 
Other side 
effects. 
Please record all 
applicable: 
Dry skin=D 
Rash=R 
Itch=I 
Blister=B 
Cold sores=C 
Brown at the 
edges=H 
Contacted 
research 
team?  
Yes/No 
(only 
complete if 
any side 
effects) 
If yes, 
was 
advised 
WR« 
Reduce the 
dose=1 
Skip a 
treatment=
2 
See a 
doctor=3 
Comments 
(e.g. take a note here if 
you have missed a 
session) 
1 
 
 
  
 
 
 
 
 
       
 
 
 
         
 
 
 
         
 
 
 
 
 
         
  
 
 
 
 
 
APPENDIX 6 
 
END OF STUDY QUESTIONNAIRE  
HI-LIGHT TRIAL 
Final hospital visit 
Week 16 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
If completed by co-ordinating centre over the phone please tick  
 
Your opinion on the success of the treatment 
 
 
2. Please rate the colour match of your vitiligo patches following light 
treatment  
(please tick one option) 
Lesion 
name 
Bad Fair Good Excellent 
Darkening 
of the skin 
around the 
lesion is 
present 
(Y/N) 
      
      
      
 
 
 
 
 
 
Date of completion: _ _ / _ _ / _ _ _ _    
1. How satisfied are you with the treatment? 
(please tick one option) 
Very  
dissatisfied 
somewhat 
dissatisfied 
Neutral Somewhat 
satisfied 
Very  
satisfied 
  
Now have a look at the photographs of your representative patches 
before starting the treatment. 
 
Looking at the photographs of before treatment and comparing to 
your patches today: 
 
 
3. How would you rate the overall changes in your vitiligo? 
(Please tick one option) 
Much worse A bit worse No change A bit better Much better 
 
 
Your opinion on the hand held phototherapy lamp and the training 
session 
 
 
Waldmann 
Dermfix 
1000 
4. Which device did you have?   
 
 Yes No Unsure 
 
 
5. Please say what you liked the most about this lamp?  
 
 
 
 
 
 
 
  
6.  Please say what you liked the least about this lamp? 
 
 
 
 
 
 
 
 
 Yes No Unsure 
7. Do you think the training session at the 
beginning of the trial was sufficient for you 
to operate the device at home with limited 
medical supervision?  
   
 
8. If you answered no or unsure on the previous question please tell us 
how the training session could be improved? 
 
 
 
 
 
 
 Yes No Unsure 
9. Did you find it difficult when deciding on 
the grade of erythema (redness)? 
   
10. If you replied yes or unsure on the following question please explain. 
  
 
 
 
 
 
 Yes No Unsure 
11. Did you have any difficulties with 
operating the lamp? 
   
 
12. If you replied yes or unsure on the following question please explain. 
 
 
 
 
 
 
 
 
Never 
Some 
of the 
time 
Most 
of 
the 
time 
Always 
13. Did you follow your treatment 
schedule as prescribed by your doctor 
i.e. light therapy 3 times a week? 
    
 
 
 
 
 
14. If you did NOT use the treatment as recommended, why not? 
  
 
 
 
 
 Active Dummy 
15. Do you think you have had an active device or a 
dummy device in this trial? 
  
 
 Yes No Maybe 
16. Would you use the lamp again?    
17. Would you recommend the lamp to 
others? 
   
 
 
Your opinion on this trial and future research into vitiligo 
 
18. What did you like the most about this trial? 
 
 
 
 
 
 
 
19. How do you think the trial could be improved? 
  
 
 
 
 
 
 
Would you be willing to take part  in 
future clinical trials for vitiligo 
comparing: 
Yes No Unsure 
20. Ultraviolet light to dummy lamp?    
21. Ultraviolet light to steroid cream?    
22. Combination of ultraviolet light and 
steroid creams to steroid cream alone and 
to light therapy alone 
   
 
 
 
 
23. Please tell us the reasons for your answers above 
 
 
 
 
 
 
 
Yes No 
24. Would you be happy for us to contact you about 
the results of this trial and our future research work 
on vitiligo? 
  
  
 
 
 
 
 
 
APPENDIX 7 
HI-LIGHT TRIAL 
TREATMENT PLANS AND ADULT CONSENT FORMS 
Patients personal treatment time schedule SKIN TYPE I
version 2.0 15122011
Skin type I-very white
Treatment
session number
Treatment time
1. 15 seconds
2. 18 seconds
3. 21 seconds
4. 24 seconds
5. 27 seconds
6. 30 seconds
7. 33 seconds
8. 36 seconds
9. 39 seconds
10. 42 seconds
11. 45 seconds
12. 48 seconds
13. 51 seconds
14. 54 seconds
15. 57 seconds
16. 1 minute
17. 1 minute 3 seconds
18. 1 minute 6 seconds
19. 1 minute 9 seconds
20. 1 minute 12 seconds
21. 1 minute 15 seconds
22. 1 minute 18 seconds
23. 1 minute 21 seconds
24. 1 minute 24 seconds
25. 1 minute 27 seconds
26. 1 minute 30 seconds
27. 1 minute 33 seconds
28. 1 minute 36 seconds
29. 1 minute 39 seconds
30. 1 minute 42 seconds
31. 1 minute 45 seconds
32. 1 minute 48 seconds
33. 1 minute 51 seconds
34. 1 minute 54 seconds
35. 1 minute 57 seconds
36. 2 minutes
37. 2 minutes 3 seconds
38. 2 minutes 6 seconds
39. 2 minutes 9 seconds
40. 2 minutes 12 seconds
41. 2 minutes 15 seconds
42. 2 minutes 18 seconds
Patients personal treatment time schedule SKIN TYPE I
version 2.0 15122011
43. 2 minutes 21 seconds
44. 2 minutes 24 seconds
45. 2 minutes 27 seconds
46. 2 minutes 30 seconds
47. 2 minutes 33 seconds
48. 2 minutes 36 seconds
49. 2 minutes 39 seconds
50. 2 minutes 42 seconds
51. 2 minutes 45 seconds
52. 2 minutes 48 seconds
53. 2 minutes 51 seconds
54. 2 minutes 54 seconds
55. 2 minutes 57 seconds
56. 3 minutes Maximum exposure time
57. 3 minutes Maximum exposure time
58. 3 minutes Maximum exposure time
59. 3 minutes Maximum exposure time
60. 3 minutes Maximum exposure time
Patients personal treatment time schedule SKIN TYPE II
version 2.0 15122011
Skin type II- white
Treatment
session number
Treatment time in seconds
1. 20 seconds
2. 24 seconds
3. 28 seconds
4. 32 seconds
5. 36 seconds
6. 40 seconds
7. 44 seconds
8. 48 seconds
9. 52 seconds
10. 56 seconds
11. 1 minute
12. 1 minute 4 seconds
13. 1 minute 8 seconds
14. 1 minute 12 seconds
15. 1 minute 16 seconds
16. 1 minute 20 seconds
17. 1 minute 24 seconds
18. 1 minute 28 seconds
19. 1 minute 32 seconds
20. 1 minute 36 seconds
21. 1 minute 40 seconds
22. 1 minute 44 seconds
23. 1 minute 48 seconds
24. 1 minute 52 seconds
25. 1 minute 56 seconds
26. 2 minutes
27. 2 minutes 4 seconds
28. 2 minutes 8 seconds
29. 2 minutes 12 seconds
30. 2 minutes 16 seconds
31. 2 minutes 20 seconds
32. 2 minutes 24 seconds
33. 2 minutes 28 seconds
34. 2 minutes 32 seconds
35. 2 minutes 36 seconds
36. 2 minutes 40 seconds
37. 2 minutes 44 seconds
38. 2 minutes 48 seconds
39. 2 minutes 52 seconds
40. 2 minutes 56 seconds
41. 3 minutes
42. 3 minutes 4 seconds
43. 3 minutes 8 seconds
44. 3 minutes 12 seconds
Patients personal treatment time schedule SKIN TYPE II
version 2.0 15122011
45. 3 minutes 16 seconds
46. 3 minutes 20 seconds
47. 3 minutes 24 seconds
48. 3 minutes 28 seconds
49. 3 minutes 32 seconds
50. 3 minutes 36 seconds
51. 3 minutes 40 seconds
52. 3 minutes 44 seconds
53. 3 minutes 48 seconds
54. 3 minutes 52 seconds
55. 3 minutes 56 seconds
56. 4 minutes Maximum exposure time
57. 4 minutes Maximum exposure time
58. 4 minutes Maximum exposure time
59. 4 minutes Maximum exposure time
60. 4 minutes Maximum exposure time
Patients personal treatment time schedule SKIN TYPE III
version 2.0 15122011
Skin type III- olive
Treatment
session number
Treatment time in seconds
1. 25 seconds
2. 30 seconds
3. 35 seconds
4. 40 seconds
5. 45 seconds
6. 50 seconds
7. 55 seconds
8. 1 minute
9. 1 minute 5 seconds
10. 1 minute 10 seconds
11. 1 minute 15 seconds
12. 1 minute 20 seconds
13. 1 minute 25 seconds
14. 1 minute 30 seconds
15. 1 minute 35 seconds
16. 1 minute 40 seconds
17. 1 minute 45 seconds
18. 1 minute 50 seconds
19. 1 minute 55 seconds
20. 2 minutes
21. 2 minutes 5 seconds
22. 2 minutes 10 seconds
23. 2 minutes 15 seconds
24. 2 minutes 20 seconds
25. 2 minutes 25 seconds
26. 2 minutes 30 seconds
27. 2 minutes 35 seconds
28. 2 minutes 40 seconds
29. 2 minutes 45 seconds
30. 2 minutes 50 seconds
31. 2 minutes 55 seconds
32. 3 minutes
33. 3 minutes 5 seconds
34. 3 minutes 10 seconds
35. 3 minutes 15 seconds
36. 3 minutes 20 seconds
37. 3 minutes 25 seconds
38. 3 minutes 30 seconds
39. 3 minutes 35 seconds
40. 3 minutes 40 seconds
41. 3 minutes 45 seconds
42. 3 minutes 50 seconds
43. 3 minutes 55 s conds
44. 4 minutes
Patients personal treatment time schedule SKIN TYPE III
version 2.0 15122011
45. 4 minutes 5 seconds
46. 4 minutes 10 seconds
47. 4 minutes 15 seconds
48. 4 minutes 20 seconds
49. 4 minutes 25 seconds
50. 4 minutes 30seconds
51. 4 minutes 35 seconds
52. 4 minutes 40 seconds
53. 4 minutes 45 seconds
54. 4 minutes 50 seconds
55. 4 minutes 55 seconds
56. 5 minutes Maximum exposure time
57. 5 minutes Maximum exposure time
58. 5 minutes Maximum exposure time
59. 5 minutes Maximum exposure time
60. 5 minutes Maximum exposure time
Patients personal treatment time schedule SKIN TYPE IV-VI
version 2.0 15122011
Skin type IV, V, VI- brown, black
Treatment
session number
Treatment time in seconds
1. 30 seconds
2. 36 seconds
3. 42 seconds
4. 48 seconds
5. 54 seconds
6. 1 minute
7. 1 minute 6 seconds
8. 1 minute 12 seconds
9. 1 minute 18 seconds
10. 1 minute 24 seconds
11. 1 minute 30 seconds
12. 1 minute 36 seconds
13. 1 minute 42 seconds
14. 1 minute 48 seconds
15. 1 minute 54 seconds
16. 2 minutes
17. 2 minutes 6 seconds
18. 2 minutes 12 seconds
19. 2 minutes 18 seconds
20. 2 minutes 24 seconds
21. 2 minutes 30 seconds
22. 2 minutes 36 seconds
23. 2 minutes 42 seconds
24. 2 minutes 48 seconds
25. 2 minutes 54 seconds
26. 3 minutes
27. 3 minutes 6 seconds
28. 3 minutes 12 seconds
29. 3 minutes 18 seconds
30. 3 minutes 24 seconds
31. 3 minutes 30 seconds
32. 3 minutes 36 seconds
33. 3 minutes 42 seconds
34. 3 minutes 48 seconds
35. 3 minutes 54 seconds
36. 4 minutes
37. 4 minutes 6 seconds
38. 4 minutes 12 seconds
39. 4 minutes 18 seconds
40. 4 minutes 24 seconds
41. 4 minutes 30 seconds
42. 4 minutes 36 seconds
Patients personal treatment time schedule SKIN TYPE IV-VI
version 2.0 15122011
43. 4 minutes 42 seconds
44. 4 minutes 48 seconds
45. 4 minutes 54 seconds
46. 5 minutes
47. 5 minutes 6 seconds
48. 5 minutes 12 seconds
49. 5 minutes 18 seconds
50. 5 minutes 24 seconds
51. 5 minutes 30 seconds
52. 5 minutes 36 seconds
53. 5 minutes 42 seconds
54. 5 minutes 48 seconds
55. 5 minutes 54 seconds
56. 6 minutes Maximum exposure time
57. 6 minutes Maximum exposure time
58. 6 minutes Maximum exposure time
59. 6 minutes Maximum exposure time
60. 6 minutes Maximum exposure time
HI-Light_Home NB-UVB for focal or early
vitiligo_Consent_Adult_version1.0_150811.doc
4 copies: 1 for participant, 1 for file and 2 for the medical notes (hospital and GP)
CONSENT FORM
ADULT WITH VITILIGO
Title of Study: HI-Light vitiligo trial (Home Intervention of light therapy
for the treatment of vitiligo)
REC ref: 11/EM/0331
Name of Researcher: Professor Hywel Williams
Name of Participant:
1. I confirm that I have read and understand the information
sheet version number 3.0 10 November 2011 for the above
study and have had the opportunity to ask questions.
2. I understand that my participation is voluntary and that I am
free to withdraw at any time, without giving any reason, and
without my medical care or legal rights being affected. I
understand that should I withdraw then the information
collected so far cannot be erased and that this information
may still be used in the project analysis.
3. I understand that relevant sections of my medical notes and
data collected in the study may be looked at by authorised
individuals from the University of Nottingham, the research
group and regulatory authorities where it is relevant to my
taking part in this study. I give permission for these
individuals to have access to these records and to collect,
store, analyse and publish information obtained from my
participation in this study. I understand that my personal
details will be kept confidential.
4. I agree to an MED test and a photograph of my skin being
taken as part of the study procedures.
5. I agree to follow the treatment regimen and to use the hand
held device only for the purpose of this trial, and only for my treatment
as discussed in the educational session.
6. I agree to my GP being informed of my participation in this
study.
7. I agree for my personal contact details to be kept by the
research team so that they can contact me after the end of
the study (optional).
8. I agree to take part in the above study.
_______________ ______________ __________
Name of Participant Date Signature
______________________ ____________ ____________
Name of Person taking consent Date Signature
Please initial box
HI-Light_Adult Consent post training_Nottm_v 1.0_ 150811.doc
REC ref: 11/EM/0331 Centre: Participant ID:
Title of the trial: HI-Light vitiligo trial
(Home Intervention of light therapy for the treatment of vitiligo)
Name of the participant:
__________________________________________________
Consent form for person administering the NB-UVB home
phototherapy
I ________________________ confirm that I have read and understand the
instructions for using the hand held home phototherapy lamp, and possible
side effects of this treatment. I also confirm that I am able to administer a
course of such treatment to myself.
A trained member of research staff demonstrated the proper use of the unit,
fully explained the nature and purpose of the treatment and answered any
questions or doubts I may have regarding the treatment schedule and use of
the lamp.
I confirm that I will use the treatment as I have been taught, and that I
accept full responsibility for administering the treatment. I also understand
that the hand held phototherapy lamp should not be used on areas other
than the areas agreed with a member of the research team and that I
should not use it on anyone else.
Signed: Date: dd/mm/yyyy
I understand that once the trial is over, the phototherapy lamp (including
safety goggles and glasses) should be returned to the research team.
Signed: Date:
dd/mm/yyyy .......................
To be completed by research nurse:
I confirm that I have demonstrated the proper use of the hand held home
phototherapy lamp. I have explained the nature and purpose of the therapy,
including the possible side effects. I also confirm that
________________________________ showed competence in using the
equipment as per the treatment protocol.
Name: ..............................................................
Signed: Date: dd/mm/yyyy
